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SUMMARY.
A brief review of histamine antagonists is presented in Chapter 1 with particular 
reference to the importance of chirality in drug-receptor activity.
A main aim of the work described in this thesis was to synthesise novel phenindamine 
analogues as potential Hr-histamine antagonists. The syntheses and stereochemical 
analyses of novel N-2 substituted phenindamine analogues and their precursors are 
discussed in Chapter 2. It was found that analogues of phenindamine may be 
synthesised in which the indene double bond may be relocated from the 9,9a position to 
the more pharmacologically active 4a,9a site. Both 
2-alkyl-9-phenyl-2,3,4,4a-tetrahydro-l//- indeno[2,l-c]pyridines and
2-alkyl-9-phenyl-2,3,4,9- tetrahydro-l//-indeno[2,l-c]pyridines were isolated. An 
investigation into the chiral separation of phenindamine analogues using HPLC 
techniques is also presented.
A route towards the synthesis of novel aryl-substituted phenindamine analogues is also 
presented in Chapter 2. Conformational analyses of the precursor piperidines are also 
discussed.
The NMR analysis of Histryl, a clinically useful antihistamine, showed that it exists 
as two clearly defined conformers. Chapter 3 deals with the syntheses and 
stereochemical studies of novel confomnationally-restricted analogues of Histryl for the 
purpose of elucidating which conformer is the more biologically active. The synthesis 
and separation of cis-(c 3-Me r-4-OCHPh2), trans- 
(r-3-Me-r-4-OCHPh2)-l,3-dimethyl-4-benzhydryl ethers and 
a-l,2-dimethyl-4-benzhydryl ether are discussed.
Pharmacological results on a selection of the compounds synthesised in this work are 
presented in Chapter 4. The in vitro tests showed
3-benzoyl-l-ethyl-4-hydroxy-4-phenyl piperidine HC1,
2-ethyl-9-phenyl-2,3-dihydro- l//-indeno [2,l-c]pyridine HBr and 
2-Benzyl-9-phenyl-2,3,4,9- tetrahydro-l//-indeno[2,l-c]pyridine HC1 were the most 
active compounds. In in vivo test systems, the most active compounds were 
2-methyl-9-phenyl-2,3,4,4a-tetrahydro- l//-indeno[2,l-c]pyridine HBr and an isomeric 
mixture of 2-ethyl-9-phenyl-2,3,4,9- and 2,3,4,4a-tetrahydro-l//- indeno[2,l-c]pyridine
HC1. Activity was also shown in 9-phenyl-2,3-dihydro-l//-indeno[2,l-c]pyridine HBr,
✓
2-ethyl-9-phenyl-2,3,4,4a-tetrahydro-l//-indeno[2,l-c] pyridine HBr and
2-phenethyl-9-phenyl-2,3,4,4a-tetrahydro- l//-indeno[2,l-c]pyridine HBr.
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1. IN TR O D U C TIO N .
Histamine or 2-(imidazol-4-yl)ethylamine [1] was first reported by Windaus and Vogt1 
who synthesised it out o f chemical interest as a partial structure o f the naturally 
occurring a-amino acid histidine. They appeared to have no knowledge, however, o f 
the biological implications o f histamine, as it was not known at the time that it  occurred 
in living organisms. In 1910, Dale and Laidlaw2, published the first o f a series o f 
papers describing the pharmacological effects o f histamine; in particular, they noted the 
powerful effects o f histamine in stimulating contractions o f smooth muscle, and its 
potent action in lowering blood pressure.
In the body, histamine is stored in vesicles in its inactive form histidine. It is activated 
by the enzyme histidine decarboxylase. Histamine is catabolised by diamine oxidase 
(Histaminase) and methyl transferase. Both enzymes are not specific to the degradation 
o f histamine, indicating that histamine may be widely distributed in the body.
Histamine is closely associated with mast cells3 and its long established role as a 
mediator o f inflammation led to its general description as an autocoid (local hoimone); 
produced by cells, is released to the tissue fluid, and only acts on adjacent cells. Much 
interest has been concentrated on a large list o f pharmacological agents, in addition to 
immunogloblins, that can produce mast cell degradation and the biochemical events 
associated with histamine release4,5,6. However, not all tissue histamine is associated 
with mast cells, and, depending upon species, histamine has been detected in basophils, 
platelets7, enterochromaffin-like cells8, endothelial cells9 and neurons10. There is also 
some evidence that histamine synthesis can be induced, and histamine made available
HN N [1]
1
in an unstored diffusible form, in tissue undergoing rapid growth and repair11. These 
additional sites of histamine synthesis and storage suggest that there are alternative 
physiological roles for histamine.
Histamine has a dramatic effect when it is liberated into the tissue during allergic or 
anaphylactic reactions. Histamine has been shown to play a considerable part in gut 
motility, gastric acid secretion and in the stimulation of smooth muscles in the lungs 
and blood vessels.
1.1 H ISTAM INE RECEPTORS.
It is well known that the majority, if not all, of the effects of histamine can be attributed 
to activation of either H j-, H2~, and recently H3-histamine receptors, on the basis of 
quantitative in vitro studies in isolated peripheral tissue and brain slice preparations.
Histamine receptors were initially subdivided by Ash and Schild12 when they 
introduced the term Hj-receptor to describe the class of histamine receptors that were 
sensitive to inhibition by low concentrations of classical antihistamines (synonymous 
with H 1-receptor antagonists). Prior to this, it was well established that only certain of 
the responses to histamine were sensitive to these agents.
Classic Hj-receptor-mediated responses include contractions of many visceral smooth 
muscles including guinea pig trachea, uterus, and the longitudinal smooth muscles of 
the ileum12*13. However, a number of responses to histamine, most notably stimulation 
of acid secretion from the gastric mucosa, the chronotropic responses of guinea pig 
right atrium, and the inhibition of electrically evoked contractions of rat uterine horn, 
were resistant to H r  antagonists such as mepyramine12’14. The receptor responsible for
2
these latter responses was eventually defined as the H2-receptor by Sir James Black and 
his colleagues14, when they successfully developed a selective antagonist of this 
receptor, namely burimamide14. The third histamine receptor (H3) was originally 
postulated in 1983 to explain the atypical pharmacological properties of the histamine 
autoreceptor responsible for controlling the release of histamine from rat cerebral 
cortical slices15. More recently, the Hr  and H2-histamine receptors have been 
cloned16*17. A recent review on the histamine receptors has been published by H ill18.
1.1.1 H t-Receptor.
*
In most tissue, H :-receptor stimulation leads to the hydrolysis of 
phosphatidylinositol-4,5-diphosphate with the consequent formation of 
inositol-1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DG)19. IP3 which is released 
into the cytosol, has been shown to mobilise calcium from intracellular stores19. The 
influx of calcium ions has a direct effect on the contractile apparatus. DG, which is 
retained within the membrane environment activates protein kinase C19. In many 
tissues, formation of inositol-1,3,4,5- tetrakisphosphate from IP3 occurs and this 
molecule may have a role in controlling calcium influx and refilling of intracellular 
stores19.
Histamine was first thought to stimulate, indirectly, the breakdown of membrane 
inositol phospholipids in rat brains20 and guinea pig ileum21. This was later confirmed 
using [3H] inositol phosphate accumulation in the presence of lithium ions, which 
inhibits inositol monophosphate, following prelabeling of tissues with [3H] 
myo-inositol22. In guinea pig brain slices, the regional distribution and pharmacological 
characteristics of the inositol phosphate responses to histamine closely parallels that of 
the histamine Hj-receptor22*23. The guinea pig cerebellum contains the largest inositol
3
phosphate responses to histamine, and this is selectively inhibited by Hpreceptor 
antagonists23. Similar Hj-receptor-mediated responses have also been detected in rat 
cerebral cortex24 and mouse cerebral cortex25. r.
Histamine-stimulated inositol phospholipid hydrolysis has been demonstrated in a 
number of peripheral tissues, including canine and bovine trachea26,27, bovine 
adrenalchromaffm cells28, human umbilical endothelial cells29, guinea pig ileum23, 
guinea pig bladder30, and guinea pig aorta31. In most of these tissues, pharmacological 
characterizations of the inositol phospholipid responses to histamine is consistent with 
an Hj-receptor-mediated response.
*
One of the pharmacological consequences of producing a raised intracellular level of 
inositol-1,4,5-triphosphate is mobilisation of intracellular calcium, although only small 
rises in the actual level of inositol-1,4,5- triphosphate following Hj-receptor 
stimulation have been demonstrated in a number of tissues29. The largest accumulation 
of the metabolites inositol-1,3,4-triphosphate and inositol-1,4-bisphosphate suggests 
that the flux through inositol-1,4,5-triphosphate may be large. A release of calcium 
from intracellular stores by histamine Hj-receptor stimulation has been shown in 
endothelial cells29,32, airway smooth muscle33 and rat aorta34.
The effect of histamine Hj-receptor stimulation on the opening of plasma membrane 
ion channels is an area in which little, and often indirect, evidence is available. Most 
information has come from studies of the calcium dependence of histamine-induced 
contractile activity in various smooth muscle preparations, in particular guinea pig 
intestinal smooth muscle. Histamine can initiate smooth muscle contraction by 
releasing intracellular calcium or by opening either receptor-operated or 
voltage-operated calcium channels35.
4
In intestinal smooth muscle, histamine can activate ion channels permeable to sodium, 
potassium and probably calcium ions leading to depolarisation, an increase in action 
potential discharge, and smooth muscle contraction36. It is likely that the depolarisation 
produced is sufficient to open voltage-operated calcium channels, which are partly 
responsible for smooth muscle contraction.
Histamine is one of the most potent stimulants of cyclic adenosine monophosphate 
(cAMP) accumulation in guinea pig and rabbit brain slices37’38. This elevation of 
cAMP levels produced by histamine appears to involve two separate mechanisms. One 
is via the Hj-receptor, the other through the H2-receptor sites (see later). The 
H j -re cep tor-mediated responses to cAMP depends upon the prior stimulation of the 
H2-receptor. The Hj-receptor-mediated response is thought to be an indirect 
stimulation. It is likely that a secondary messenger is involved because the effects are 
lost in broken cell preparations39.
It has been suggested that the indirect Hj-receptor stimulation of cAMP accumulation 
may be mediated at the levels of cAMP synthesis40. It has also been established that 
histamine Hj-receptors can elicit the release of catecholamines from adrenal glands41. 
Histamine (via the Hj-sites) has also been known to exert a powerful stimulant effect 
on the breakdown of glycolysis in mammalian brain slices, suggesting that it may have 
an important role to play in modulating carbohydrate metabolism in cerebral tissue42.
As stated before, histamine is a potent stimulant of cAMP accumulation in many cells, 
and particularly those of the central nervous system (CNS)43. Pharmacological studies 
in brain slices44 gastric mucosal cells and glands45, dog fat cells46, cardiac myocytes47, 
vascular smooth muscle48, basophils49, and neutrophils50 indicate that H2-receptor
5
stimulation is intimately involved in those responses.
1.12 Ho-Receptor.
H2-Receptor stimulation, leads to the influx of calcium ions, but, unlike Hj-receptor 
stimulation, this is secondary to the stimulation of the contractile apparatus. The influx 
of calcium ions regulates protein kinase C, which, in turn produces the desired agonist 
effect. The H2-receptor also relies on the adenylate cyclase mechanism which is absent 
in Hj-receptor stimulation.
✓
Histamine ^ -receptor-stimulated adenylate cyclase was first demonstrated by Klein 
and Levey51 in broken cell preparation of guinea pig cardiac muscle, and in the brain 
by Hegstrand and co-workers39. It was later showed that guanine nucleotides were 
necessary for histamine induced activation of both of these tissues52.
Histamine H2-receptor stimulated adenylate cyclase activity in mammalian brain is 
sensitive to a range of psychotropic drugs53. Thus, a number of neutrophils54, and 
D-lysergic acid diethylamide are potent inhibitors of the H2-linked cyclase in broken 
cell preparations from mammalian brain. Many appear to act as competitive antagonists 
of the H2-receptor in this system.
It has been proposed that H2-receptor-mediated increase in intracellular cAMP levels 
leads to an increase in slow inward calcium ion current (ICa) as a result of 
cAMP-dependent phosphorylation of calcium channels which increases the number of 
channels that may open during depolarisation55.
In isolated gastric mucosal parietal cells, histamine- stimulated secretion of
6
hydrochloric acid (HC1) has been associated with increased intracellular levels o f 
cAMP56, and is little altered by removal o f extracellular calcium ions57. Furthermore, 
studies in single parietal cells have confirmed that H 2-receptor stimulation can release 
calcium from intracellular stores58.
The potent effect o f H2-receptor stimulation on gastric acid secretion in vivo and the 
inhibitory effects o f the H 2-receptor antagonists on pentagastrin-stimulated acid 
secretion indicates a physiological role for histamine in the control o f gastric acid 
secretion59,60. Up to now, the mechanism o f inhibition o f the H2-receptor with the 
antagonists has still not been resolved. Some hypotheses have been put forward. The 
first, by Black and Shankley60, is that histamine acts as the final common mediator o f 
the actions o f acetylcholine and gastrin; the other, by Soil and Berglindh56, suggested 
that potentiating interactions occur among histamine, gastrin, and acetylcholine at the 
levels o f parietal cells.
1.2 HISTAMINE Hr ANTAGONISTS.
The firs t compound reported capable o f counteracting some o f the effects o f histamine 
in animals was 2-(l-piperidinomethyl)-l,4-benzodioxane [2] which protected guinea 
pigs from bronchial spasm induced by a histamine spray61. This led to the development 
o f a wide range o f clinically useful classical H^receptor drugs.
O
[2 ]
The classical histamine H!-receptor antagonists are structurally very similar and are 
represented by the general formula shown in figure 1. A  disubstituted terminal amino 
group (usually a dimethylamino substituent) is connected to an atom X  via a short
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carbon chain. This chain may be saturated, unsaturated, or part o f a ring system, and 
where X  can be an oxygen, nitrogen or a carbon atom; X links the side chain to an 
"aromatic head". This "aromatic head" contains two aromatic rings (e.g; Ph, CH2Ph, 
2-Py), which may be fused.
Thus, most antihistaminics are chemically stable, no members contain labile ester or 
amide functionalities, and aryl substituents that facilitate oxidation such as phenolic 
hydroxy and amino are absent. The most important physical property o f antihistaminic 
drugs is that o f the equilibrium between the base and its conjugate acid, as measured by
In 1955, Marchall63 measured the pKa values o f a wide range of antihistaminic drugs 
which were representative o f almost all classes o f the drugs in clinical use. The pKa 
values ranged from Chlorocyclizine (pKa 8.15) to Antazoline (pKa 10.00). The range 
o f magnitudes were such that all the compounds were extensively protonated (90% or 
greater) at physiological pH.
Because o f their basic properties, the antihistamine drugs may be administered orally in 
the form o f water-soluble salts. Hydrochloride and maleate salts are the most popular, 
but salts o f citric, succinic, tartaric, and phosphoric acids are also used. In general, 
however, some fu lly ionised quaternary ammonium salts o f antihistaminics are less 
effective than salts from acids, probably as a result o f inferior absorption after oral 
administration and adverse differences in distribution after entry into the blood.
FIGURE 1.
A r ’ R ”
pKa62.
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1.2.1 Classical Histamine Hr Receptor Antagonists.
Based on the general formula in figure 1, the classical H r receptor antagonists can be 
subdivided into several classes. This subject has been reviwed by Casy64.
1.21.1 Ethylenediamines.
Halpem65 synthesised the first clinically useful antihistaminic drug 
N-benzyl-N’ ,N ’-dimethyl-N- phenylethylenediamine [3a] (phenbenzamine, Antergan). 
A  more potent and less toxic compound resulted when the N-phenyl group was 
replaced by 2-pyridyl and the discovery led to the development o f mepyramine [3b] 
which is still in use clinically as the maleate salt66,67. Modifications o f the parent
structure have been synthesised with potential antihistaminic activity68’69.








In America, during the 1940s, the medicinal chemists investigated antihistamines in 
which the arylamino nitrogen was replaced by oxygen to give a series o f basic ethers70. 
This work led to the introduction o f 2-dimethylaminoethyl benzhydrylether [4] 
(diphenhydramine, Benadryl). This is not a potent antihistaminic drug and had a short 
duration o f action as well as having anticholinergic activity. Sedative properties were 
also a side effect. Para substitution o f the phenyl groups by methoxy, chloro, and 




Knox and Knapp73 varied the diphenhydramine structure by incorporating a piperidine 
ring instead o f the alkylamino chain. This compound, known as diphenylpyraline [5] 
(H istryl) was considerably more potent than diphenhydramine74. Histryl is discussed in 






The clin ica lly important member o f this class is pyrrobutamine diphosphate [6] 
(Pyronil) which provided both structural and geometrical isomers that are o f value in 
the investigation o f the chemical and stereochemical requirements for the blockade o f 
Hj-histamine receptors7S. The antihistaminic potency o f pyrrobutamine depends upon 
the rig id ity  and specific'disposition o f the alkenic bond. It was important to have a 
planar ArCH.CH2N unit and an aromatic substituent at C -l in 
l,2-diaryl-4-aminobut-2-enes for antihistaminic activity76.
Cl c h 2 c h 2- n  





Investigation o f 1,1 -diary 1-3-aminopropenes was in itia lly  investigated by White and 
co-workers77. The 2-pyridyl group was introduced as one o f the aryl groups present due 
to the elevated potency o f this heterocycle in other classes o f antihistamines78. This led 
to the synthesis o f E-l-(2-pyridyl)-3-(l-pyrro lid ino)-l-(4-to lyl)-prop-l-ene [7] 
(triprolidine, Actid il), a clinically very potent antihistaminic drug79,80. On the basis o f 
PMR and UV data o f salts, assignment o f the cis-trans pair has been achieved81.
monitoring separation and consequent purification o f isomeric mixtures. 
Stereochemical features o f triprolidine itself have been confirmed by X-ray 
crystallography82,83. The special role o f the pyrrolidino group in the blockade o f 
-histamine receptors is apparent in this series, as it is in the aminobutenes.
The positions o f the aromatic system in 1,1-diaryl-3- aminopropenes is an important
Observation o f vinylic protons and other signals provided a convenient method for
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factor for antihistaminic activity84 and two geminal aryl substituents attached to C- 1 
alkenic carbon atoms are needed for antihistaminic activity.
1.21.5 3-Amino-l-Arvl-(2-Pyridyl)Propenes (Pheniramines).
The pheniramines are saturated analogues o f 3-amino-1- aryl-l-(2-pyridyl)-propenes. 
The halogen derivatives [8b] (chloropheniramine) and [8c] (bromopheniramine) are 





The pheniramines are chiral molecules and potency differences between enantiomenc 
pairs have been reported87 (See section 1.4), although the racemates are clinically 
employed. The configuration o f antipodal pheniramines has been established by a 
chemical method88 and confirmed by X-ray crystallography82,83.
R
1.21.6 Phenothiazine Derivatives.
The best known member o f this class is 10-(2-dimethylaminopropyl)phenothiazine [9] 
(promethazine) which is still a popular clinical drug89.
CH2CH(CH3)N(CH3):
Many variants o f promethazine have been made. Antihistaminic activity is raised when
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C -l o f the molecule is replaced by nitrogen to give 1-azaphenothiazine derivatives. 
Isothipendryl [10] has a shorter duration o f action and less sedative properties than 
phenothiazine90.
CH2CH(CH3)N(CH3):
Both promethazine and isothiopendyl have been resolved91. Enantiomers o f
promethazine have similar antihistaminic and pharmacological properties in contrast to
studies o f pheniramines.
1.21.7 Other tricyclic derivatives.
O f this class, 5-(l-methylpiperidylidene-4)-5//-dibenzo- [a,d]-cycloheptene [11] 




Cyproheptadine and its thioxanthene congener [12] are the most potent o f many 
analogues prepared; the sulphur derivative is also known to antagonise seratonergic, 
bradykininergic, cholinergic receptor sites as well as histaminic sites. The sulfoxide 





Other cyproheptadine analogues have been studied, most o f which antagonise 
histamine at the Hj-receptors94.
1.21.8 Miscellaneous Types.
Two indene derivatives are o f importance as antihistamines. The first is
l-[l-(2 -pyridy le thy l)]-2 - (2-dimethylaminoethyl)indene [13] (dimethindene, 
dimethpyrindene). The pharmacological activity is found to reside mainly in the levo 
isomer. Structurally it bears some resemblance to the l,2-diaryl-4-aminobut-2-enes, in 
that the aromatic ring o f the dimethpyrindene is trans to the aminoalkyl substituent95,96.
[13]
The other clin ically useful drug o f interest is phenindamine [14] (Thephorin), which 
w ill be dealt w ith in more detail in chapter 2.
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N - C H
[14]
Many other ring system analogues with antihistaminic
properties have been reported, mainly the derivatives o f 1 -phenylpyrrolidine,
anthracene, and indole97,98,99.
Therapeutic uses o f the classical Hj-receptor antagonists have been the symptomatic 
treatment o f several allergic responses where histamine release from mast cells is 
induced via immunological mechanisms. Histamine-induced contraction o f smooth 
muscles and increase in capillary permeability can be antagonised via Hj-receptor 
blockade, resulting in an improvement o f asthmatic conditions and a reduction in 
formation o f oedema and cutaneous wheal. The classical Hj-receptor antagonists, 
however, are usually ineffective in bronchial asthma, but they can successfully be 
employed in allergic rhinitis, conjunctivitis, and dermatitis. This discrepancy may be 
explained by the fact that histamine probably plays an important part in dermatitis, 
whereas arachidonic acid metabolites appear to be primarily responsible for asthmatic 
diseases100. Another explanation is that some drug concentrations achieved in the target 
organ (lungs) are not high enough for effective Hj-receptor blockade.
Raising the applied dosage has limited interest due to unacceptable side-effects. At 
therapeutic doses, the classical H r receptor antagonists generally produce sedation.
This usually unwanted effect is probably caused by H r receptor blockade in the CNS.
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Recent data have shown that H!-receptors are involved in the regulation o f sleep and 
wakefulness in both the rat and in man101. Presently, however, it  is not known i f  the 
H rreceptor blockade increases the sleep duration or decreases the latency to sleep 
onset in man. Other observed side-effects are probably caused by anticholinergic 
activity o f some o f the compounds102. Such activity can result in dryness o f the mouth.
Some o f the classical H rreceptor antagonists possess CNS stimulatory activity. This 
action may be explained by the fact that these compounds are able to interact w ith other 
neurotransmitter systems in the brain. Interaction w ith noradrenergic, seratonergic, and 
dopaminergic uptake systems have been reported, and these activities may play a role 
in behavioural effects o f these antagonists103,104.
1.22 Modem fy-H istam ine Antagonists.
As a result o f a greater understanding o f the pharmacological aspects o f the histamine 
receptors, modem H 2-receptor antagonists have been synthesised which combine 
Hj-antagonism with other clin ically useful pharmacological activities in one molecule. 
This subject has been reviewed by Leurs et a/.,105.
Tozzi et a/.,106 reported the synthesis o f Azatidine [15a] and Ketotifen [15b], both o f 
which are derivatives o f the classical tricyclic compound, cyproheptadine.
1 6
[15a] ON [15b]
CH3 c h 3
Azatidine is a potent antagonist o f the H r receptor as well as the muscarinic, 
seratonergic, both in in vitro and in in vivo models. Azatidine is approximately nine 
times more potent than cyproheptadine. Ketotifen is a noncompetitive H!-receptor 
antagonist w ith minor anticholinergic and seratonergic activity107. Clinically Ketotifen 
is employed for the treatment o f asthma.
Azelastine [16], a phthalazinone derivative is structurally unrelated to the classical 
Hi-antagonists. Azelastine has negligible anticholinergic activity, with moderate 
seratonergic antagonism108. In several in vivo test systems on allergic conditions, 
azelastine proved to be a long-lasting, orally effective agent109.
l-(2-Ethoxyethyl)-2-(4-methyl-l-homopiperazinyl)- benzimidazole [17] (KB-2413) is a 
selective potent Hj-receptor blocker. It is forty times more potent than 
chloropheniramine in in vivo studies. KB-2413 is highly effective in preventing
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anaphylactic broncho-constriction in guinea pigs. KB-2413 is ineffective at 




Tazifylline [18] is a selective H r blocker in both in vivo and in vitro test systems111,112. 
It has weak a ffin ity towards adrenergic, saratonergic and muscarinic receptors14. As a 
consequence, tazifylline has few side-effects, and with a long duration o f action, it 
might prove to be a very successful anti-allergic drug.
CH3
NH




Astemizole [19], is potent antihistaminic drug with a short onset and a long duration o f 
action. It was discovered by Janssens et a/MH3,ll4,ll5 while looking for a neuroleptic 




Astemizole has moderate 5HT2 activity, and has a high affin ity for the a-adrenergic 
receptor. Astemizole does not cross the blood-brain barrier and hence has no noticable 
CNS and sedative properties116. Astemizole is commercially available and is used in 
allergic disorders117.
Cabastine [20], one o f a series o f the 4-phenylcyclohexylamines, is a chiral compound 
with the levocabastine the more potent enantiomer. It has no noticable anticholinergic 
or antisaratonergic activity118. Cabastine is approximately 100 times more potent than 
astemizole.
Levocabastine has already been evaluated in several clinical trials; low doses resulted 
in a significant reduction o f symptoms o f allergic conjunctivitis and rhinitis with no 
adverse side-effects.





In a clinical trial, temelastine showed significant antihistaminic activity and produced 
no sedation121. Its efficacy in allergic conditions has yet to be shown.
The antihistaminics, acrivastine [22], a triprolidine analogue, was designed specifically 
as drugs that w ill not cross the blood-brain barrier. In doing so, the major side-effects 
may be avoided, as interaction with the CNS is lost122.
Cetirizine [23a],a metabolite o f hydroxyzine [23b], a H r  blocker based on the classical 
H]-receptor antagonists, does not cross the blood-brain barrier. It is a potent antagonist 
with little affin ity for adrenergic, dopaminergic and seratonergic receptors123.
CH=CHCOOH
CH3




Cetirizine has long lasting activity, with no sedative side-effects124. It is effective in 
blocking the histamine receptors in the skin and lungs125,126.
The c lin ically useful terfenadine [24], is a selective Hpreceptor antagonist with no 
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[24]
Therapeutically, terfenadine is employed in the treatment o f allergic rhinitis, bronchial 
asthma and skin diseases.
Based on the azatidine series, loratidine [25] is devoid o f any anticholinergic and 
CNS-depressant activity128. Pharmacological evaluation o f loratidine by Ahn and 
Barnett129 has produced interesting results, in the sense that they showed selectivity o f 
the drug in tissues that contain Hj-receptors.
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Due to the reduced basicity o f the piperidine nitrogen, loratidine is rapidly absorbed 
after oral administration and therefore shows a rapid onset o f action. Since the major 
metabolite o f loratidine, descarboxyethoxyloratidine, is also a potent H j -receptor 
antagonist, the in vivo activity is long-lasting128. As a consequence o f the favourable 
pharmacokinetic profile, loratidine can be administered once a day for effectiveness in 
allergic conditions.
1.23 Histamine H?-Receptor Antagonists.
It has long been recognised that the actions o f histamine on intestinal smooth muscle 
and on gastric acid secretion are distinctly different, the former being antagonised by 
Hj-blockers which do not affect the secretion o f gastric acid in response to histamine. 
This subject has been reviewed by Daly and Price130 and by Leurs and colleagues105.
Black and his colleagues14 showed that buramimide [26], the first selective 
H2-histamine antagonist, blocked the H2-receptor-stimulated action of gastric acid 
secretion.
. (CH2)4* NHC-NHCH3 
'I
r \
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Cimetidine [27a], was later marketed as the first H2-antagonist and is used clinically
fo r the treatment o f stomach ulcerations. Cimetidine is a competitive antagonist which 
inhibits the contraction o f isolated uterus and the secretion o f gastric acid as well as 
increasing the constriction o f guinea pig isolated atrium14.
Etinidine [27b], an analogue o f cimetidine, was found to be twice as active as 
cimetidine131,132. Other cimetidine analogues have been synthesised with selective 
antagonism at the H 2-site.





CH 2( = C H
Improvement o f the H 2-antagonist activity was achieved by Bradshaw et a/.,133 in 
ranitidine [28], whereby the imidazole ring was replaced by a furyl system. Analogues 
o f ranitidine were also synthesised134,135.
CH2SCH2CH2N?CNHCH3
[28] NO
Changing the heterocyclic moiety o f cimetidine produced a potent H2-antagonist in 
tiotidine [29] (derived from the 1,3-thiazole heterocycle)136.
[29]
H2N—  C '
c h 2 s c h 2c h ^ ih c n h c h 3
NCN
Tiotidine failed its clinical test due to damaging side-effects. Tiotidine, however, is
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being used as a radioligand in histamine H2-receptor binding studies137. In contrast to 
what has been found in cimetidine, the replacement o f the sulphur atom in the side 
chain o f tiotidine does not lead to a reduction in H2-antagonist activity138.
A  particularly interesting modification o f the structure o f tiotidine can be found in 
which the flexible alkyl chain is incorporated into a cyclohexane ring system [30], 
rendering the whole structure fairly rigid. The H2-antagonistic activity o f compound 






A  further development o f the H2-receptor antagonists was achieved by the synthesis o f 
pifatidine [31a] a potent H2-antagonistic activity. In in vivo studies pifatidine was 
shown to be six times more active than cimetidine139. Pifatidine has been introduced 
into the market. It is applied on a once-daily dose for providing fast pain relief when 
compared with cimetidine and ranitidine140.
The benzothiazole analogue of this series, zolatidine [31b] is also a potent antagonist at 
the H 2-receptors. Zolatidine is a brain penetrating H2-receptor antagonist, which could 
make it a valuable tool for investigating the pharmacological and pathological roles o f 
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Mifentidine [32] has an altogether different structure to the known potent 
H2-antagonists whereby the flexible alkyl chain connecting the aromatic substituent to 
the polar group is substituted with another aryl group142. M ifentidine is currently 
undergoing clinical trials, and has so far been found to be devoid o f negative inotropic 
effects and non-specific effects on the human atrium and m otility o f the 
gastro-intestinal tract in various animal species143.
Therapeutically, the H 2-histamine antagonists play a major role in the treatment o f 
gastric ulcers. W ith regard to potency and duration o f action, however, research for 
new H2-antagonists has been redirected because complete inhibition o f gastric acid 
secretion has been found to result in severe gastric damage.
1.3 HISTAMINE H? RECEPTORS.
Histamine H 3-receptors were originally identified as inhibitory autoreceptors on 
histamine-containing nerve terminals in rat cerebral cortex143, but have since been 
shown to inhib it the release o f a variety o f neurotransmitters in both central and




1.31 Histamine H ?-receptor Antagonists.
The original definition o f a novel H3-receptor controlling histamine release in rat 
cerebral cortical slices was based on the finding that several existing H r  and 
H2-receptor agonists and antagonists were effective H3-receptor antagonists15,146. Thus, 
the weak H2-antagonist burimamide is approximately two orders o f magnitude more 
potent as an inhibitor o f H 3-receptor-mediated responses. The H2-agonist impromidine 
and the H r agonist betahistamine also posses H3-receptor antagonist properties.
Thioperamide [33] is,however, now recognised as the primary H3-antagonist for 
receptor classification studies because o f its high affinity and good receptor 
selectivity144. This compound also appears to cross the blood-brain barrier and should 
be o f u tility  in unravelling the behavioural role o f H3-receptors in the CNS.
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1.4 C H IR A L IT Y .
This section is presented because it is relevant to the work done in this thesis. Many o f 
the compounds synthesised in this work contain one or more chiral centres (See chapter 
2 and 3). Structural isomerisation and conformational studies are also discussed, and 
are relevant (See chapter 2 and 3).
One o f the major driv ing forces at present for the increasing awareness o f the 
consequence o f stereochemistry and biological activity is the increasing interest the 
drug regulatory authorities are taking in the subject. Indeed in FDA guidelines147 it  is 
stated that, even in racemates, enantiomers may be considered as impurities and that 
safety and efficacy data need to be produced for each stereoisomer including physical 
and chemical information. This means that an "inactive" stereoisomer may be treated as 
a 50% im purity unless a lo t o f supporting work is available. Thus the importance o f 
developing single enantiomers is vital.
In terms o f regulation comes the question as to what to do about drugs marketed at 
present. Many older drugs were introduced without adequate information on their 
stereochemical identity or composition. For example, the antihypertensive agent 
cyclothiazide [34] is marketed as a mixture o f two racemates and small but significant 
differences in batches o f the marketed drug have been observed148. Whether this is o f 
therapeutic consequence is unclear, and may never be resolved, but it serves to 
highlight the lack o f concern in the past on this issue.
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A more positive consequence of the re-examination o f older drugs may be the 
marketing o f a single enantiomer, where a racemate has been marketed previously, thus 
avoiding undesirable side-effects giving an older drug new life. This has happened with 
thalidomide [35]149, where the (+) enantiomer provides the desired hypnotic effects and 
the (-) isomer is responsible for the adverse teratogenic effects150. This particular 
example highlights the need for chiral resolution o f drug compounds.
Many drugs with chiral centres have been resolved in order to increase the potency o f 
the drug and/or reduce the unwanted side-effects151. For instance, an in vitro study o f 
the antihistaminic drug chlorpheniramine [8b] showed that the dextro isomer was twice 
as potent as the racemate, and 200 times more active than the levo isomer152.
Recently, Casy e ta l.}^  described the resolution o f the chiral H r histamine antagonists 
chlorpheniramine [8b], dimethindene [13], carbinoxamine [36], and 
mebrophenhydramine [37]. The optical purities o f the antipodal products were 









0 (C H 2)2NMe2 0(C H 2)2NMe2
The same authors tested the antipodal pairs o f chlorpheniramine [8b] and dimethindene
[13] in biological systems for antihistaminic activity. They found that the levo isomer 
o f dimethindene was 70 times more potent than its antipode in guinea pig ileum 
preparations.
Geometric isomers o f triprolidine analogues have also been resolved and tested154. It 
was found that tripolidine [7] is the most active, whilst E-isomers of triprolidine 
analogues were generally more active in in vivo studies than the Z-isomers. The active 















Conformational diastereomers can also lead to unexpected pharmacological results. A 
good example is that o f the 3-methyl reversed esters of pethidine (meperidine), where 
the configuration o f alphaprodine and betaprodine have been established unequivocally 
by X-ray crystallography as trans-isomer [41] (r-3-Me r-4-Ph) and the c/s-isomer [42] 
(c-3-Me r-4-Ph) respectively155 with the two isomers in the following conformations in 












Biologically, it has been shown that betaprodine is five times more active than 
alphaprodine as an analgesic agent.
Recent examples o f conformational isomers are seen in some o f the phencyclidine 
derivitives156, as analgesics. The trans-isomer [43] (r-3-Me r-4-Ph) was found to be 










The next chapter in this thesis deals with the geometric isomers o f phenindamine 
analogues, which possess chiral centres. Some of the precursors synthesised are 














Chapter 3, deals with the synthesis and conformational analysis o f histryl and some o f
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2.1 IN TR O D U C TIO N .
This chapter deals with the synthesis and stereochemical evaluations o f the precursors 
and corresponding phenindamine analogues as potential H r  and/or H2-histamine 
receptor antagonists. An investigation into the chiral separation o f the phenindamine 
analogues synthesised was also undertaken.
In 1950, Plati and Wenner157,158 synthesised a structurally unrelated antihistaminic 
compound. This compound, more commonly known as phenindamine tartrate [14] 
(Thephorin, 2-methyl-9-phenyl-2,3,4,9-tetrahydro-l-pyridindene tartrate, 
2-methyl-2,3,4,9-tetrahydro-9- phenyl-l//-indeno[2,l-c|pyridine tartrate), was a rigid 
compound although still contained the CH2CH2N substituent thought to be required for 
antihistaminic activity.
The synthetic pathway by which phenindamine was obtained is outlined in Scheme 1. 
Plati and Wenner1*"'7 predicted that phenindamine can exist as two out o f the possible 
three structural isomers with respect to the indene alkenic double bond (Figure 9), 
based on ultra violet studies o f the hydrobromide salt o f [51] and the tartrate salt o f
[14]. Structure [52] was never isolated.
FIGURE 9.
In a short communication, Branch et al.,1:>y provided ]H NMR and 13C NMR evidence 
to show that Plati and Wenner were right to predict the structure o f phenindamine
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SCHEM E 1.
PhCOCH3 HC1, CH20 PhCOCH
► PhCOCH2CH2N - HR 
.HC1
(PhCOCH2CH2)2N - R 







R = alkyl 
X = halide
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tartrate [14] and phenindamine hydrobromide [51]. The same authors also isolated 
phenindamine as its free base and showed, using 13C NMR that it contained a mixture 
o f structural isomers [14] and [51].
In 1992, Casy and colleagues160 published results o f some o f the aryl-substituted 
analogues o f phenindamine o f the type [53] based on the synthetic pathway outlined in 
Scheme 1. The l3C NMR and ]H NMR data of the salts o f these analogues showed that 
the indene alkenic double bond was situated in the 9,9a position. No salts o f these 
analogues were isolated in which the position o f the double bond was situated at the 
4a,9a position.
N - C H
[53]
2.1«1 Nomenclature.
The nomenclature o f the phenindamine molecule is based on the fusion o f an indene 
fragment to a pyridine ring. Indene and pyridine rings can be fused in several ways 






Two structural isomers may be considered in naming phenindamine and its analogues.
The offic ia l IUPAC name o f [A] is 9//-indeno[2,l-c]pyridine and structure [B] is 
described as the l//-indeno[2,l-c]pyrid ine161. The letters and numbers within the 
brackets refer to the point o f fusion o f the indene and the pyridine as shown in Figure 
10 above. Thus, the two structural isomers o f phenindamine are officia lly named (under 
the IUPAC nomenclature rules) as
2-methyl-9-phenyl-2,3,4,9-tetrahydro-l//-indeno[2,l-c] pyridine for structure [14] and
2-methyl-9-phenyl-2,3,4,4a- tetrahydro-l//-indeno[2,l-c]pyridine for structure [51].
2.12 Pharmacology.
Lehmann demonstrated that phenindamine tartrate was a potent antagonist o f histamine 
at H j -histamine receptors. Phenindamine tartrate [14] was found to be a considerably 
more potent antagonist o f histamine than phenindamine hydrobromide [51] on isolated 
guinea pig ’s ileum, in the spray test, against intracardial histamine and against 
anaphylactic shock162. Recently, Casy et a/.,160 demonstrated that the 4a,9a isomer o f 
phenindamine was more active than the 9,9a isomer in in vivo studies. Phenindamine
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tartrate [14] was shown to be a very potent antagonist o f histamine induced 
hypotension in anaesthetised cats. Phenindamine tartrate [14] effectively protected 
unanaesthetised rabbits against lethal doses o f histamine163.
Phenindamine tartrate [14] was shown to reduce histamine induced gastric acid 
secretion in unanaesthetised dogs by a factor o f about 30%. Phenindamine tartrate [14] 
was also shown to be a effective as an anti-ulcer drug in rats163. These tests indicate 
that phenindamine tartrate [14] is a moderate H2-histamine antagonist.
The aryl-substituted 9,9a-ene analogues o f phenindamine showed little  or no 
antihistaminic activity when compared to phenindamine tartrate [14] in compound 
48/80 lethality tests160.
2.13 Toxicology.
Acute toxic ity o f Thephorin [14] was determined in mice , rats, and guinea pigs. 
Thephorin was about as toxic as benadryl. Fatal doses o f Thephorin caused severe 
convulsions followed by paralysis and cessation o f respiration.
Chronic toxic ity studies on oral administration were carried out in rats and dogs up to 
eight months without encountering severe symptoms. Blood analyses were normal and 
histological tissue examination did not show any pathological changes.
2.14 Clinical Uses.
Thephorin [14] has the properties and uses o f the antihistaminic drugs considered to act 
prim arily on H r histamine receptors. It is less potent than promethazine hydrochloride,
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but it does not produce drowsiness as encountered by many other antihistamines. I t  also 
has a moderate anticholinergic action.
Thephorin [14] is given orally in doses o f 25-50mg once or twice a day, indicating that 
it is a long-acting drug. It may be applied locally for the re lie f o f pruritic allergic 
dermatoses and insect bites/stings.
Thephorin [14] is used therapeutically fo r pallitative treatment in allergic reactions. It 
may be administered to seasonal hay fever sufferers. It has also been used for the 
prevention and treatment o f motion sickness.
2.15 Aims and Objectives.
So far, it has been demonstrated that the position o f the indene double bond o f the 
phenindamine structure is a major determinant o f antihistaminic activity160,162, and as 
yet, no analogues o f phenindamine salts have been isolated where the double bond is 
situated in the 4a,9a position. As a consequence o f this, a major aim o f this work is to 
synthesise analogues o f phenindamine in which the indene double bond is situated in 
the more pharmacologically active 4a,9a position. The use o f NM R and 13C N M R  
techniques is o f valuable use for determining the position o f the alkenic double bond o f 
the phenindamine analogues synthesised.
Before the discovery o f the I^-receptor14, Lehmann and Stefko163 realised that 
phenindamine tartrate , although a potent antagonist at the H r histamine receptor, was 
also a moderate antagonist at the H2-histamine receptor. W ith the evidence that very 
potent H2-histamine receptor antagonists such as cimetidine and ranitidine may cause 
stomach cancer in the long term, due to their ability to block completely the acid
38
secretion, it was anticipated that the synthesis of phenindamine analogues in which the 
N-2 position or at the aryl rings may produce a shift from H r  to H2-antihistamine 
activity.
Due to the rigidity of the phenindamine framework, analogues synthesised may be of 
use as probes for histamine receptor recognition.
Due to the increasing understanding of the importance of chirality in biological 
activity, this work also aims to separate the racemic mixture of the marketed 
phenindamine tartrate [14] and some of its analogues using chromatographic 
techniques, for pharmacological evaluations (See section 2.44).
Some studies of the fully reduced phenindamine analogues of structure type [54] w ill 




Syntheses o f phenindamine analogues where the fused rings are "broken" to form 
non-rigid compounds were also investigated. The emphasis of such a study was to try 
and retain the double bond in the right position for antihistaminic activity.
The detailed aims and objectives of the first part of this work thus entail:-
1) Synthesis and stereochemical studies of piperidine intermediates.
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2) Synthesis and stereochemical studies o f the diene compounds derived from the 
piperidines.
3) Synthesis and stereochemical studies o f N-2 and aryl-substituted phenindamine 
analogues.
4) Synthesis and stereochemical studies o f fully-reduced phenindamine analogues.
5) Synthesis o f  N-dealkylated products o f phenindamine and precursor piperidines and 
dienes, and subsequent realkylation with a variety o f substituents.
6) Synthesis and stereochemistry o f other analogues o f phenindamine.
7) Pharmacological evaluation o f the phenindamine analogues and some o f their 
precursors.
One pathway by which phenindamine analogues may be synthesised is by varying the 
substituent on the N-2 position (Scheme 1). This route, considered to be the Mannich 
Route, was to some extent researched by Plati and Wenner165, however, apart from  the 
microanalytical data, the compounds synthesised were not characterized fu lly , and only 
phenindamine was synthesised as the pharmacologically active compound.
2.2 T H E  M A N N IC H  REAC TIO N .
The synthesis o f precursors to phenindamine and its analogues involves the application 
o f the Mannich reaction. The first observation o f the Mannich reaction was made by
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3 PhCOCH3 + 3 HCOH + NH4C1 ► (PhCOCH2CH2)3N .HC1 + 3 H20
[55]
For the purpose of the present work, the Mannich reaction involved the condensation of 
formaldehyde and acetophenone with a primary amine. The reaction was catalysed by 
aqueous acid.
The present view of the reaction mechanism (Scheme 2) involves the nucleophilic 
attack by the lone pair electrons of nitrogen (of the primary amine) on the carbonyl 
carbon atom of the formaldehyde. This is followed by the elimination of water to yield 
a resonance-stabilized carbocation. Attack by the enol form of acetophenone on the 
carbon atom of the carbanion gives the mono-Mannich product. (Repetition of this 
process leads to the formation of the bis-Mannich product as the hydrochloride salt).
The carbonyl addition reaction is powerfully catalysed by the aqueous acid, since 
protnation of the carbonyl oxygen renders the carbonyl carbon considerably more 
electrophilic which in turn makes it more readily attacked by a nucleophile.
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SCHEME 2: THE MANNICH REACTION.
r -n h 2




H ,C == O H  ► R -+N ^C H 2/OH 4  R N = ^C H -
A H
H , C =  O
o f
H JH -V
ph— c ^ y  x =  Ph— c^ r
c h 2 ^ c h 2
o
P h- C — CH2-  C l f  NR HCI . PhCOCH.3’ H. . p h - C -  CH2-  CH2-  NHRHC1 
2 H2CO,





When the Mannich reaction was first carried out using two moles of acetophenone, one 
mole of the amine hydrochloride, excess formaldehyde, in the presence of 10% w/v of 
hydrochloric acid for a 0.75 h reflux, the mo«<?-Mannich base hydrochloride was 
isolated in compounds [56], [57] and [58]. Under similar conditions, but with 30% w/v 
dilute acid used, and a two hour reflux,*H NMR, 13C NMR and infra red data showed 
that the piperidine hydrochloride was formed in compounds [59]-[67] and [69] (See 
section 2.22). This was unexpected as it was thought that the /?/.v-Mannich product 
would be formed168. The next section involves the synthetic aspects in forming the 
piperidines and their stereochemical evaluations.
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2.21 The Piperidines.
Plati and Wenner165,167 synthesized a series o f the
l-alkyl-3-benzoyl-4-hydroxy-4-phenylpiperidines by the addition o f base to the 
6/s-Mannich products. As discussed earlier, the piperidines were obtained from the 
Mannich reaction. This result may be explained via aldol condensation mechanisms, 
which are discussed next.
Under the influence o f dilute base or dilute acid, two molecules o f an aldehyde or 
ketone may combine to form a p-hydroxyaldehyde or p-hydroxyketone. This reaction is 
called the aldol condensation. I f  the aldehyde or ketone does not have an a-hydrogen, 
the aldol condensation cannot take place.
Plati and Wenner161*’167 synthesised the piperidines from the ^/.y-Mannich product. This 
type o f reaction undergoes via a base-catalysed aldol condensation. As depicted in 
Scheme 3, the base catalysed intramolecular aldol condensation may be achieved by 
the addition o f a solution o f sodium hydroxide to a suspension o f the fc/.y-Mannich 
product. The mechanism o f this type o f reaction depends upon the base abstracting the 
acidic a-hydrogen o f the ketone, which in turn attacks the electropositive carbon o f the 
other carbonyl group forming the cyclized tertiary alcohol.
43
SCHEME 3: Base-Catalysed Aldol Condensation.
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As depicted in Scheme 4, the acid promotes the formation o f an ambient concentration 
o f the enol form o f the ketone, and this undergoes attack by the protonated form of the 
second molecule o f the carbonyl compound, a carbocation. The fact that the "one pot" 
Mannich reaction gave the piperidine hydrochloride was a result o f the formation o f the 
b/s-Mannich product (not isolated) followed by an acid catalysed aldol condensation.
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SCHEME 4: Acid-Catalysed Aldol condensation.
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For this work, the addition of aqueous base to the mr-mo Mannich products gave the 
corresponding piperidines (61] and [68] (Scheme 5). The route by which this reaction 
proceeds differs from the one explained above.
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Scheme 5.
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When the /mwo-Mannich base hydrochloride is added to a solutuion of sodium 
hydroxide (30% w/v) with stirring, the molecule can form two intermediates; the 
mono-Mannich base, and the vinylic ketone (via a Hoffmann degredation). These two 
compounds then combine to form the /?/.v-Mannich base. The /w-Mannich base readily 
cyclizes to the piperidine via the base catalysed intramolecular aldol condensation (see 
earlier).
The next section of the work deals with the stereochemical studies using ’ H NMR and 







2.22 Structural Evidence of the Piperidines.
Little  evidence apart from combustion analysis was published in the original 
work165,167. It was deemed important to investigate the structural evidence o f the 
piperidines using NMR techniques. The piperidines are chemically versatile 
intermediates168 and have been reported to exert biological activity169. The analogues 
synthesised in this work are presented in Figure 11 below;












The infra red spectra o f the piperidines synthesised showed the presence o f the C =0
stretch at around 1690 cm '1 and a small broad peak at 3400 cm '1 corresponding a to
tertiary hydroxy substituent, which was absent in the mono-Mannich products.
2.22.1 13C NMR Analysis o f the Piperidines.
The 13C NMR spectrum (Spectrum 1) o f 3-benzoyl-l-benzyl-4- 
hydroxy-4-phenylpiperidine [61] is used as an example to illustrate the structural
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SPECTRUM 1: 67.8 MHz 13C NMR (CDCI3) OF
3-BENZOYL-1-BENZYL-4-HYDROXY-4-PHENYLPIPERIDINE HCI [61J









evidence of the piperidines.
D ifficu lty  was experienced in assigning the aromatic carbons, as some o f the signals 
were very close to each other. Overlapping o f two o f the signals was experienced. Out 
o f the nine possible aromatic CH signals (equivalent CH signals were expected due to 
symmetry o f the compound), only eight were observed in the spectrum.
The aliphatic carbon atoms o f the methine, methylene and methyl were identified using 
DEPT experiments. Assignments o f the methylene carbons was based on their chemical 
shift. The highest field CH2 at 835.42 was assigned to the C-5, since nitrogen has a 
strong deshielding influence causing low field shift o f C-2, C-6 and the N-benzyl CH2. 
The lowest field methylene at 859.39 was assigned to the N-benzyl CH2 which is 
doubly deshielded by the nitrogen and the phenyl group. The C-2 carbon suffers 
p-deshielding effect from the 3-benzoyl group thus giving it  a lower field chemical 
shift (849.75) than the C-6 carbon. The signal at 846.41 was thus assigned to the C-6 
carbon. The C-4 quaternal signal resonated at 870.77, while the C-3 methine carbon 
appeared at 845.80. The carbonyl signal (8199.90) was within its expected range 
(8162-8214)170.
Only one signal for each carbon was present in the 13C NMR o f
3-benzoyl-l-benzyl-4-hydroxy-4-phenylpiperidine [61], im plying that only one 
diastereomer, out o f the possible two was formed (See section 2.22.3). The 13C NM R 
analyses o f the remaining N-siibsiiiuted piperidines (figure 11) were assigned in a 
sim ilar fashion to the example given above. Similarly, all the 13C NMR spectra o f the 
analogues showed only one signal for each carbon atom present. Table 4 (in 
Experimental) shows the.13C NMR data for the piperidine analogues (See section 5.22).
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2.22.2 *H NMR Analysis of the Piperidines.
To illustrate the structural analysis o f the piperidines synthesised, a 400 M Hz NM R 
(Spectrum 2) 3-benzoyl-4-hydroxy-l-methyl-4-phenylpiperidine [59] is used as an 
example.
The aromatic protons resonated in the region o f 87.90-7.10, in which two protons were 
deshielded and were assigned to the two ortho hydrogens o f the ring o f the benzoyl 
substituent. The remaining eight protons were centered around 57.5(3H), 57.4(2H), 
87.2(2H) and 57.1(1 H).
An unresolved doublet o f doublets at 82.93 was assigned to the equatorial H-2 proton. 
This proton was mainly assigned as such because it is in the equatorial plane and is 
p-deshielded by the benzoyl group. The equatorial H -6 proton was a multiplet at 82.77. 
A  multiplet at 82.72-2.65 which integrated to two protons was assigned to the axial H-2 
and H -6 hydrogens. The N-methyl singlet resonated at 52.39. The position o f this signal 
is comparable to the literature value (52.3)m .
The two most shielded signals were assigned to the H-5 protons. The multiplet centred 
around 82.07 was assigned to the axial H-5 proton, whilst the doublet o f triplets at 
81.84 was given to the equatorial 11-5 proton. The m ultip lic ity o f the former signal is 
due to one di-axial coupling with the axial H -6 proton, one axial-equatorial coupling 
w ith the equatorial H -6 and one geniinal coupling with H-5 protons.
The doublet o f doublets at 54.40 was assigned to the H-3 proton, as it is the most 
deshielded proton o f the piperidine ring due to the presence o f the electron withdrawing 
alpha carbonyl. The m ultip lic ity  o f this signal can be justified by the coupling o f one
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SPECTRUM 2: 400 MHz *H NMR (CDC13) OF
3-BENZO YL-4-H YDROX Y -1 -METH YL-4-PHEN YLPIPEREDINE [59]
ax H-3
J
axial-axial (11.28 Hz) and one axial-equatorial (3.22 Hz) interaction with the H-2 
protons. On the basis of these coupling constants the H-3 proton must be situated in the 
axial position. Consequently, the benzoyl group must lie in the more spacious 
equatorial plane. Lastly, the hydroxy proton (55.16) showed a doublet of magnitude 
2.56 Hz. This signal disappeared with the deuterium oxide shake (See section 2.22.3).
The piperidines synthesised have asymmetric centres in the ring, namely at the 3- and
4-positions. This can gives rise to four possible conformers (Figure 12). The *H and 13C 
NMR data for all the piperidines synthesised, confirmed that only one diastereomer 
was produced for each analogue. In all of the piperidines analogues, all of the H-3 
proton signals of the NMR were doublet of doublets with one large coupling 
(10.99-12.09 Hz) and one small coupling (4.43-4.03 Hz), indicating that it lies in the 
axial plane.
Out of the eleven piperidine synthesised, seven showed the hydroxy proton as a doublet 
(Table 5 in Experimental), the remaining four gave singlets (Table 6 in Experimental). 
The doublet from the hydroxy signal, and the axial position of the H-3 proton play a 
significant part in determining the conformation of the piperidines, which is discussed 
next.
2.22.3 Conformation of the Piperidines.
This section deals with the conformational analyses of the diastereomeric piperidines. 
Out of the possible four conformers illustrated in Figure 12, it is clear that conformer 
[C] will not exhibit intramolecular covalent hydrogen bonding between the 3-benzoyl 















Conformers [A] and [C] show that the 3-methine proton o f the ring is situated in the 
equatorial plane, and as stated earlier (See Section 2.22.2), the piperidines formed had 
the 3-methine proton in the axial position. On this assumption, it would seem unlikely 
that such a structure would be formed from the aldol condensation, and thus ruled out. 
Out o f the remaining two possible stereomers, conformer [B] exhibits a W-pathway 
from the hydroxy proton to the axial H-5 proton (see Newman Diagram, Figure 13). A 
W-pathway o f this nature only exists i f  the molecule concerned is o f a Fixed 
orientation, as is the case in this example (due to conformational restriction caused by 







Newman Diagram for Structure [B]
I f  a W-pathway exists between the 4-hydroxy proton to the axial H-5 proton, a doublet 
of magnitude 1-3 Hz of the proton NMR signal of the hydroxy proton would be 
observed. Thus, the seven piperidine analogues that showed such a doublet, must 
therefore have structure [B]. Structure [DJ thus corresponds to the remaining four 
piperidine analogues as the H-3 proton is axial and no W-pathway exists; the hydroxy 
does not show up as a doublet. The apperarence of the doublet signal of the 4-hydroxy 
proton was also reported by Casy and Co-workers160.
2.22.4 Mass Spectral Analyses of the Piperidines.
Analyses of the mass spectra of the piperidines showed the molecular ion (M +). 
Common major signals were detected indicating a similar molecular "backbone" exists. 
A similar breakdown pattern was also seen (Table 1, Scheme 6).
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SCHEME 6.




ION TYPE  
A B C D E
[59] 8 82 57 21 26 -
[60] 57 100 69 25 8 -
(61) 1 100 89 30 26 23
[621 13 100 69 30 - 43
[63] 7 100 80 19 1 14
[641 1 47 37 9 1 1
[65] 1 100 81 31 1 15
[67] 1 100 79 36 1 9
[69] 1 81 61 24 1 6
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2.3 THE 2.3-DIHYDRO-l//-INDENO[2,l-c]PYRIDINES.
2.31 Synthesis of Cyclic Dienes.
The synthesis o f the diene compounds 2,3-dihydro-\H -  indeno[2,l-c]pyridines can be 
carried out in two ways171. Firstly, they can be prepared directly from the to-M annich 
hydrochloride using hydrobromic acid (40-48%) or concentrated sulphuric acid at 
elevated temperatures. Alternatively, they may be synthesised from the corresponding 
piperidine with the same dehydrating reagents. For this work, all the dienes (Figure 14) 
were synthesised from the corresponding piperidines. The analogues synthesised are 
presented below;
COMPDNo. R 










The reaction mechanisms involved in the synthesis o f the diene compounds from their
corresponding piperidines are ring closure and dehydration. As depicted in Scheme 7, 
the in itial process involves protonation o f the 4-hydroxyl substituent to form the 
carbocation with the consequent loss o f water. The alkene formed then cyclizes to give 
the tricyclic ring system via a second dehydration process, in which the double bond 
from the aromatic species attacks the carbonyl carbocation. The aromaticity is then 
regenerated by the abstraction o f the proton o f the ring by the negatively charged
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carbonyl intermediate. Once the tricyclic compound is formed, the tertiary alcohol is













2.32 Evidence of Structure of the Dienes.
R
The infra-red spectra o f the dienes synthesised showed the absence o f the carbonyl 
stretch (1690 cm '1), and the hydroxyl stretch at around 3400 cm*1 present in the 
precursor piperidines.
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2.32.1 *H NMR Analysis of the Dienes.
For the purpose of discussing the structural evidence of the dienes, the *H NMR 
spectrum of 2-ethyl-9-phenyl- 2,3-dihydro-l//-indeno[2,l-c]pyridine [71] (Spectrum
3)is used as an example.
The aromatic signals were observed as a multiplet centred at 87.63. The lowest field 
aliphatic signal (86.63) was assigned to the vinylic H-4 proton. This is because it is 
fully conjugated to the aryl groups giving it a lower field resonance than the other 
non-aromatic protons. The H-4 proton resonance appeared as a triplet due to the equal 
coupling of the two H-3 protons. The signal up-field from the H-4 resonance (84.45), 
which integrated to two hydrogens can be assigned to the H -l protons because it 
appears as a singlet as vicinal protons are absent. The signal centred around 84.16, is 
due to the H-3 protons, which appears as a broad singlet. Ideally, this signal should be a 
doublet due to the coupling with the vinylic proton.
Since the geminal protons at C -l (84.45) have the same resonance position, their 
magnetic environment cannot differ. Similarly, geminal protons at C-3 (84.16) are 
equivalent This situation is probably brought about by a rapid (NMR-fast) 
interconversion between the two chair conformations of the nitrogen-containing ring 
(Figure 15, below).
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I f  the conformational interconversion is slow (NMR-slow), then the geminal pairs o f 
protons at C -l and C-3 become non-equivalent, and their chemical shifts would differ. 
Such protons may produce multiplet resonance signals.
The *H NM R spectra o f compounds [72](R=CH2Ph), [74](R=butyl),
[75](R=CH{ CH2CH3} 2), [76](R=hexyl), [77](R=cyclohexyl) and
[78](R=cyclohexylmethyl) were far more complex than the original one described 
above. It must be assumed that the complexity o f these spectra must be due to the 
NMR-slow interconversion rate. To illustrate this, the spectrum of 
2-butyl-2,3-dihydro-l//-indeno[2,l-c] pyridine [74] is analysed below (Spectrum 4).
Firstly, the geminal pair o f protons at C -l (ax H - l:  4.30ppm, eq H - l:  4.54ppm) and 
C-3(ax H-3: 4.06ppm, eq H-3: 4.36ppm) are magnetically non-equivalent. In 
consequence, each geminal pair gave rise to an NMR signal o f an AB type (doublet 
pair o f separation 13-16 Hz., typical o f geminal coupling) further complicated by 
vicinal coupling to +N-H and H-4. Thus the C -l protons produced a net doublet o f 
doublets, whilst the C-3 pair formed a doublet o f triplets because these protons are 
v icinally coupled to the vinylic H-4 proton as well as the +N-H. Assignments o f signals 
in the region 4-5ppm could be made with confidence on this basis even though the two 
AB  pairs overlapped.
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SPECTRUM 4: 270 MHz 'H NMR (CDC13) OF
0 >
2-BUTYL-9-PHENYL-2,3-DIHYDRO-l//-INDENO[2,l-c]PYRIDINE HBr [74].
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2.32.2 13C NMR Evidence of the Dienes.
As an example, the 13C NMR spectrum (Spectrum 5) of
2-(l-ethylpropyl)-9-phenyl-2,3-dihydro-l//-indeno[2,l-c] pyridine hydrobromide [75] 
is analysed. The assignments of the carbons were based on DEPT experiments and 
chemical shifts. Seven signals were observed for the aromatic C-H (6115.44-129.06). It 
was accepted that overlapping had occurred as there should have been nine. Three 
signals were detected for the aromatic Cq(5131.85-142.49).
The methylene carbons were assigned on chemical shift grounds; the highest field 
signals at 621.57 and 521.05 was assigned to the N-CH(CH2CH3)2, whilst the lowest 
field methylenes were assigned to C-l (646.67) and C-3 (547.52) respectively. The high 
field methine signal at 663.96. was assigned to N-CH(CH2CH3)2, and two signals at 
69.99 and 59.86 were assigned to the methyl signals (N-CH[CH2CH3]2). The aliphatic 
quatemal signals at 5121.21, 5131.85, and 5133.02 were assigned to the C-4a, C-9a, 
and C-9.
2.32.3 Mass Spectral Analysis of the Dienes.
The mass spectra of the diene analogues did not show many fragment ions under low 
eV. E.I., probably due to the stability of the ring system. The results are presented in 
Table 2, and the fragmentation is outlined in Scheme 8 below.
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TABLE 2.
COMPD. No. M*+ M +- l M ,+-2
[70] 100 55 33
[71] 96 29 16
[72] 100 27 6
[73] 66 22 31
[74] 100 80 23
[75] 96 100 13








2.4 N-2 SUBSTITUTED P H E N IN P A M IN E  ANALOGUES.
As stated earlier (Section 2.1), phenindamine was first synthesised by Plati and 
Wenner157’158 via the Mannich route. Two geometric isomers were isolated, one as the 
tartrate salt [14], and the other as the hydrobromide salt [51].
4
4a
N - C H
[14][51]
In 1992, Casy and colleagues160 published some results o f some o f the aryl-substituted 
analogues o f phenindamine. These compounds, all 9,9a-enes, however showed little or 
no activity at the Hj-histamine receptor. They confirmed that the position o f the indene 
double bond was a major factor for antihistaminic activity. For the purpose o f this 
work, it was hoped that varying the substituent at the N-2 site may affect the position of 
the indene double bond to shift from the 9,9a position to the more active 4a,9a site.
2.41 Synthesis o f Phenindamine Analogues.
Plati and Wenner157 reduced 2-methyl-9-phenyl-2,3- dihydro-l//-indeno[2,l-c]pyridine 
hydrobromide [70] with Raney nickel at room temperature for 4 h to give 
phenindamine hydrobromide [51]. The hydrobromide [51] was basified and treated 
with D-tartaric acid to give the pharmacologically active phenindamine tartrate [14].
Casy et a/.,160 successfully synthesised aryl-substituted phenindamine analogues 
(where the indene double bond was situated in the 9,9a position) from their precursor
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diene analogues using palladium catalyst at room temperature but under pressure. The 
reduction process used in this work was similar to the one used by Casy and 
co-workers160 but an examination of the reaction time was also included as part of this 
work. The longer reaction time afforded a cleaner product. It was also found that the 
reaction time was a major factor involved in the isomerization of the mono-enes (See 
section 2.42).
A selection of the N-substituted dienes synthesised in this work (See below) were 
reduced under mild catalytic conditions to give their corresponding mono-enes 
(phenindamine analogues). For some of these analogues, the anionic components were 
changed to try to isomerise the indene double bond from the 9,9a to the 4a,9a position. 
For some of the analogues, this was achieved, and is discussed next.
Scheme 9 illustrates the catalytic reductions of a selection of the dienes. In all cases 
where the diene hydrobromides were catalytically reduced for a period of 6 h, the 
double bond in the products were found to be situated in the 9,9a position. However, 
when some of the analogues were reduced with a longer reaction time (16 h), isomeric 
mixtures were observed in the NMR spectra of the recrystallized products. When diene 
[76](R=hexyl, X=Br) was reduced for 48 h, only the 4a,9a isomer [85] was isolated 
(78% yield).
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When the 9,9a-enes o f compounds [80](R=CH2Ph, X=Br) and [81](R= CH2CH2Ph, 
X=Br) were basified and then convened to their corresponding hydrochloride salts, the 
indene double bond shifted to the 4a,9a position (compounds [88] and [89] 
respectively). When compound [51](R=Me, X=Br, 9,9a-ene) was convened to its 
corresponding HC1 salts the alkenic bond did not shift (compound [86]). However, 
when compound [79](R=Et, X=Br, 9,9a-ene) was convened to its HC1 salt, a mixture o f 














When compound [80](R=CH2Ph, 9,9a-ene) was dissolved in ethanol and stirred with 
palladium at room temperature for three weeks, an isomeric mixture o f the 9,9a and 






The results obtained from the analogues synthesised show that the position o f the 
indene double bond may be dependent on the anion present and/or the substituent at the
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N-2 position. A detailed examination of these results indicate that a more logical 
solution may exist.
Although both double bonds of the diene molecule are conjugated to the phenyl 
substituents, the 4,4a alkenic bond is less hindered (as the 9,9a alkenic bond is flanked 
by the 9-phenyl substituent) and hence more accessible for reduction. Thus, no 
analogues of phenindamine are formed with the double bond in the 4,4a position (See 
section 2.1). Consequently, phenindamine analogues with the double bond situated in 
the 9,9a position are afforded.
This, however, does not explain the formation of the 4a,9a-enes, which have been 
detected following reduction. It is apparent that a more complex process might be 
taking place to produce the 4a,9a-enes. Due to the mild conditions required for the 
reduction of only one of the two possible alkenic bonds in the diene derivatives, the 
remaining double bond, if left long enough with the catalyst may undergo co-ordination 
and subsequent isomerization.
2.42 Isomerization of Alkenic Double Bonds.
Isomerization is the process by which chemical bonds or groups are redistributed 
within a given molecule. Alkene isomerization involves the redistribution of the C=C 
double bond within a molecule. Many d-block elements are capable of co-ordinating to 
an alkene, and thus affect isomerisation172. During metal catalysed isomerization, an 
alkene undergoes two activation processes; activation by co-ordination and activation 
by addition.
It is the activation by addition process which is responsible for moving the hydrogen
6J9
atom around. Double bond migration essentially involves movement o f the hydrogen, 
from the a lly lic position to the a-carbon atom o f the double bond;
i O c  i c  c
It is this process which the metal complex catalyses. Mechanistically, two main types 
o f isomerization have emerged. Those involving metal-alkyl and those involving 
metal-allyl intermediates.
2.42.1 Isomerization via M etal-A lkyl Intermediates.
The essential species in this sequence is a metal-hydride complex. Co-ordination o f the 
alkene gives a hydrido-alkene-metal complex which rapidly undergoes a hydride ligand 
migration reaction to form a metal-alkyl species (Scheme 12). The migration probably 
occurs via a four-centre transition sta.j and is extremely rapid for almost all 
transition-metal hydrido-alkene complexes. Once formed, the metal-alkyl species can 
undergo a p-elimination proximity interaction via either Path A or Path B.
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SCHEME 12.












Path A results in no net migration o f the double bond. Path B, in which the hydrogen 
abstraction occurs at the sites other than at which the initial H addition occurred, results 
in a net migration o f the double bond one position along the "chain". Providing the 
alkene co-ordinated to the metal can exchange with alkene present in the reaction 
medium, the above sequence o f reaction constitutes a catalytic isomerization cycle.
In the above isomerization system, the active metal-hydride species was either added as 
such or generated in situ from a suitable hydrogen source. In the second mechanistic 
class o f metal-catalysed isomerization reactions, the metal hydride species is generated 
from the suitable alkene.
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2.42.2 Isomerization via Metal-Allyl Intermediates.
An alternative pathway leading to alkene isomerization (Scheme 13) is via the
double bond to give the hydrido-metal-allyl species. In such a species, generally 
referred to as an ally l complex, the C3 unit is then n bonded to the metal, all three 
carbon atoms are w ithin bonding distance o f the metal centre and the unit effectively 
occupies two co-ordination sites in the complex.
Whether or not double bond migration occurs depends on how the hydride is 
re-inserted back to the ally l unit. Path X results in no net movement o f the double bond. 
Path Y  moves the double bond one step along the carbon skeleton.
In going from the 7i-alkene complex to the hydrido-7t-allyl species there is an increase 
o f the two units in both the formal oxidation state and co-ordination number o f the 
metal centre. Unlike metal-alkyl isomerization systems previously discussed, the 
isomerization catalysis cycle involves the 7i-allyl-metal species involves a redox 
sequence. Such a sequence can be adapted to the palladium catalyst;
formation o f a metal-allyl complex. In this sequence in itia l alkene co-ordination is 
followed by hydrogen abstraction from a sp3 hybridized carbon centre adjacent to the
SCHEM E 13. H  CR’R ”
M -







Pd° ► Pd2 ► Pd°
This mechanism is only available to metal complexes in a low oxidation state, for
which x+2 is readily attainable, as is the case for palladium173.
The common feature of the two alkene isomerizations outlined above is the presence at 
some stage in the catalysis cycle of the metal-hydrido species. Palladium has been 
researched in the isomerization of several types of alkenic molecules, in some 
organometallic reactions173,174,175 As a catalyst, palladium, may be implicated in such 
isomerization processes.
2.42.3 Isomerization of Phenindamine Analogues.
Both explanations are supported by the fact that when [79](R=Et, X=Br) was reduced 
for a period of 6h, only the 9,9a ene was produced, however, when the same starting 
material was reduced for 18 h, a mixture of the 9-9a ene and 4a-9a ene products were 
afforded. Also, when the diene [76](R=hexyl) was reduced for a period of 48 h, only 
the 4a-9a ene isomer was afforded in high yield (78%). Furthermore, when compound
[80](R=CH2Ph, 9,9a-ene), was stirred with palladium in ethanol for a long period of 
time, in the absence of hydrogen, a mixture of isomers resulted. This experiment 
showed clearly that the palladium is involved in isomerization of alkenic bonds.
Thus, the reduction products are susceptible to isomerization by the palladium catalyst 
if time permits. The hydrogens required for the isomerization process can either be 
abstracted from the compound concerned, or from the H2 in the hydrogenation vessel. 
However, it is more likely that the hydrogens are abstracted from the compound; 
isomerization of [80](R=CH2Ph, X=Br, 9,9a-ene) in the absence of H2 did afford a 
mixture of isomers [90](R=CH2Ph, X=Br).
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In principle, all reactions are reversible; an equilibrium distribution of products will 
result from any reaction if proper experimental conditions are found. In practice, 
however, it is often difficult or impossible to reach equilibrium, and nonequilibrium 
product distribution results. Thus, for the purpose of this work, the hydrogenation of the 
dienes, the 9,9a-ene isomers are formed faster than the 4a,9a enes as the 4,4a alkenic 
bond is less sterically hindered and more accessible for reduction. Such a process is 
thermodynamically controlled (a reversible reaction) and hence affords the 
thermodynamic products. However, when the reaction conditions are altered (by time 
or other parameters), whereby irreversible conditions are imposed, the reaction is 
governed kinetically. Thus, it would be true to say that the 4a,9a enes are the kinetic 
products.
2.43 Structural Evidence of the Phenindamine Analogues.
2.43.1 13C NMR Evidence of Phenindamine Analogues.
The assignments of the non-aromatic CH signals were based on the chemical shift data 
already published160. It was realised that a CH signal observed around 55ppm may be 
assigned to the 9-carbon atom, whilst a CH signal situated at approximately 45ppm 
may be assigned to the 4a-carbon atom.
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(54-56ppm 13C NMR) 
H
% 4-46ppm  13C NMR)
The 13C NMR spectra o f the phenindamine analogues synthesised provided evidence o f 
the presence o f either one single structure, epimerization (with respect to the nitrogen 
atom) or isomeric mixtures. These observations are discussed in more detail below.
The 13C NMR spectra o f compounds [51](R=CH3, X=Br), [80](R=CH2Ph, X=Br) and 
[81](R=CH2CH2Ph, X=Br) showed doubling up o f some o f the signals. Compound 
[51](R=CH3, X=Br) had two high field aliphatic CH signals at 545.28 and 545.93 
clearly indicating the presence o f two epimers o f the 9,9a-ene isomer. The 13C NMR 
spectra o f compounds [80](R=CH2Ph) and [81](R=CH2CH2Ph) showed the presence o f 
only one high field CH signal (545.90 for [80] and 545.82 for [81]), however, other 
signals were duplicated, indicating that epimerization had occurred. The 13C NMR 
spectrum o f compound [79](R=CH2CH3, X=Br), showed the presence o f one high field 
non-aromatic methine signal (545.67), and all other signals were not duplicated 
indicating that only one epimer o f the 9,9a-ene salt was afforded.
The 13C NMR spectra o f mixtures [82](R=CH2CH3, X=Br), [87](R=CH2CH3, X=C1), 
[83](R=CH(CH2CH3)2, X=Br) and [84](R=cyclohexyl, X=Br), showed the presence o f 
two non-aromatic CH signals, one in the region o f 45ppm and the other around 55ppm. 
Other signals were also duplicated. This type o f duplication indicates that geometric 
isomers (9,9a- and 4a,9a-enes) were afforded.
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The 13C NMR spectra o f compounds [88](R=CH2Ph, X=C1) and [89](R=CH2CH2Ph, 
X=C1) also showed doubling up o f the signals, however, the high field methine signals 
allocated to the non-aromatic CH were in the region o f 55-56ppm. This indicates that 
epimers o f the 4a,9a-enes were afforded. This type o f epimerization is brought about as 
a result o f the two modes o f addition o f a proton to the nitrogen lone pair of electrons 




Usually axial addition is the preferred route as the N-R substituent adopts the less 
crowded equatorial conformation. However, epimers o f this kind are known in 
derivatives where a conformational change leads to a fall in the energy o f the axial N-R 
chair conformation. The epimeric ratio varied considerably in different N-2 substituted 
products depending upon the purity o f the solvent and o f the nature of the R group and 
counter ion.
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2.43.2 *H NMR Evidence of Phenindamine Analogues.
Assignments of all of the protons of the NMR spectra of the phenindamine 
analogues were difficult but resolution of the H-4a and H-9 protons were possible.
Most of the aliphatic protons were seen as multiplets around the region of 52-4.5, the 
aromatic signals were situated between 57 and 58. Using published data159 on 
phenindamine hydrobromide (9,9a isomer) and phenindamine tartrate (4a,9a isomer), it 
was possible to assign some of the protons of the phenindamine analogues by 
comparative deductions. The lowest field signal (54-5) were assigned to the H-9 proton 
(observed in the 4a,9a-enes and mixtures of geometric isomers), whilst the highest field 
signals were assigned to the axial H-4 proton in the region l-2ppm (only observed in 
the 9,9a-enes).
The 9,9a-ene compounds showed the presence of the axial H-4 protons as a doublet of 
quartets, which were absent in the 4a,9a-ene compounds. The *H NMR spectra of the 
4a,9a-enes showed the presence of the H-9 proton as broad signals. The *H NMR 
spectra, where geometric isomers were present, the H-9 signal integrated between 
0.2-0.5 of a proton, whilst the H-4a signal was part of a multiplet which included the 
H -l and H-3 protons.
The *H NMR spectra of compounds [81](R=CH2CH2Ph, X=Br) and 
[89](R=CH2CH2Ph, X=C1) are shown in spectra 6 and 7 respectively. It can be seen 
clearly that compound [81](9,9a-ene) is lacking the H-9 proton, although a peak at 
54.74 is observed which integrated to 0.5 of a proton and is in fact part of the multiplet 
around 54.41 assigned to the H -l protons. Also, an undefined doublet of quartets at
51.54 is assigned to the axial H-4 proton. Compound [89](4a,9a-ene) lacks the axial 
H-4 proton, but has a broad signal at 54.82 assigned to the H-9 proton.
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SPECTRUM 6: 270 MHz *H NMR (DMSO-d6) OF
2-PHENETHYL-9-PHENYL-2.3.4.4a-TETRAHYDRO-IW-INDENO|2.1-c]PYRIDINE
HBr [81) (9-9a ISOMER).
SPECTRUM 7: 270 MHz 'H NMR (DMSO-d6) OF
2-PHENETHYL-9-PHENYL-2.3.4.9 TETR A HYDRO- I//-IN  [)ENO| 2.1 -c|PYRlDINE 
HC1 (89) (4a-9a ISOMER)
FI




Overall, it was recognised that the *H NMR spectra of the phenindamine analogues 
complemented the corresponding 13C NMR spectra. For instance, if epimerization was 
evident in the 13C NMR, two exchangable singlets were observed for the +N-H proton. 
In conclusion, it was found easier to determine the structures of the phenindamine 
analogues using 13C NMR data than the *H NMR data, as the main emphasis of the 
compounds synthesised was to determine the position of the indene double bond i.e. be 
it in the 4a,9a or 9,9a position.
2.44 Chiral Separation of Phenindamine Analogues,
In the last fifteen years or so, chromatographic techniques, and particularly high 
performance liquid chromatography (HPLC) have become predominant in 
pharmaceutical analysis and separations, owing to their high speed, efficiency and ease 
of automation. This has been particularly true in the separation and analysis of 
enantiomers, where selectivities are often low, and high separation efficiencies are 
therefore critical. Chromatographic separation of enantiomers may be effected either by 
derivatization and separation of the resulting diastereomers, or by incorporation of a 
chiral species into the stationary or mobile phase. The development of chiral 
chromatography has been rapid in recent years, and a range of chiral derivatizing 
reagents, stationary phases, and mobile phase additives are now in use.
A variety of HPLC chiral separation techniques have been developed in recent years, 
some of which have proved suitable for preparative applications. Many racemates of 
known drugs have been resolved using such procedures, including the phenothiazine 
antihistamine trimeprazine which was resolved into its antipodes at greater than 95% 
optically purity176.
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F IG U R E  18.
8
Chiral separation o f phenindamine tartrate 
using SGE-C8 8/5 column containing 
P-cyclodextrin hydrate,
•"»—i— 
zs \ ° i
Chiral separation o f 2-phenethyl-9-phenyl- 
2,3,4,4a-tetrahydro- l//-indeno[2,1 -cjpyridine HBr 
using LC-ABZ column containingp-cyclodextrin hydrate.
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The criterion for chiral separation of compounds using HPLC techniques incorporated 
with a chiral complexing reagent such as p-cyclodextrins, is that the substrate should 
contain at least one aromatic substituent, and an electronegative atom. The chiral centre 
should be close (one or two bonds away) to the aromatic group, and be between three to 
four bonds away from the electronegative atom. Such criteria fit the phenindamine 
analogues synthesised.
The procedure for the separation of chiral compounds described by Cooper and 
Jefferies176, which was used for semi-preparative chiral separation of trimeprazine (an 
antihistamine), was also utilised for the chiral separation of phenindamine tartrate. The 
mobile phase used was acetonitrile and aqueous triethylammonium acetate (0.8% TEA 
v/v, acetic acid to pH4). The column (SGE-C8 8/5) contained 20mg/ml of 
(3-cyclodextrin hydrate. Base line separation was achieved (Figure 16). This implies 
that both enantiomers may be separated.
Thephorin [14] and seven other derivatives synthesised in this work (Figure 17) were 
examined using a LC-ABZ column and various mobile phases containing 
p-cyclodextrins to effect enantiomeric resolution. The derivatives used differed in the 
position of the indene double bond be it in the 9,9a position or the 4a,9a position. This 
would give rise to a chiral centre in the 4a position or 9 position respectively. The 
mobile phase was kept at an acidic pH (3.5) so that the analogues were always in the 
salt form. This is important as isomerization may result if the free bases were 
produced159. Of the derivatives used, and under these conditions only two compounds 
showed that chiral separation was achieved. These compounds were [79](9,9a isomer 
R=Et) and [81](9,9a isomer, R=CH2CH2Ph). Figure 18 shows the chiral separation of
[81]. Other parameters such as pH and solvent were changed to try and achieve
8 1




[14] R = CH3 [51] R = CH3
[85] R = Hexyl [79] R = CH2CH3
[88] R = CH2Ph [80] R = CH2Ph
[89] R = CH2CH2Ph [81] R = CH2CH2Ph
As a result o f these tests, it seems hopeful that within time these chiral molecules may
be resolved177, using semi-preparative techniques and hence allow evaluation o f the 
pharmacological activity o f the different enantiomers.
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2.5 THE 2,3,4,4a,9,9a-HEXAHYDR()-l//-INDEN()[2,l-c]PYRIDINES.
Plati and Wenner157 prepared the hexahydro product from the diene [70] by the use o f 
platinum oxide as the hydrogenating catalyst at 60-70°C to accelerate the absorption o f 
two moles o f hydrogen. Ham and Leeming178 also investigated the hexahydro 
compound [91] which was considered correctly to be a single compound using a 60 
M Hz !H NMR spectrometer. Treatment o f the base with potassium hydroxide in 
butan-l-ol gave a second isomer. Casy et a/.,160 synthesised and fu lly characterised the 
hexahydro product o f phenindamine (Scheme 14). The antihistaminic activity o f the all 
cis hexahydro product [91] was negligible whilst the trans-hcxahydvo product [92] was 
slightly active when compared to phenindamine tartrate.
SCHEME 14. H
Pd/C, H2,N - C H N - C H
60 °C, 6 h
[70] [91]
KOH, n-BuOH N - C H
[92]
The all cis product is denoted as such, when the hydrogens in the 9, 9a, and 4a 
positions are on the same side as expected from catalytic processes. The trans product 
is termed so, by epimerisation o f the c/.v-isomer at the H-9 hydrogen.
The aim of this work was to characterize fu lly  the N-dealkylated cis and trans 
hexahydro products and to realkylate with a variety o f substituents to try and modify
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the antihistaminic potency.
Catalytic reduction o f diene [72](R=CH2Ph) with palladium on charcoal at 70°C for 6 
hours yielded the all c/.v-9-phenyl-2,3,4,4a,9,9a-hexahydro-l//-indeno[2,l-c] pyridine 
[93] as the hydrobromide salt. Treatment o f the product with a hot suspension o f 
potassium hydroxide in butan-l-ol gave the trans product [94] (Scheme 15).
s c h e m e  i s .
N -  CH?Ph Pd/C>H: N - H





It was expected, that the catalytic product [93] would be o f a cis stereochemistry and 
would have no benzyl group. The mechanism by which the cis product is converted to 
the trans is one where the base (‘OH) would abstract the most acidic proton, which in 
this case is the 9-methine, and re-insert it to form the trans product179,180.
2.51 S tructura l Evidence for the Cis- and Trans-Hexahydro Products.
The ]H NMR (Spectrum 8) o f the cis product [93] showed a doublet corresponding to 
one proton at 54.56 with a coupling constant 5.86 Hz. The signal was assigned to the 
9-methine proton (on chemical shift grounds as well as multiplicity). The magnitude of 
the coupling constant is similar to the normal signal for cis stereochemistry. In
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SPECTRUM H: 270 MHz 'H NMR (DMSO-d6) OF THE Al.L CIS
9-PHEN YL-2.3,4,4a.9,9a-HEXAHYDRO- lW-INDENO|2.1-c)P r k iu INE HBr |93|
SPECTRU M  9: 270 MHz 'H  NMR (UMSO dh)O F  11 iE TRANS 
9-PHENYL-2,3.4.4at9.9a-H E X A H Y D R O -l// IND ENO |2.Tc|PYR lD INE HCI |94|
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comparison, the *H NMR (Spectrum 9) o f the trans product [94] gave a doublet at
54.55 with a coupling constant o f 9.89 Hz. These values can be explained in more 




For the cis isomer, the dihedral angle (<j>) between H-9 and H-9a is significantly smaller
than that in the trans epimer (20-30° in cis isomer, approaching 180° in trans epimer).
From the 3J/<j> relationship o f Karplus181, a dihedral angle approaching 180° should lead
to a coupling interaction o f greater magnitude than the one in the 20-30° range. Hence,
the magnitude o f 3J o f the H-9 doublet o f the trans epimer should be greater than that
o f the cis isomer i f  these arguments are valid, and this was found to be the case.
However, an eclipsed cis conformation (large J value) and a syaggered trans
conformation (small J value) is also possible.
The 13C NMR o f the cis isomer [93] gave the three methine signals at 539.76 ppm, 
542.62 ppm and 553.03 ppm, which correspond to the C-9a, C-4a, and C-9 respectively. 
The allocations o f these signals were based on those explained earlier for the 
phenindamine analogues, where it was shown that the 9-carbon signal was the most 
deshielded. However, in the absence o f the indene double bond, the 9a-carbon signal 
would be further downfield than the 4a-carbon as it  is (3-deshielded by the N-2 nitrogen. 
Similarly, signals at 539.15, 545.93, and 650.08 ppm were allocated to the C-9a, C-4a, 
C-9 carbons from the trans [94] 13C NM R spectrum.
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2.52 Re-alkylation of the Hexahydro Products.
In the presence o f base and dry solvent, the all cis hexahydro product [93] reacted with 
phenethyl bromide to give the m-2-phenethyl-9-phenyl-2,3,4,4a,9,9a- 
hexahydro-l//-indeno[2,l-c]pyridine [95] in 82% yield (Scheme 16).
SCHEME 16.
N -  CH9CH9PhN - H
[95][93]
The !H NMR spectrum o f [95] showed a doublet at 54.69 o f magnitude 5.9 Hz 
corresponding to the H-9 proton. The presence o f the phenethyl side chain was also 
detected, which was not present in the starting material. The 13C NMR of [95] showed 
the presence o f the N-CH2 (556.66) and N -C H ^ ^ P h  (521.31) signals which were 
absent in the starting material.
To summarize, the hexahydro products [93] and [94] were fu lly  characterized using 
NMR experiments. It was also realized that re-alkylation o f the N-2 unsubstituted sites 
may be possible. Further work on this section should include the realkylation o f the cis 
and trans isomers with varying substituents for comparative pharmacological analysis.
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2.6 N-DEALKYLATION.
One of the disadvantages of the synthesis of phenindamine analogues via the Mannich 
route (See section 2.1) is that only a certain number of primary amines can be utilised 
to produce N-2 substituted analogues of phenindamine. A variety of N-2 substituents 
that contain double bonds or other reducible groups cannot be used as the initial 
primary amine in the Mannich reaction as subsequent catalytic reduction to afford the 
phenindamine analogues may reduce the substituents. As a result, N-dealkylation of 
some of the phenindamine analogues and their precursors were investigated in order to 
prepare the dealkylated products which may then be re-alkylated with a wider range of 
substituents at the N-2 position.
There are several methods that are available for N-dealkylation reactions. These 
methods are well documented in the literature182’183’184’185. Apart from catalytic 
N-debenzylation, most N-dealkylation (including N-debenzylation) processes occur via 
a two-step synthesis. The first step involves the protection of the amine centre by 
substitution with another more accessible group which may be readily removed to give 
the desired product This first step is usually formed under mild conditions. The second 
step, which forms the N-dealkylated product, usually occurs under vigorous 
conditions185. The relatively severe reaction conditions necessary for the formation of 
the N-dealkylated product limits the synthetic utility. However, it has been found that 
carbamates, derived from 2,2,2-trichloroethyl chloroformates can be cleaved using mild 
conditions186.
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2.6.1 N-Dealkvlation of the Piperidines.
Although interest lay in the formation of the N-dealkylated products of phenindamine 
analogues, it was realised that N-dealkylation of the precursors (the piperidines and the 
dienes) was necessary for synthetic purposes.
When 3-benzoyl-l-benzyl-4-hydroxy-4-phenyl piperidine [61] was treated with
2,2,2-trichloroethyl chloroformate, the carbamate [96] was formed which was 
confirmed by NMR data. The 13C NMR spectrum of carbamate [96] showed the 
presence of the amide C=0 at 5146.15, and a low field methylene signal at 575.28 
corresponding to N-CO2CH2CCI3, which were absent in the starting material. The 
NMR spectrum showed the presence of two protons in the region of 55.09-4.66 
assigned to the methylene protons of the 2,2,2-trichloroethyl substituent.
Reaction of the carbamate [96] with zinc and acetic acid under reflux gave 
3-benzoyl-4-hydroxy-4-phenyl piperidine [97], which was isolated as the hydrochloride 
salt (Scheme 17), which was verified by microanalytical data. Subsequent cyclization 
of the product with dehydrating agents such as acetic acid and hydrochloric acid gave a 















The above method was used used to demethylate 3-benzoyl-4- 
hydroxy-l-methyl-4-phenylpiperidine [59] to give the carbamate [96]. Reaction o f the 
carbamate [96] with potassium hydroxide at elevated temperature gave a product which 
was black in appearance. The TLC showed a multicomponent product which was not 
















Catalytic reduction o f 3-benzoyl-l-benzyl-4-hydroxy-4- phenylpiperidine [61] with 
either palladium on charcoal at 70 °C for 6 h, or platinum hydroxide at the same 
temperature for 2 h gave the same product. NMR analysis o f this product showed that 
the N-benzyl grouping was eliminated, but, the carbonyl function at the 3-position o f 
the ring was reduced to the alcohol [98]. When the same catalytic conditions were 
repeated at room temperature, but with a longer reaction time (36 h), the starting 
material was recovered (Scheme 19, below).





2.62 N-Dealkvlation of the Diene.
Reaction o f 2-benzyl-9-phenyl-2,3-dihydro-l//-indeno[2,l-c] pyridine [72] with
2.2.2-trichloroethyl chloroformate gave the desired carbamate [99]. The 13 C NMR of 
carbamate [99] showed the presence o f a low field methylene CH2 at 875.22 which was 
assigned to N-CO2CH2CCI3, which was absent in the starting material. The aromatic 
signals o f the spectrum o f carbamate [99] integrated to 9 protons, whilst the starting 
material [72] had 14 aromatic protons.
Reaction o f the intermediate carbamate with zinc and acetic acid gave the 
N-dealkylated diene [100] which was characterised as the hydrochloride salt (Scheme 
20). The *H NMR o f the N-dealkylated product [100] showed the absence o f the
2.2.2-trichloroethyl substituent, in the sense that a singlet at 89.92 integrated to two 











2.63 N-Dealkylation of the Phenindamine Analogues.
2-Benzyl-9-phenyl-2,3,4,4a-tetrahydro-l//-indeno[2,l-c] pyridine hydrobromide [81] 
was basified with ammonia solution extracted into toluene and treated with
2,2 ,2-trichloroethyl chloroformate to give a thick yellow oil [101] which was then 
treated w ith zinc and acetic acid under reflux to give an isomeric mixture o f the 4a,9a 
and 9,9a-enes which was isolated as the HC1 salt (Scheme 21). This was confirmed by 
13C NM R data, which showed that there was two non-aromatic methine signals in 
which one was situated at 845.80 and the other at 854.91. The NMR spectrum 
(Spectrum 10) showed a signal at 81.42 (0.73 o f a proton) assigned to the axial H-4a 
and another signal at 84.68 (0.27 o f a proton) assigned to the H-9 proton (See Spectrum 
10). The fact that an isomeric mixture o f the N-dealkylated product [102] o f the 
phenindamine analogue was formed may mean that when the N-benzyl starting 
material was basified, a mixture o f the isomers was formed159,160.
SCHEME 21.
N CO?CH9CClN - CHoPh
[101]
[81]
i) Zn /AcOH, A
ii)  HC1
[102]
In conclusion, this work was successful in the sense that non-catalytic N-debenzylation 
was achieved for all the precursors. Further work would be required to N-realkylate 
with other alkyl substituents.
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SPECTRUM 10: 270 MHz lH NMR (DMSO-d6) OF 9-PHENYL-2,3,4,4a- AND 




rrr ' i , i u i ! , i— t — i 
7 . 6 7 . 5 7 . 4 7 . 3 7 . 2 7  l
T TT
2.7 T H E  A R E C O LIN E  ROUTE TO  P H E N IN D A M IN E  AN ALO G U ES.
The Mannich route cannot be exploited to give access to phenindamine analogues with 
different substituents in the two aromatic rings, and an alternative route was sought in 
which the two aromatic substituents are introduced separately. To this end, arecoline 
was selected as the starting material.
Scheme 22 outlines the route towards the synthesis o f phenindamine and its analogues. 
The reaction o f arecoline [103] with phenylmagnesium bromide gives a diastereomeric 
product o f esters [104] and [105]. Hydrolysis o f the esters gives the corresponding a- 
and p- acids [106] and [107]. The acids are converted to their acid chlorides ([108] and 
[109]) and then treated with aluminum chloride to give
2-methyl-9-oxo-9-phenyl-2,3,4,4a,9,9a-hexahydro-l//- indeno[2,l-c]pyridine [110]18S. 
Reaction o f the 9-keto product [110] with aryllithium  reagents afford the 
9-aryl-9-hydroxy-2-methyl-2,3,4,4a,9,9a-hexahydro-l//-indeno[2,l-c]pyridine [111] 
which i f  dehydrated should give 9-aryl-2-methyl-2,3,4,4a-tetrahydro-l//-indeno[2,l-c] 
pyridine [112] or 9-aryl-2-methyl-2,3,4,9-tetrahydro- l//-indeno[2 ,l-c ]pyrid ine [113].
Plati et fl/.,187, utilised the Arecoline route for the synthesis o f phenindamine. They also 
separated the two diastereomers (a- and p-) o f the esters by first crystallising the 
hydrobromide salt o f the a-isomer [104] from the reaction mixture. The mother liquor 
was then neutralized, extracted, and the free base was then converted to the oxalate 
salts to give the p-product [105]. They offered no discussion on the conformational 
aspects o f these two diastereomers.
Clarke and co-workers188, while investigating the pharmacological activity o f cocaine 
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corresponding alcohols. They stipulated that the p-alcohol showed intramolecular 
hydrogen bonding at high dilution, and as a consequence, assigned it  as the cw-isomer 
(c-3-OH r-4-Ph). The a- and p-esters were evaluated fo r biological activity. No N M R  
data were published to support their findings. These are reported in section 2.71.2.
The present work was undertaken to investigate the synthesis o f analogues o f 
phenindamine with various aromatic substituents at the 9-position. Particular interest 
was also taken to try and determine the stereochemical aspects o f the precursor 
synthesised, using NMR experiments.
2.7*1 Methyl l-Methvl-4-Phenvlpiperidine-3-Carboxvlates and 
l-Methvl-4-PhenvlpiDeridine-3-Carboxvlic Acids.
The reaction o f arecoline [103] with phenylmagnesium bromide gave a 
diastereoisomeric mixture o f methyl l-methyl-4-phenyIpiperidine-3-carboxylates [104] 
and [105]. Addition o f hydrogen chloride gas to the crude product in ether yielded the 
hydrochloride salt. Recrystallization from ethanol gave the a-isomer [104]. The mother 
liquor was evaporated and recrystallized from acetone to give the p-isomer o f methyl 
l-methyl-4-phenylpiperidine-3- carboxylate [105].
Hydrolysis o f the esters [104] and [105] with concentrated hydrochloric acid and 
consequent removal o f the formed methanol by distillation gave the corresponding a- 
and p-acids [106] and [107] (Scheme 23). The melting points o f the two isolated 
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2.71.1 Conformational Analysis o f the Isomers o f Methyl 
l-Methyl-4-Phenvlpiperidine-3-Carboxylates and their Corresponding Acids.
Due to the presence o f two asymmetric carbon atoms at the 3- and 4-positions o f the 
ring, four different conformers can be proposed for the diastereoisomers o f methyl

























Conformers [B] and [D] are unlikely to be the more stable trans and cis arrangements 
as they show the 4-phenyl substituents in the axial plane, and subject to 1,3-diaxial 
interactions. The remaining conformers [A ] and [C] are proposed for a- and (3-isomers 
which have been isolated as their hydrochloride salts in this work.
2.7.1.2 Spectroscopic Analysis o f Methyl l-Methyl-4- Phenylpiperidine-3-Carboxylates 
and 1-Methyl-4- Phenvlpiperidine-3-Carboxylic Acids.
The *H NMR spectra o f the diastereomeric esters [104] and [105], gave little 
conformational information: the H-4 (expected to be the most deshielded aliphatic 
proton) was not resolved sufficiently to allow measurements o f axial and equatorial 
couplings. As a consequence, NMR data o f the two separated ester products were 
not used to provide any stereochemical conformation discussed by Clarke et a/.,188.
The mass spectra o f the different isomers were obtained, there were some common 
peaks in both spectra, but a few fragmentation ions detected in the (3-isomer were not 
present in the spectrum o f the a-isomer (See Experimental).
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The *H NM R o f the two l-methyl-4-phenylpiperidine-3- carboxylic acids [106] and 
[107] showed marked differences (See spectra 11 and 12). The *H NM R o f the a-acid 
showed a spectrum in which individual signals were resolved sufficiently for the 
assignment o f individual protons. Using literature references170, it was calculated that 
the most deshielded protons (53.65-3.45) o f the piperidine ring are the protons situated 
in the 2-position. These protons would be more deshielded than the H -6 protons due to 
the p-deshielding effect o f the 3-carboxyl substituents.
A  triplet o f doublets at 53.39 was assigned to the axH-4 proton. Coupling constants o f 
3.5Hz. and 8.2Hz were measured. Another triplet o f doublets at 52.97 with sim ilar 
coupling constants was assigned to the axH-3 proton.
The trip let at 63.18 (which integrated to two protons) was assigned to the axial H -2 and 
axial H -6 protons. The multiplet centered at 53.65 was assigned to the equatorial H-2. 
The multiplet centered around 53.45 was assigned to the equatorial H -6. The most 
shielded protons were assigned to the H-5protons, in which the axial H-5 (52.21) was 
further downfield than the equatorial H-5 (51.91).
I f  the a-isomer has trans (r-3-COOH r-4-Ph) stereochemistry, then the H-3 proton 
would be axial to the H-4 proton. This was the case, as a triplet o f doublets was 
encountered for the H-4 proton which coupled to two axial protons (axH-3 and axH-5), 
and one ax/eq interaction with the eqH-5 proton. The same type o f splitting was 
observed for the H-3 signal (two ax/ax couplings with axH-4 and axH-2; one ax/eq 
coupling with eqH-2) (see Figure 21).
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SPECTRUM 11: 400 MHz 'H NMR (DMSO-d6) OF a -T R A N S - ( i 3-COOH-r-4-Ph) 
-1-METHYL-4-PHENYLPIPERIDINE-3-CARBOX YLIC ACID HC1 (106)
I lo
SPECTRUM 12: 400 MHz *H NMR (DMSO-d6) OF(3-C/5-(c 3-COOH-r-4-Ph) 
-1-METHYL-4-PHENYLPIPERIDINE-3-CARBOXYLIC ACID HC1 1107]
\r










axial /  axial
axial / axial
axial /  equatorial
(f-3-COOH r-4-Ph)
Thus the ]H NMR analysis o f the a-isomer o f the acid [106] clearly indicates that it is 
the trans (/-3-COOH r-4-Ph) isomer where the 3- and 4-methine protons o f the ring are 
situated in the axial plane. It was assumed that the (3-isomer [107] (below) was the cis 









The acids were treated with thionyl chloride to yield their corresponding acid chlorides, 
which were isolated. Friedel-Crafts acylation o f the a- or (3-acids with aluminium 
chloride gave the same product of
2-methyl-9-oxo-2,3,4,4a,9,9a-hexahydro-l/-/-indeno[2,l-c] pyridine [110] in reasonable 
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[110]O
The and 13C NMR of compound [110] isolated from the two separate reactions 
where the starting material was either the a- or the (3-acids were identical. The melting 
point o f the 9-keto product was very sharp indeed (190.5-191°C). This indicated that 
the product can only be the one isomer. The infra red spectrum showed the presence o f 
the C =0 stretch at 1710 cm '1. The 'H  NMR spectrum did not, however, give any 
information about the conformation o f the ketone [110]. The 13C NMR showed the 
presence o f the C =0 (8201.81), and one signal each for the C-9a(845.24) and 
C-4a(533.92), all other carbon signals were detected and were not duplicated indicating 
that only one isomer was present.
Reaction o f the ketone [110] with phenyllithium gave
9-hydroxy-2-methyl-9-phenyl-2,3,4,4a,9,9a-hexahydro-1H- indenoj 2,1 -cjpyridine 
[114] which was dehydrated to give phenindamine. The free base was converted to its 
hydrochloride salt and then recrystallized to give the 9,9a ene product [86] (Scheme 
25). The ]H and 13C NMR analysis o f this product was identical to the one synthesised
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via the Mannich Route, and so was the melting point.
SCHEME 25.
Reaction o f the same ketone [110] with 2-bromopyridine in the presence of 
butyllithium, afforded 9-hydroxy-2-methyl-
9-(2-pyridyl)-2,3,4,4a,9,9a-hexahydro-l//-indeno[2,l-c] pyridine [115] (Scheme 26), in 
low yield. Mass spectral data showed the presence o f the molecular ion (M + 280), as 
well as a fragment ion o f magnitude 262, which could be attributed to the loss o f water. 
Work was stopped at this stage. The eventual synthesis o f compounds [116] and [117] 









ii")NH46 H N - C H 3
►
N - C H
[117]
Overall, this work did demonstrate that this synthetic route is feasible for the synthesis 
o f aryl substituted analogues o f phenindamine, especially i f  halogenated groups are 
required to be inserted in the aryl fractions.
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2.8 OTHER P H E N IN D A M IN E  ANALOGUES.
In in vitro studies, it was shown that 3-benzoyl-4-benzyl- l-ethyl-4-phenylpiperidine 
[60] was a potent antagonist o f histamine at the Hj-receptor (See Chapter 4). As a 
result, an investigation into the synthesis o f analogues o f phenindamine o f type [118] 




As shown in Scheme 27, a Wolff-Kishner reaction o f
3-benzoyl-4-hydroxy-l-methyl-4-phenylpiperidine [59] afforded the intermediate
[119], which when heated gave 3-benzyl-4-hydroxy-l-methyl-4-phenylpiperidine
[120]. A number o f dehydrating agents were employed to dehydrate compound [120] to 
give 3-benzyl-l-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine [121], but were 




It has already been discussed (section 2.61) that the reduction product of 
l-benzyl-3-benzoyl-4-hydroxy-4- phenylpiperidine [72] using palladium hydroxide and 
heat afforded 4-hydroxy-3-(a-hydroxybenzyl)-4-phenylpiperidine [98]. It was realized 
that dehydration o f this compound would give 3-(benzylidene)-4-phenyl-l,2,5,6- 
tetrahydropyridine (an "open chain" analogue o f the dienes). When the reaction was 
carried out however, NMR data showed that "ring-opening" had occurred, i.e. the 
desired product was not synthesised (Scheme 28). A t this stage, the reaction for the 
formation o f "open chain" analogues o f phenindamine was not further investigated.
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OH SCHEME 28.
N - H N - HHO
[98]
H
Ph— C — CH2— CH2-  N — CH2— CH= C H - Ph 
s
The infra red spectrum of product [122] showed the presence o f a carbonyl peak at 
1690 cm*1, which was absent from the starting material [98]. The *H NMR spectrum o f 
compound [122] indicated that the product was in fact the E-isomer. The mechanism 














HCH2 c h 2 
[ 122]
Further work on this topic would be to re-examine the synthesis of
3-benzyl- l-methyl-4-phenyl-1,2,5,6- tetrahydropyridine [121] via the pathway depicted
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in Scheme 30, which utilises l-methyl-4-piperidone [123] as the starting material.








This route (the enamine route) would in fact be useful as various aromatic substituents 





This chapter deals with the synthesis and conformational studies o f novel diastereomers 
o f H istryl as potential histamine H r antagonists. This work was undertaken as a result 
o f the *H NMR evidence provided for the precise structure o f Histryl, which was 
shown to exist as two clearly defined conformers (See section 3.12.2).
H istryl [5] (l-methyl-4-piperidyl benzhydryl ether hydrochloride), was first synthesised 
in 194973, and was found to be a potent antihistaminic with sedative side effects74. 
Histryl is still in clinical use today and is marketed by SmithKline Beecham189,190. 
H istryl is also used in combination with other drugs to counter the effects o f the 
common cold191. Apart from its antihistaminic activity, Histryl was found to have 





3.1.1 Aims and Objectives.
The primary aim o f this work is to examine conformational aspects o f Histryl using *H 
NMR spectroscopy. A second aim w ill be to prepare and fully characterize 
diastereomeric analogues o f Histryl as potential Hj-histamine antagonists.
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The detailed aims and objectives of part of this work entails:-
1) An examination of the conformation of Histryl using modem NMR techniques.
2) The synthesis of 1,2- and l,3-dimethyl-4-piperidones.
3) The synthesis and separation of diastereomeric 1,2- and l,3-dimethyl-4-piperidinols.
4) Conformational studies of the piperidinols using NMR experiments.
5) Synthesis and stereochemical studies of diastereomeric Histryl analogues.
6) Biological evaluation of the Histryl analogues synthesised.
3.12 Structure of Histryl.
The structure of Histryl was derived from the diphenylhydramine "backbone", 
however, a piperidyl ring was introduced. Histryl, like many other classical 
antihistamines contains not only the CH2CH2N fragment, but also the X-CHAr2 group 
(See section 1.2). Due to the presence of the piperidyl ring in the molecule, Histryl may 
exhibit two different conformers, the significance of which is discussed next.
3.12.1 Conformation of Histryl.
Histryl can exist as two conformers, one in which the 4-methine proton of the ring is in 
the equatorial position, and the other when it is in the axial" plane (Figure 22). The two 
conformers come about by the interconversion of the two possible chair structures of
m
the molecule. Chemical shifts and coupling constants o f these protons in both 
conformers would be different for both structures.
FIGURE 22.
3.12.2 Conformational Analysis o f Histryl.
A 400MHz NMR o f Histryl (Spectrum 13) showed a broad signal at 83.8 and a 
septet at 83.61 each signal integrating to 0.5 o f a proton. The chemical shifts o f both 
signals were consistent with literature value for the methine signal o f the general 
structure RCH-OR (83.7 where R is an alkyl group)170. Poor resolution o f most o f the 
signals led to the use o f a technique o f measuring base widths and half widths o f the 
undefined signals previously reported by Ison and Cas.,81. The base width is a measure 
o f the base o f the signal (in Hz), and the half width is a measure o f the width o f the 
signal at half its height (also in Hz).
The broad signal (83.8) had a base width o f 24 Hz, and a more accurate half width o f 9 
Hz, which corresponds to a signal o f a proton experiencing two axial/equatorial and 
two equatorial/equatorial couplings. The literature170 average of axial/equatorial and 
equatorial/equatorial is in the region o f 5-6 Hz. This confirms that the 4-methine proton 
is in an equatorial position. The apparent septet (83.6) corresponds to two di-axial and 
two axial/ equatorial couplings. The base width is 40 Hz. Moreover, the *H NMR 
spectrum o f histryl, shows a doubling-up o f all the remaining signals confirming that 
there are two conformers present in the compound. The N-methyl signal shows two 
singlets (82.71 and 82.73), similarly, two singlets are observed for the Ph2CH-0- 
proton (85.6 and 85.7).
H
OCHPh
[A ] [B] OCHPh2
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The remaining protons o f the spectrum were assigned on chemical shift grounds. The 
equatorial H-2 proton was shown to be a broad signal at 53.4. A  broad signal was also 
observed at 53.2 and was assigned to the equatorial H -6 protons. A t 53.1, an undefined 
triplet o f doublets was assigned to the axial H-2. A t 52.7, the signal showed a rquHf -  
p l t t  . which corresponded to 4 protons, this signal corresponds to the N-methyl 
proton with the extra proton assigned to the axial H -6 proton. The broad signals at 62.2 
and 52.1 were assigned to the equatorial H-3 proton and the equatorial H-5 proton 
respectively. Lastly, a multiplet at the range 51.8-1.7 which integrated to two protons 
were assigned to the axial H-3 and axial H-5 protons.
The fact that the 400MHz *H NMR o f Histryl is showing two non-equivalent signals o f 
the same protons indicates that interconversion rate o f both possible conformers o f 
H istry l is slow enough to be detected (Figure 22). This phenomenon is known as 
NMR-slow. There are two possible reasons why most o f the signals o f the H istryl *H 
N M R  spectrum are broad. One may be due to efficient relaxation and the other to 
environmental changes.
The "efficient relaxation" would not be acceptable in this case as it depends upon the 
interconversion o f the histryl molecule from one conformer to the other being rapid 
enough as not to be detected within the NMR time scale (NMR-fast). In which case, an 
average signal o f the same proton for both conformers would be observed as a 
broadened line (this is a consequence o f the Heisenberg Uncertainty principle). It has 
already been discussed why there must be a slow NMR time scale.
The other alternative to why the signals are broadened must hence lie with the 
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environment to another is greater than the frequency difference of the proton 
resonances in the separate environments. Thus at one extreme, if the rate of exchange is 
very slow, the proton will appear as separate signals, and at the other, when the rate of 
exchange is very fast, they appear as a single line. In between, as is the case in this 
example, when the rate constant is comparable to the frequency difference, broadened 
lines are detected.
From these deductions, it can be said that histryl exists as a 1:1 ratio of the 4-axial and
4-equatorial Ph2CHO- conformers. As a consequence it was decided to try and 
synthesise and isolate conformationally restricted analogues of Histryl. It was 
considered this could be achieved by synthesising and separating analogues of novel 
diastereomeric analogues of Histryl by inserting a methyl group at the 2- and
3-positions of the piperidyl ring. This would enable pharmacological studies to be 
carried out to determine which conformer of Histryl confers biological activity and test 
the proposal151 that three-dimensional A t/A t  and N+ arrangement is an important 
criterion for activity. The pathway outlined in Scheme 31 was utilised for the synthesis 
of diastereomeric l,3-dimethyl-4- piperidyl benzhydryl ethers. The first pan of the 
synthesis involves the synthsis of l,3-dimethyl-4- piperidone, which is discussed next.
3.2 1.3-DIMETHYL-4-PIPERIDONE.
The overall mechanistic pathway for the formation of l,3-dimethyl-4-piperidone is 
shown in Scheme 32, in which methylamine [126] takes pan in a 1,4-conjugate 
Michael addition to methyl methacrylate [127]. The product anion [128] is formed 
which, in turn abstracts the available proton from the positively charged methylamine 
cation to yield methyl 2-methyl-3-(methylamino)propanoate [129]. A second Michael 
addition with ethyl acrylate takes place to give methyl
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SCHEME 32.
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3-[N-(2-ethoxycarbonylethyl)-N-methylamino]-2- methylpropanoate [ 130].
In a Dieckmann cyclization, the base abstracts an acidic hydrogen a to one of the ester 
substituents. Out of the two possible a-hydrogens from the diester product [130], the 
a-hydrogen of the methyl methacrylate chain is more stable, due to the +1 effect of the 
methyl group, and hence less acidic than the a-hydrogen of the ethyl aciylate chain. 
Consequently, the abstraction occurs at the latter chain yielding an ester enolate [131]: 
a nucleophilic addition to the second ester substituent giving the cyclized intermediate 
[132]. The intermediate is not stable and hence expels the methoxide ion to yield the 
(3-keto ester [133]. The expelled methoxide ion converts the product into the ketone. 
This drives the reaction to completion.
In the presence of aqueous acid, the ester is first activated [134] towards nucleophilic 
attack by the protonation of the carboxyl oxygen atom. Nucleophilic attack by water, 
followed by the transfer of a proton and elimination gives the (5-keto acid [135]. On 
heating (over 100°C), the (5-keto acid [135] is decarboxylated by a cyclic mechanism. 
The initial product is an enol [136], which rapidly converts to the corresponding ketone 
[137].
The next section deals with the synthesis and separation of diasteromers of
1,3-dimethyl-4-piperidinols.
3.3 l,3-DIMETHYL-4-PIPERIDINOLS.
Reductions of cyclic ketones are well documented in the literature192’193,194, both 
chemically and catalytically. By increasing the size of the reducing agents, the more of 
the thermodynamically less stable axial alcohol is thought to be produced. It is
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generally accepted that catalytic hydrogenation is thought to occur through cis addition 
of hydrogen to that side of the molecule which presents the least steric hinderance to 
adsorption by the catalyst195.
Casy and Jeffries196 reduced l,3-dimethyl-4-piperidone [137] with lithium aluminum 
hydride (LAH) to give a diastereomeric mixture of l,3-dimethyl-4-piperidinols [138] 
and [139]. They successfully isolated the a-isomer [138] as its hydrochloride salt. The 
p-isomer [139] was isolated as its methyl ester, which was then converted back to 
|3-l,3-dimethyl-4-piperidinol [139]. The same authors196 also postulated the 
conformation of the a- and (3-isomers, which is discussed next.
3.31 Conformation of 1,3-DimethvM-Piperidinols.
l,3-Dimethyl-4-piperidinol has two chiral centres, one in the 3-position and the other in 
the 4-position of the ring. This gives rise to four possible isomers (Figure 23). Two 






















Casy and Jeffries1 9 6  characterized the diastereomers of l,3-dimethyl-4-piperidinols 
using a 60 MHz *H NMR and stipulated that the a-isomer was the trans-(t 3-Me 
r-4-OH)-l,3,-dimethyl-4-piperidinol of conformation [A ] and the p-isomer was the 
cis-(c 3-Me r-4-OH)-l,3-dimethyl-4- piperidinol of conformation [C]. These findings 
were based on base width and half width measurements of the most deshielded protons 
(the 4-methines).
3.32 Synthesis o f Diasteroinc‘ric l,3-D imethvl-4- Piperidinols.
The same procedure adopted by Casy and Jeffries1 9 6  was used in this work (Scheme 
33), in which a mixture of isomeric l,3-dimethyl-4-piperidinols (from LAH reduction) 
was converted to its hydrochloride salt and then recrystallized to give 
a-l,3-dimethyl-4-piperidinol HC1 [138]. The only difference encountered from 
published results1 9 6  was that the free base of a-l,3-dimethyl-4-piperidinol [138] 
synthesised in this work, was infact a low melting solid (34-36°C), and not an oil.
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Derivatization of the diastereomeric piperidinols to the corresponding acetate esters
[140] and [141] and subsequent recrystallization gave the pure (3-acetate ester [141]. 
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A number of reductive reactions were carried out on l,3-dimethyl-4-piperidone [137] to 
give the corresponding piperidinols. When l,3-dimethyl-4-piperidone [137] was 
reduced with lithium aluminum hydride (LAH) or aluminum isopropoxide, a mixture o f 
isomers resulted. Similarly, when the piperidone was reduced catalytically with
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platinum oxide at 50 psi a mixture of diastereomers of 1,3-dimethyl-4-piperidinols 
[138] and [139] was also afforded. In all of the reductive conditions, the piperidinols 
afforded were distilled under reduced pressure to give colourless oils.
3.33 Evidence of Structure of l,3-Dimethvl-4-Piperidinols.
The infra red spectra of the l,3-dimethyl-4-piperidinols showed the presence of a large 
signal at 3200 cm' 1 corresponding to the OH stretch, which was absent in the starting 
material.
In order to ascertain the conformation of the piperidinols synthesized, the most 
deshielded signal of the NMR spectra, which was assigned to the 4-methine proton, 
was analysed. It was thought that the multiplicity of this signal, may provide coupling 
constants which would give sufficent information about the position of the 4-hydroxy 
and 3-methyl groups. Previous NMR characterization of the
l,3-dimethyl-4-piperidinols, were based base width and half width measurements of the 
4-methine signals on 60 MHz !H NMR spectrometer196 (See section 3.12.2).
The !H NMR spectra of isomeric mixture of l,3-dimethyl-4- piperidinols showed the 
presence of two lowest field signals assigned to the 4-methine protons. One was in the 
region of 53.8 and the other at 53.1. Both signals integrated to one proton, in which the 
most deshielded signal was assigned to the 4-methine proton in the equatorial position, 
and the other assigned to the 4-methine in the axial position170. In all of these spectra, 
the signals assigned to the H-4 protons were undefined, however, base width and half 
width measurements were calculated. Defined signals of these protons were observed 
in the corresponding esters (See section 3.34.1).
1 2 2
The 270 MHz NMR of isomeric 1,3-dimethyl-4-piperidinol isolated from the LAH 
reduction showed an undefined doublet of doublets at 53.8 assigned to the 4-methine 
proton situated in the equatorial position. The base width of this signal was measured at 
17.8 Hz, whilst the more accurate half-width corresponded to 10.1 Hz. The base width 
of 17.8 Hz is accounted for by one axial/equatorial and one equatorial/equatorial 
coupling constants (2x5 Hz) with the H-5 protons as well as an axial/equatorial 
coupling constant with the axial H-3 proton (approx. 5 Hz), giving a total value of 15 
Hz. The same spectrum also showed an undefined triplet of doublets at 53.1 
corresponding to 4-methine proton situated in the axial plane. The splitting patterns 
accounts for two di-axial (with axH-5 and axH-3) and one axial/equatorial (with eqH-5) 
interactions. A signal centred at 52.3 assigned to the N-CH3 protons was duplicated.
The *H NMR spectrum of isomeric piperidinol isolated from the platinum oxide 
reduction (at 20 psi) showed a doublet of doublets at 53.8 assigned to the 4-methine 
signal in the equatorial position. Coupling constants of 3.3 Hz and 6.6 Hz were 
measured. These coupling constants also verify that the 4-methine proton is situated in 
the equatorial position. The same spectrum also showed an undefined sextet at 53.1 
corresponding to the 4-methine signal in the axial plane. The ratios of the a- to 
p-isomers in the isomeric mixtures of the piperidinols were calculated by measuring the 
integral of the 4-methine signals from *H NMR spectra (Table 3), where a denotes the 
a-isomer whilst P denotes the P-isomer.
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TABLE 3.
COMPOUND CONDITIONS a P
1,3-Dimethyl-4-piperidone L iA lH 4 30 70
1,3-E)imethyl-4-piperidone Al[OCH(CH 3 ) 2 ] 3 50 50
1 ,3-Dimethy 1-4-piperidone Pt20  /  50 psi 27 73
1,3-dimethyM-piperidone Pt20  /  20 psi 14 8 6
The 270 MHz NMR spectrum of the pure a-l,3-dimethyl-4- piperidinol HC1 [138] 
gave an undefined triplet of doublets at 53.1 integrating to one proton was assigned to 
the 4-methine proton in the axial plane. A singlet at 52.2 was assigned to the N-CH3  
protons.
The NMR spectrum of the (}-l,3-dimethyl-4-piperidinol [139] showed an undefined 
doublet of doublets at 53.8 was assigned to the 4-methine proton situated in the 
equatorial position. The base width was measured at 13.7 Hz and a half width measured 
at 7.8Hz.
To summerize, the *H NMR spectra of the various diastereomeric
l,3-dimethyl-4-piperidinols show conclusively that the a-piperidinol has the trans 
(r-3-Me r-4-OH) conformation with the 3-methyl and 4-hydroxyl groups of the ring 
equatorial to one another and that the (Tpiperidinol has cis (c 3-Me-r-4-OH) 
conformation with the 3-methyl group situated in the equatorial plane and the 














The next section deals with the conformation of the l,3-dimethyl-4-piperidyl acetates 
to support the findings of the conformation of the l,3-dimethyl-4-piperidinols discussed 
above.
3.34 Synthesis o f l,3-D im ethvl-4-P ipendvl Acetate Esters.
As discussed in section 3.32, the a-isomer of l,3-dimethyl-4-piperidinol [138] was 
isolated as the hydrochloride salt from the LAH reduction. Isolation of the p-isomer 
from the mother liquor was not achieved and so the crude residue (which contained 
mainly the p-isomer) was basified to liberate the free base which was treated with 
acetyl chloride to form the acetate ester. The p-l,3-dimethyl-4-piperidyl acetate HC1
[141] was isolated from this reaction. The a-l,3-dimethyl-4-piperidinol [138] isolated 
as the hydrochloride salt, was basified and treated with acetyl chloride to yield the 
corresponding a-l,3-dimethyl-4-piperidyl acetate [140]. The acetates were prepared to 
validate the conformational assignments attributed to the precursor piperidinols.
3.34.1 Evidence o f Structure o f l,3-D im ethyl-4-P iperidvl Acetate Esters.
The *H NMR spectrum of a-l,3-dimethyl-4-piperidyl acetate hydrochloride [140] 
(Spectrum 14) showed a doublet of triplets centred at 54.8. The peaks were resolved 
sufficiently to measure their coupling constants. Coupling constants of 6.1 Hz. were
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SPECTRUM 15: 270 MHz lH NMR (DMSO-d6) OF 3-(C/5)-1,3-DIMETH YL-4-PIPERIDYL 
ACETATE ESTER [141].
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measured which corresponded to equatorial/equatorial or axial/equatorial interactions, 
and constants of 10.1 Hz corresponded to di-axial interactions. This signal confirms 
that the 4-methine proton must be situated in an axial position, which was expected as 
it is more stable, since the larger substituent prefers to be in the sterically less crowded 
equatorial position.
Spectrum 15, shows the *H NMR of the pure P-l,3-dimethyl-4- piperidyl acetate ester 
hydrochloride [141]. The most deshielded proton was an unresolved signal at 54.9 
which was assigned to the 4-methine proton. The signal width was 21.0 Hz, and the 
half width was 6.0 Hz. These measurements confirm that the proton lies in the 
equatorial plane showing two equatorial/axial interactions with axial H-3 and axial H-5 
as well as an equatorial/equatorial interaction with equatorial H-5.
Overall, the *H NMR evidence obtained from this work showed that the 
a-(rrfl/i5)-isomers (r-3-Me r-4-OR) [138] and [140] had the 3-methine and 4-methine 
protons in the axial positions giving rise to the highly stable axial-axial conformation. 
The p(c«)-isomers (c-3-Me-r-4-OR) [139] and [141] had the 3-methine proton in an 
axial position whilst the 4-methine was in the equatorial position.
3.4 l,2-DIMETHYL-4-PlPERIDlNOLS.
Other Histryl analogues may be synthesised by inserting a methyl substituent in the 
2-position of the ring rather than in the 3-position. The synthesis (Scheme 34) involved 
the stepwise Michael addition of ethyl crotonate [142] and then ethyl acrylate to 
methylamine [126] yielding the diester [143]. This diester in the presence of a strong 
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Reduction of l,2-dimethyl-4-piperidone [144] with platinum oxide at room 
temperature, under hydrogen gave the [3-1,2-dimetliy 1-4-piperidinol [146] exclusively 
as a white solid.
Reduction of l,2-dimethyl-4-piperidone [144] with LAH gave a mixture of 
diastereomers (a-[145] and [3-[146]). When the free bases were converted to the 
corresponding HC1 salts, and recrystallized from ethanol, a-l,2-dimethyl-4- piperidinol 
HC1 [145] crystallized out. Like the previous examples (See section 3.32) it was not 
possible to obtain a pure sample of the p-isomer from the mother liquor.
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3.4.1 Conformational Analyses of l,2-Dimethyl-4- Piperidinols.
Like the l,3-dimethyl-4-piperidinols, the l,2-dimethyl-4- piperidinols possess two 
chiral centres and hence four conformers can be drawn (Figure 24). Conformer [A ] is 
possibly the most stable as both the methyl and hydroxyl substituents are situated in the 
more spacious equatorial planes. Conformer [B] is the least stable as the 2-methyl and 
4-hydroxyl could suffer 1,3-diaxial interactions. Conformer [C] is probably more stable 
than conformer [D] due to steric hinderence that is encountered in the latter by the 







The next section o f this work deals with the conformational analyses of the
l,2-dimethyl-4-piperidinols synthesised using lH and 13C NMR data.
3.42 Evidence o f Structure o f l,2-Dimethyl-4-Piperidinols.
A similar spectroscopic procedure used for ascertaining the conformations of
l,3-dimethyl-4-piperidinols was adopted to evaluate the conformations of
l,2-dimethyl-4-piperidinols, whereby the most deshielded protons encountered in the 
!H NMR spectra were assigned to the 4-methine protons. These signals were used to 
validate the conformation o f l,2-dimethyl-4-piperidinols. As a rule is assumed that
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equatorial protons are more deshielded than axial ones170 attached to the same carbon 
atom. This criterion was used to assign the equatorial and axial H-4 protons.
The *H NMR of diastereomeric l,2-dimethyl-4-piperidino!s (Spectrum 16) (from LAH 
reduction) showed two signals, one at 54.1 which integrated to 0.2 of a proton, and the 
other at 53.66 which integrated to 0.8 of a proton, observed for the 4-methine proton. 
The quintet at 54.1 with coupling constants of 3.4 Hz indicated that there are two 
axial/equatorial and two equatorial/equatorial interactions, and as such, this signal was 
assigned to the 4-methine signal in the equatorial position. The triplet of triplets at 53.7 
was assigned to the 4-methine in the axial position as coupling constants of 4.6 Hz 
were recorded for axial-equatorial interactions (with equatorial H-3 and H-5), and 
coupling constants of 11.2 Hz were recorded for axial-axial interactions (with axial H-3 
and H-5).
The *H NMR spectrum of a -1,2-dimethyl-4-piperidinol [145] (Spectrum 17) showed 
only an undefined triplet of triplets at 53.7 was present corresponding to the 4-axial 
methine proton (see above). The spectrum showed no signal at 54.0 allocated to the 
4-methine signal in the equatorial position. The P-l,2-dimethyl-4-piperidinol [146] 
isolated from the platinum oxide reduction, gave a broad peak at 54.0 corresponding to 
the 4-methine signal in the equatorial position.
The *H NMR spectra of the 1,2-dimethyl-4-piperidinols confirm that the a-isomer has 
the 4-hydroxyl group in the equatorial position, and the p-isomer has the hydroxyl 
group in the axial position. The spectra however, did not provide sufficient information 
about the position of the of the 2-methyl substituent, although it was assumed that it 
was situated in the more spacious equatorial position.
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SPECTRUM 16: 270 MHz lH NMR (CDC13) OF DIASTER&jMERIC 
1,2-DIMETH YL-4-PIPERIDINOLS.
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CH3 (Hsomer [146]CH3 a-isomer [145]
The 13C NMR spectrum o f diastereomeric l,2-dimethyl-4- piperidinol showed 
doubling-up o f most o f the signals. Two different signals were clearly observed for the 
C-4 (668.37 and 657.47), C-6 (555.07 and 650.17), C-2 (543.40 and 641.09), C-2 
(642.68 and 642.07) and C-5 (535.06 and 532.92), although there was only one signal 
for the N-CH3 (642.13) and for CH3 at position 2 (520.47). The 13C NMR spectrum of 
a-l,2-dimethyl-4-piperidinol showed the presence o f only one signal for each carbon 
atom signifying that only one conformer was present.
3.5 H IS T R Y L ANALOGES.
Papa and co-workers197, synthesised a series o f benzhydryl ethers by reacting the 
precursor alkyl piperidinols with benzhydryl bromides, and other aryl substituted 
benzhydryl halides in the presence o f base. However, no conformational analyses were 
reported. Some o f the compounds synthesised by Papa et a/.,197 exhibited prolonged 
antihistaminic effects as well as substantial anticholinergic properties. The next section 
o f this work deals with the synthesis of novel conformationally restricted analogues of 
Histryl.
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3.5.1 Synthesis of l,3-Dimclhvl-4-Pipcridvl Benzhydryl Ethers.
The Williamson synthesis (Scheme 35) depends upon the ionisation o f the hydroxyl 
group o f the alcohol by a suitable base, and the subsequent nucleophilic substitution by 
the alkoxide ion o f the halide ion in the alkyl halide.
SCHEME 35.
CH CH
Cl— CH 047 ]
alcohol alkoxide






As depicted in Scheme 36, the reaction o f the rrart.v-l,3-dimethyl-4-piperidinol [138], 
in the presence o f dry potassium carbonate, with chlorodiphenylmethane [147] was 
successful in yielding r/w/j.v-l,3-dimethyl-4-piperidyl benzhydryl ether [148]. A similar 
reaction was employed using n'.v-l,3-dimethyl-4-piperidinol [139]. This reaction gave 
the desired product o f t7.v-l,3-dimeihyl-4-piperidyl benzhydryl ether [149].
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Initia l treatment o f the trims- l,3-dimethyl-4-piperidinol [138] with 
bromodiphenylmethane in the presence o f anhydrous potassium carbonate gave the 
starting material. A possible reason for the failure o f the reaction was thought to havs 
been concerned with steric hindrance. The bulky bromide atom may have impeded tie 
reaction; this was overcome by using the alkyl chloride. When sodium hydride was 
employed as the base, only(N-diphenylmethyl) methylamine HC1 [150] was isolatedin 
a 10% yield. This indicated that a degradation process o f the type illustrated in schene 
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3.5.1.1 Evidence o f Structure o f 1,3-Dimethvl-4-PiperidvI Benzhydryl Ethers.
The NMR spectrum o f /r«//.v-(/-3-Mer*4-OCHPh2)- l,3-dimethyl-4-piperidyl 
benzhydryl ether [ 148] (Spectrum 18), derived from the pure rrr/«i-l,3-dimethyl-4- 
piperidinol, showed a multiplei at 83.24 corresponding to three protons. This signal was 
assigned to the axial 4-methine, the equatorial H-2 and the equatorial H-6 protons. Due 
to the complexity o f this signal, no conformational assignment was made.
The NMR spectrum of c7.v-(c-3-Me r-4-OCHPh2)- 1,3-dimethyl-4-piperidyl 
benzhydryl ether [149] (Spectrum 19) gave a broad signal at 83.52 corresponding to 
one proton. This signal was assigned to the 4-methine proton an chemical shift grounds. 
The base width for this signal was calculated at 21.0 Hz, and the half width had a value 
o f 9.0 Hz. These results were similar to those found for the precursor piperidinol
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Sl'iXnU JN IJS: 270 Mllz 'II NMR (DMSO d6) OF 1,3-DIMETHYL-4-PIPERIDYI
BFNZIIYDRYL ETHER MCI [I48|
SPECTRUM 19: 270 'H NMR (DMSO-d6) OF C IS -  1.3-DIMETHYL-4-P1PERIDYL 
BENZHYDRYL ETHER OXALATE [149].
compound and hence the 4-methine proton was assigned to the equatorial position, with 
the benzhydryl substituent situated in the axial plane. This was unexpected as it was 
thought that a more stable conformer would be afforded by the bulky benzhydryl group 
occupying the equatorial plane through ring flipping.
3.52 Synthesis o f l,2-P im ethyl-4 -P iperidvl Benzhydryl Ethers.
The free base o f the a-l,2-dimethyl-4-piperidinol [145] was fused with 
chlorodiphenylmethane [147] in the presence of dried potassium carbonate in an 
anhydrous environment to give the corresponding a-l,2-dimethyl-4-piperidyl 
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The NMR spectrum of a-l,3-dimethyl-4-piperidyl benzhydryl ether [151] 
(Spectrum 20) showed that only one isomer was formed as no doubling-up of the 
signals occurred. The multiplet centred at 57.3 integrated to ten protons and was 
assigned to the aromatic hydrogens. The most deshielded aliphatic signal (55.7) was 
assigned to OCHPh2. Equatorial protons attached to the same carbon atom were more 
downfield than the axial protons. On this basis , the equatorial H - 6  proton (53.4) was 
more deshielded than the axial H- 6  (53.1). When compared with the H - 6  protons, the 




SPECTRUM 20: 270 MHz >H NMR (CDCl3) OF a -1,2-DIMETHYL-4-PIPERLDYL 
BENZHYDRYL ETHER MCI [151].
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A  singlet at 52.6 corresponding to three protons was allocated to the N-methyl 
substituent. A  doublet at 51.3 was assigned to the 2-methyl group. The multiplet at 52.2 
(2H) was assigned to the equatorial H-3 and equatorial H-5 protons. Similarly, the 
m ultiplet at 51.7 was allocated to the axial protons at C-3 and C-5. The most deshielded 
proton o f the piperidyl ring was a multiplet at 53.5. This signal assigned to the H-4 
proton.
In order to ascertain the conformation o f a-l,2-dim ethyl-4- piperidyl benzhydryl ether 
[137], the positions o f the benzhydryl and 2-methyl substituents needed to be 
investigated. However, both the H-4 and axial H-2 protons overlapped to some extent 
with neighbouring signals, so, the base width were not measured. Nevertheless, the half 
width o f H-2 signal was measured at 21 Hz, indicating that it  lies in the axial plane 
thus, leaving the methyl to occupy the more spacious equatorial position. The half 
width measurements o f the H-4 signal was calculated at 30 Hz, this, also indicates that 
the proton lies in the axial plane. Consequently, the benzhydryl substituent occupies the 
equatorial position.
Further work should include the synthesis o f the P-l,2-dimethyl-4-piperidyl benzhydryl 





In general terms, a drug interacts reversibly with a receptor to form a drug-receptor 
complex which then in some way produces a response. Under these conditions, the 
drug may be described as an agonist which will have an affinity for the receptor and 
also an efficacy or intrinsic activity at the receptor which results in the response. The 
potency of the drug is its ability to provoke the response; this is essentially a product of 
the affinity and the efficacy. So, a drug may have a poor affinity for the receptor but 
have a large effect there and appear to be very potent.
If  another molecule is able to compete with the drug for binding sites at the receptor 
and yet has no efficacy itself, it can thereby prevent the response to the drug and is 
described as an antagonist The term partial agonist also exists to describe drugs of low 
efficacy which does not provoke a full response.
4.1 PHARMACOLOGY OF PHENINDAMINE TARTRATE.
The biological activity of phenindamine tartrate is discussed in the literature161,162. 
Phenindamine tartrate was found to antagonise histaminic activity at Hj-receptor sites. 
What was interesting at the time was that phenindamine tartrate also protected dogs and 
rats, to some extent, against gastric acid secretion163. Phenindamine tartrate also 
possessed more potent anaesthetic actions than procaine hydrochloride161.
Phenindamine tartrate differed from other antihistaminic drugs studied in that it 
produced evidence of central excitation, of the nervous system, rather than depression. 
This effect of phenindamine was increased by amphetamine and caffeine, but the 
depressant action of promethazine was potentiated by phenindamine.
141
4.2 IN  V ITRO  E V A L U A T IO N S  A T  H IS T A M IN E  H r RECEPTORS.
4.21 Protocol.
Guinea Pig Ileum Preparation.
Female guinea pigs (approx 500g in weight) were killed by cervical dislocation and a 
piece o f distal ileum, approximately 3 cm in length, was removed from the ileo-caecal 
junction. The tissue was suspended isotonically in a 10 ml organ bath under a tension 
o f lg  and gassed w ith carbogen (95% oxygen and 5% carbon dioxide). The tissue was 
perfused w ith Tyrodes solution o f the fo llow ing composition:
NaCl, 40g/5L; KC1, 2g/5L; CaCl2, 9 ml o f 1M solution/5M; NaHC03,0.5g/5L; 
NaH2P 04, 0.325g/5L; M gC l2.6H20 , 2g/5L; Glucose 5g/5L.
A ll drug solutions and their serial dilutions were made up in Tyrodes solution.
The Tyrodes solution was maintained at 32°C and the tissue allowed to equilibrate w ith 
its bathing solution fo r 20 min before addition o f any agonists. One end o f each tissue 
preparation was attached to a hook on the gassing side arm while the other end was 
attached to a Washington T2 or T3 isotonic transducer which was linked to a 
Washington 400 MD2R oscillograph via a Washington FC 117 isotonic/isometric 
coupler. A  3 min time cycle was used which allowed histamine to remain in contact 
w ith the tissue for 30 seconds before it  was washed out, the tissue being allowed to 
recover for 2.5 min before the next agonist addition.
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Dose response curves were constructed for histamine in the absence and presence of 
phenindamine tartrate [14], and compounds [51], [59], [60], [70], [71], [82], [88] and 
[89] the tissue being allowed to equilibrate with each concentration of antagonist for 30 
min prior to retesting the agonist action of histamine.
Dose response curves were plotted as a percentage of the histamine maximum response 
in the absence of antagonists (y axis) against log10 of the histamine concentration 
(molar).
The standard error o f the means were within 10% in all cases and are omitted for the 
sake of clarity.
4.22 In  Vitro Results.
COMPOUND: Phenindamine Tartrate [14] (Thephorin).
N - C H
H 0 2CCH(0H)CH(0H)C02H
The dose-response curve (Figure 25) showed that phenindamine tartrate was, as 
expected, a good histamine Hj antagonist. However, what was interesting was that at 












FIGURE 25: DOSE-RESPONSE CURVE OF THEPHORIN 114| AGAINST HISTAMINE ON 
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Unlike Thephorin, piperidine [59] exhibits a dose-response curve (Figure 26) that is 
typical o f a non-competitive antagonist, when compared to histamine (agonist).




At a concentration o f l x lO '8 and l x lO '7 M, piperidine [60], appears to act as a good 
antagonist o f histamine at the Hj-sites. A t higher concentration ( l x l  0"6 M), the drug 











FIGURE 26: DOSE-RESPONSE CURVE OF PIPERIDINE |59| AGAINST HISTAMINE ON
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FIG UR E 27: DOSE RESPONSE CURVE OF PIPERIDINE (60) AGAINST HISTAMINE ON 
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COMPOUND: 2-Methyl-9-phenyl-2,3-dihydro-ltf- indeno[2,l-c]pyridine HBr [70].
The dose-response curve (Figure 28) shows that diene [70] is acting as antagonist to 
histamine, though, like Thephorin, it acts as a non-competitive inhibitor at high 
concentration o f the drug (1x10*6M).
COMPOUND: 2-Ethyl-9-phenyl-2,3-dihydro-l//- indeno[2,l-c]pyridine HBr [71].
Figure 29 shows the drug to be a good inhibitor o f histamine H j receptors even at high 












FIGURE 28: DOSE-RESPONSE CURVE OF DIENE |7()| AGAINST HISTAMINE ON
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FIGURE 29: DOSE-RESPONSE CURVE OF DIENE [7 11 AGAINST HISTAMINE ON 
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COMPOUND: 2-Methyl-9-phenyl-2,3,4,4a-tetrahydro-ltf- indeno[2,l-c]pyridine HBr
[51].
N -  CH 
HBr
The drug acts as a competitive inhibitor at a concentration o f lx lO *8 M, but is 
non-competitive at 1x10'7M. The drug is inactive at 1x10'6M concentration (Figure 30).
COMPOUND: Structural isomers o f 2-Ethyl-9-phenyl- 2,3.4,4a and
2,3,4,9-tetrahydro-l//-indeno[2,l-c]pyridine HBr [82].
The dose-response curve (Figure 31) is analogous to the theoretical one that is 











FIGURE 30: DOSE-RESPONSE CURVE OF MONO ENE (9.9a ISOMER) |5l| AGAINST











FIGURE 31: DOSE-RESPONSE CURVE OF ISOMERIC MONO ENE |82| AGAINST 
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COMPOUND: 2-Benzyl-9-phenyl-2,3,4,9-tetrahydro-l//- indeno[2,l-c]pyridine HC1 
[88].
The dose-response curve (Figure 32) is similar to the theoretical plots that are 
obtainable for a reversible competitive antagonist. From these results, it appears that 
this drug is a better Hj-histamine antagonist than Thephorin in in vitro environments.
COMPOUND: 2-Phenethyl-9-phenyl-2,3,4,9-tetrahydro- l//-indeno[2,l-c]pyrid ine 
HC1 [89].




















FIG UR E 32: DOSE-RESPONSE CURVE OF MONO-ENE (4a.9a ISOMER) (8 8 ) AGAINST 
HISTAM INE ON ISOLATED GUINEA PIG ILEA AT 10 *(•). 10 7(o) AND 10 6(«i MOLAR 











^ URE 33: DOSE-RESPONSE CURVE OF MONO-ENE (4a.9a ISOMER) (89) AGAINST 
HISTAM INE ON ISOLATED GUINEA PIG ILEA AT 10 *0 . 10 7(a) AND 10 6(.) MOLAR 
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4.3 IN  VIVO ANTIHISTAMINIC ACTIVITY.
4.31 Protocol.
Compound 48/80, a recognised potent histamine releasing agent, was injected
intravenously at a challenge dose o f 0.5 mg/kg. The compounds tested were
administered subcutaneously at 40 mg/Kg and at lOmg/Kg, with the exception o f the
commercial sample o f Thephorin, which was administered at 10 mg/Kg and at 2.5
mg/Kg. Compounds which gave survival times o f more than 240 minutes were
considered as having useful antihistaminic activity. Results are summarized in Figure
35. The compounds tested are presented in Figure 34.
F IGURE 34,
R R ,N -R
.HX.HX .HX
R X X R X
[14] CH3 tartrate [51] CH3 Br [100] H Cl
[88] CH2Ph Cl [79] CH2CH3 Br
[89] CH2CH2Ph Cl [80] CH2Ph Br
[81] CH2CH2Ph Br 
[87] * CH2CH3 Cl
* Compound [87] is a mixture o f the 9,9a- and 4a,9a-enes.
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FIGURE 35
S U R V IV A L  AT SUBCUTANEOUS DOSE LE V E L  OF:
CO M PO UND 40mg/kg lOmg/kg 2.5mg/kg
[14] - 2/2 1/2
[51] 2/2 1/2 -
[79] 1/2 0/2 -
[80] 0/2 0/2 -
[81] 1/2 0/2 -
[88] 0/2 0/2 -
[89] 0/2 0/2 -
[87] 2/2 1/2 -
[ 100] 1/2 0/2 -
Doses " - "  means not tested at this level.
4.32 In  Vivo Results.
40 mg/Kg Dose:
Compounds [51] (R=CH3; X=Br) and [87] (R=CH2CH3; X=C1) gave survival times for 
both rats o f greater than 240 minutes. These compounds were classed as active at the 
administered dose.
For compounds [100] (diene R= H; X=C1), [81] (R=CH2CH2Ph; X=Br), and [79] 
(R=CH2CH3; X=Br), one o f the two rats survived more than 240 minutes. These 
compounds can be classed as less active than compounds [51] and [87].
Compounds [80] (R=CH2Ph; X=Br), [88] (R=CH2Ph; X=C1), and [89] (R=CH2CH2Ph; 
X=C1) were inactive, as both rats did not survive past the required 240 minutes.
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10 mg/Kg Dose:
Both rats which were treated with Thephorin [14] survived the required time. 
Compounds [51] and [87] were found to give a survival time o f more than 240 minutes 
in  one rat, but the other rat died before hand. Compounds [51] and [87],though active 
were less active than Thephorin [14].
The remaining compounds [79], [80], [81], [88], [89], [100], provided little  or no 
protection against histamine, both rats died w ithin the required time lim it.
2.5 mg/Kg Dose:
When Thephorin [14] was administered at a lower dose o f 2.5 mg/Kg subcutaneously, 
only one o f the rats was protected. The ED50 o f Thephorin was considered to be 2.5 
mg/Kg (compared with astemizole 0.11 mg/Kg s.c and orally).
4.4 Conclusions.
Possible explanations for the drug*[88] and [89] having antagonistic effects in vitro and 
not in vivo could be accounted for by the toxicology o f the drug to the animal, its 
distribution to the effector organs and its biotransformation largely by the liver. The 
drug may have physiological actions other than its antihistaminic effects and may 
therefore have adverse effects in the in vivo but not in the in vitro situation where a 
restricted array o f physiological processes exist. The drug-may be highly lipophilic and 
so be absorbed by tissue fats and therefore not reach the target organ.
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A  selection o f the compounds synthesised in this work are currently being tested for 






The 1H NMR spectra were recorded on a Jeol GX270MHz Fourier Transform (FT) 
NMR Spectrometer unless otherwise stated. The following abbreviations are used to 
describe resonance appearance in the NMR spectra: s, singlet; br, broad; d, doublet; 
t, triplet; q, quartet; m, multiplet plus combinations such as dd, doublet of doublets. The 
13C NMR spectra were recorded on a Jeol GX270MHz FT NMR Spectrometer 
operating at 67.8MHz. The multiplicity of the resonances were obtained from DEPT 
(Distortionless Enhancement by Polarisation Transfer) spectra, in which the phase of 
the signal indicated the number of protons attached to the carbon atoms giving rise to 
that signal.
The infra red spectra Oiquid as films, solids as KBr discs or nujol mulls) were recorded 
on a Unicam SP1025 Spectrometer.
Mass spectra were recorded on a VG Micromass 707E Mass Spectrometer operating at 
low eV, 70 eV, or C.I.
Elemental analyses were carried out in the School of Chemistry, University of Bath.
Melting points were recorded on a Gallenkamp apparatus and are uncorrected.
Catalytic hydrogenations were performed using a COOK low pressure hydrogenator of 
1 litre capacity.
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The term in vacuo means that a rotary evaporator Buchi Rotavapor R110 was employed 
to remove solvents.




5.21.1 2-Benzovlethvl Benzvlamine HC1 [561.
A mixture of acetophenone (30.0g, 0.25mol), benzylamine (24.6g, 0.23mol), 
formaldehyde (10% w/v, 30ml) and hydrochloric acid (36% v/v, 20ml) was heated 
under reflux for 2 h. The homogeneous solution was cooled overnight with stirring. The 
product was extracted with chloroform (3x75ml), dried (MgS04) and evaporated in 
vacuo. The product was recrystallized from absolute ethanol to give [56] (30.92g,
49%), m.p. 179-180°C.
5h (CDC13> HC1 salt): 9.95(2H, s, NH2), 7.89(10H, m, Ar-H), 4.13(2H, t, J3 5.5Hz., 
CH2Ph) 3.71(2H, t, J 7.3Hz., CH2CH2N), 3.31(2H, m, COCH2CH2).
5C (CDC13>HC1 salt): 196.85 (0=0), 135.58-128.51 (2xAr-Cq), 133.03-128.60 
(6xAr-CH), 51.02 (COCH2), 41.52 (CH2Ph), 34.67 (C H ^ ^ N ).
The above method was used for the synthesis of:-
2-Benzoylethyl tertiarybutylamine HC1 [57] (43% yield), m.p.l68-169°C.
8h (CDC13 HC1 salt): 9.18(2H, s, NH2), 7.98(5H, m, Ar-H), 3.61(2H, t, J3 6.6Hz., 
COCHj), 3.21(2H, dt, CHjCP^N), 1.34(9H, s, NClCHj^).
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5C (CDC13>HC1 salt): 196.72 (0=0), 136.06 (Ar-Cq), 133.70-127.92 (3xAr-CH), 
35.87(COCHj), 25.12 (COCHiCI^N), 25.13 (3xCH3).
and 2-Benzoylethyl cyclohexylamine HC1 [58] (47% yield), m.p.l97-198°C.
5h (C D a3> H Q  salt): 9.55(2H, s, NH2), 7.96(5H, m, Ar-H), 3.82(2H, t, J3 7.3Hz., 






A mixture of acetophenone (12.0g, O.lmol), butylamine (4.3g, 0.06mol), formaldehyde 
(38% w/v, 50 ml), and hydrochloric acid (50% v/v, 30ml) was heated under reflux for 
2h. To the cooled mixture was added water (150ml) portion wise. The precipitate was 
collected and recrystallized from ethanol to give [65] (14.91g, 90%) as a white solid, 
m.p. 184-185°C (L it,167 182-184°C).
A similar procedure was adopted for other piperidines (See table 7).
Method B.
5.22.2 3-Benzovl-1 -Benzvl-4-Hvdroxv-4-Phenvlpiperidine r611.
A suspension of 2-benzoylethyl benzylamine HC1 (13.75g, 0.05mol) was stirred with a 
solution of sodium hydroxide in water (2N, 100ml) for 18h at room temperature. The 
mixture was extracted with ether (5x50ml), dried (MgS04), and evaporated to yield a 
solid which was reciystallized from absolute ethanol to give [61] (12.14g, 61%) as a 
white solid, m.p. 203.5-204.5°C (L it,147 193-194°C).
The same procedure was adopted for the synthesis of 3-Benzoyl-1- 
cyclohexyl-4-hydroxy-4-phenylpiperidine [68].
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The analytical data fo r all o f  the piperidines synthesised are presented in Table 4 for 
13C NM R, Tables 5 and 6 fo r NMR, Table 1 for mass spectra, and Table 7 for % 
yield, m.p. and microanalytical data.
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T A B L E  4: 13C N M R  Data for 1 -Alkyl-3-Benzoyl-4-Hydroxy-4-Phenylpiperidines.
COMPD C-2 C-3 C-4 C-5 C-6 C =0 Ar (CH and Cq) N-Ra
[59] 51.57 46.19 71.19 36.59 50.66 201.16 124.28-134.70 (6xCH) 
143.65 (Cq)
43.14 CH3
[60] 51.57 45.99 71.79 36.39 50.09 201.52 127.66-133.34 (4xCH) 47.84 CH2, 9.11 CH3
[61] 49.75 45.80 70.77 35.42 46.41 199.90 123.67-133.28 (8xCH) 
127.63-143.49 (Cq)
59.39 CH2Ph








[64] 48.52 50.96 73.27 40.12 44.20 204.57 124.51-133.73 (5xCH) 54.62 CH
18.49, 18.26 2xCH3








[67] 50.68 46.02 71.68 36.36 48.46 201.68 124.39-134.83 (5xCH) 
134.62, 143.76 (Cq)
57.41 NCH2, 13.72 CHj 
30.94-22.22 4xCH2








63.96 NCH2, 25.17 CH 
31.46-25.33 4xCH2
a) see Table 7 for structure of R.
Table 5: 270 MHz lH NMR Data for l-Alkyl-3-Benzoyl-4-Hydroxy-4-Phenylpiperidines.
COMPD H-2 / H - 6 H-3 H-5 OH Ar-H N-R*
[59] 3.48, m 5.57, t. 
6.96 Hz.




8.07, m 2.90. s 
CHj
[60] 3.55, m 5.63. dd 
4.03. 11.73 Hz.




8.13, m 1.55b. t.C H j 
3.19b, q, CH2CH3
(62) 3.60. m 5.60.t 
9.52 Hz.




8.04, m 3.60, m 
CH^CHjPh
[63] 3.14, m 4.43. dd 
3.67. 11.36 Hz.




7.98, m 0.59, m. 2xCH2 
2.03. m, N-CHR
[64] 2.93, m 4.38. dd 
4.03. 10.99 Hz.




7.89, m 1.1 l.d . 6 .6 Hz. 
CH(CHi)j; 2.93. 
m. CHTCHj) 2
[6 6 ] 3.62. m 5.91, dd 
3.66, 11.72 Hz.




8.16, m 1.17, 2xt, 7.7,
7.33. 15.03 Hz. 
CH(CH-,CHi)2; 2.14, 
m. CH(£tGCH3 )2
[6 8 ] 3.58, m 5.85. dd 
3.66. 11.36 Hz.




8.15. m 2.05. m; 2.45. m 
3.58b. tt
a) see Table 7 for structure of R
b) unresolved signals
Table 6 : 270 MHz *H NMR Data for l-Alkyl-3-BenzoyT4-Hydroxy-4-Phenylpiperidines.
COMPD. H-2 / H - 6 ax-H-3 H-5 OH Ar-H N-Rb
[61] 3.65, m 5.61. dd 
4.03. 11.73 Hz
eq: 1 .91\d  
ax: 2 .8 8 . m
5.20, s 7.99. m 4.51. m
[65] 3.50. m 5.72. dd 
4 03. 12.09 Hz.
eq: 1.99. m 
ax: 3.10, m
5.08. s 8.14, m 1 .0 0 , t
7.33 Hz. 
1.99-3.06. m
[67] 3.49. m 5.71. dd 
4.03. 12.09 Hz.
eq: 1.97. m 
ax: 3.04. m
5.01. s 8.14. m 0.91, m: 1.33, 
m; 3.04. m
[69] 3.50, m 5.91. dd 
3  84. 11.90 Hz.
eq: 1.98. m 
ax: 3.05. m
5.06. s 8 . 1 2 . m 1.89. m.
3.05. tn. N-CH,
a) unresolved signal.
b) see Table 7 for structure of R
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COMPOUND R = Y IE LD SOLVENT M .p./°C FOUND (%) (REQUIRED)
FORM ULA (% ) (DECOMP.) C H N
[59)b c h 3 59 EtOH 183-184 68.8 6.71 4.17
Cl9H2,N 0 2.HCi (68.8 6.6 4 .2 )
[60]b c h 2ch3 28 EtOH 132-133 69.1 7.03 4.2
C2oH23N 0 2.HCI (69.5 6.9 4.1 )
[61]a CH2Ph 61 EtOH 203.5-204.5 73.7 6.43 3.34
C ^H^NO ^HCl (73.6 6.4 3.4)
(62]b CH2CH2Ph 38 EtOH 189-190 73.6 6.62 3.27
C26H27N 0 2.HCi (74.0 6.64 3.32)
[63]b Cyclopropyl 91 EtOH 153-154 78.3 7.18 4.26
c 2,h 23n o 2 (78.5 7.17 4.36)
[64 Jb CH(CH3)2 39 EtOH 163-164 70.2 7.25 3.92
C2|H 25N 0 2.HCI (70.1 7.23 3.89)
[65 Jb Butyl 90 EtOH 184-185 70.8 7.51 3.60
c 22h 27n o 2.h c i (70.7 7.50 3.75)
[66]b CH(CH2CH3)2 42 EtOH 180-181 714 7.76 2.89
C23H29N 0 2.HCI. (71.2 7.74 2.84)
[67] Hcxyl 84 EtOH 170-171 71.8 8.1.3 .3.45
C21H3lN 0 2 HCI (71.7 7.97 3.49)
[6S)J Cyclohexyl 49 EtOH 174-175 72.0 7.47 3.45
C24H2„N 02.HC! (72 1 7.51 3.50)
|69jb Cyclohcxyl- 58 EtOH 183-184 70.3 7.85 3.19
C2sH3i N 0 2.HCI.H20 mcthyl (69.5 7.88 3.24) ,
a) synthesised from the m o n o -Mannich product, then convened to the HCI salt.
b) synthesised from the Mannich reaction.
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5.3 The 2-Alkyl-9-Phenyl-2,3-Dihvdro-l//- Indenote.l-clpyridines.
5.312-Benzyl-9-Phenvl-2,3-Dihydro-l//-Indenc>r2,l-clpyridine Hvdrobromide T721.
3-Benzoyl-l-benzyl-4-hydroxy-4-phenylpiperidine HCI (4.0g, 0.01 mol) was stirred 
with hydrobromic acid (48% w/v, 10 ml) and distilled water (10 ml) for 2h at room 
temperature, and then heated at reflux for 2h. The cooled mixture was diluted with 
distilled water(50 ml), extracted with chloroform (3x50 ml), dried (MgS04), and 
evaporated in vacuo to give the yellow solid which was recrystallized from ethanol to 
give [72] (3.25g, 78%) as yellow crystals, m.p.196-197. (Lit.,180 188-190°C).
The same procedure was adopted for the synthesis of the remaining dienes.
For analytical data see Tables 8 (JH NMR), and 9 (13C NMR), 2 (mass spectra), and 10 
(% yields, m.p., CHN microanalysis).
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Tabic 8: 270 MHz 'H  NMR Data for the 2-Alkyl-9-Phenyl-2,3-Dihydro-l/Mndeno[2,l-c]pyridines.
COMPD. 112‘ 1 I l r 3 11-4 A r-Il N-R* N-H




7.63, m 2.93, s
(71]b 4.46, s 4.16, s 6.63, t 
4 03 Hz.
7.62, m 3.62, q, 7.33 Hz. 
N-CH2CH3, 1.40, t 
7.33 Hz.
(72] 5.82,m 5.82, m 6.62, dd 
3.12,4.96 Hz.
7.68, m 5.82, m, N-CH2Ph 12.03, s











7.61,m 3.11, 1.76, 1.31, m 








7.66, m 3.18, m, N-CH(R) 





cq: 4.60, m 
ax: 4.80,m
eq: 4.47c, dt 
ax: 4.32c, dt
6.62c t 7.65, m 3.12,2.04, m 








7.88. m 3.49, m. N-CHR 




eq: 4.74, dd 
2.56. 15.76 Hz. 
ax. 4.06, brd.
eq: 4.64c, dt 
J ax: 4.25, m
6.63c, dd 7.81, m 3.18, m, N-CH2R 
1.90, m, 5xCH2
11.35, s
a) see Tabic 10 for structure of R.
b) duterated samples
c) unresolved signals.
Table 9: 13C NMR Data for the 2-Alkyl-9-Phenyl-2,3*Dihydro- l//-Indeno[2,l-c]pyridimes.
COMPI) C-l C-3 C-4 C-4a C-9 C*9a Ar-C (C-H and C-q) N-R*
[70] 50.39 51.61 115.57 120.79 132.82 131.95 128.96-120.72 ( 6  signals) 
142.33-130.79 (3 signals)
41.39 CH3
[71] 47.81 49.01 115.47 120.89 133.11 131.91 129.03-120.66 ( 6  signals) 
142.45-139.24 (3 signals)
48.55 CH2, 10.05 CH3
[72] 47.00 48.91 114.88 120.30 133.18 131.82 131.01-120.72(8 signals) 
143.14-139.37 (3 signals)
55.89 CH2Ph




[74] 48.59 49.43 115.14 120.56 133.05 131.85 128.99-120.69 (4 signals) 
142.65-139.18 (3 signals)
53.32, 26.43, 19.85 
3xCH2; 13.36 CH3
[75] 46.67 47.52 115.44 1 2 1 . 2 1 133.02 131.85 129.06-120.78 (5 signals) 
142.49-139.89 (3 signals)
63.96 N-CH(R)2; 21.57, 21.05 
2xCH2; 9.99, 9.86 2xCH3
[76] 48.46 49.50 115.08 120.46 133.05 131.83 129.01-120.72(4 signals) 
142.59-139.20 (3 signals)
53.42, 30.81,26.12, 24.49 
22.09 5xCH2; 13.65 CH3
177] 46.06 46.80 115.73 121.31 133.08 131.91 129.06-120.72(6 signals) 
142.55-139.92 (4 signals)
61.98 N-CH-; 28.32, 27.93 
24.81, 24.29 4xCH2
[78] 49.30 49.85 114.79 120.30 133.08 131.75 129.64-120.76 ( 6  signals) 
143.17-139.11 (3 signals)
58.77 N-CHr ; 33.73 CH- 
31.04,25.46, 25.14 3xCH2
a) see Table 10 for structure of R.






M.P. / °C  
(DECOMP.)
FOUND (%) (REQUIRED) 
C H N
[70]
CI9 H 1 7N.HBr
c h 3 70 208-209 67.2 5.27 4.05 
(67.1 5.29 4.12)
[71]
C2 0 H 1 9N.HBr
c h 2 c h 3 68 194-195
( - - - )
[72]
C25H2IN.HBr




CH2 CH2Ph 65 2 0 1 - 2 0 2
( - - )
[74]
C^H^N.UBr
Butyl 87 198-199 68.9 6.35 3.61 
(69.1 6.28 3.66)
[75]
C jjH ^N .IIB r
CH(CH2 CH3 ) 2 83 207-208 69.6 6.63 3.47 
(69.7 6.57 3.54)
[76]
C2 4 H 2 7 N.HBr
Hcxyl 84 196-197 70.0 6.84 3.37 
(70.2 6.63 3.41)
[77] 
C2 4 H 2 5 N.II Br
Cyclohexyl 61 218-219 70.5 6.47 3.39 
(70.6 6.37 3.43)
[78]




( - - ■)
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5.4 PHENINDAMINE ANALOGUES.
5.41 The 2-Alkvl-9-Phenvl-23.4,4a-Tetrahvdro-l//- Indeno[2,l-c]pyridines.
5.41.1 2-Phenethvl-9-Phenvl-2.3,4,4a-Tetrahvdro-l//- Indenor2,l-cl pyridine HBr.
m u
A solution of 2-phenethyl-9-phenyl-2,3-dihydro-l//- indeno[2,l-c]pyridine HBr [73] 
(4.3g, O.Olmol) in ethanol (250ml) was hydrogenated over palladium (0.4g, 10% on 
activated carbon), at a pressure of 100 psi for 6h at room temperature. The catalyst was 
removed through celite, and the residual ethanolic solution was concentrated at the 
pump. The product was recrystallized from an ethanol-ether to give [81] (2.98g, 69%) 
as a white solid, m.p. 122-123°C.
A similar method was used for the synthesis of
2-methyl-9-phenyl-2,3,4,4a-tetrahydro-l//-indeno[2,l-c] pyridine HBr [51], 
2-ethyl-9-phenyl-2,3,4,4a-tetrahydro-l//- indeno[2,l-c] pyridine HBr [79] and 
2-benzyl-9-phenyl- 2,3,4,4a-tetrahydro-l//-indeno[2,l-c] pyridine HBr [80].
5.4.1.2 2-Methvl-9-Phenvl-2.3,4,4a-Tetrahydro-l//- Indenor2,l-c]pyridine HCI [86],
To 2-methyl-9-phenyl-2,3,4,4a-tetrahydro-l//-indeno[2,l-c] pyridine HBr [51] (l.Og, 
2.9mmol) was added ammonia solution (pH 10). The green mixture was extracted with 
ether (3x50ml), and washed with a saturated solution of ammonium chloride (50ml). 
The dried ethereal extract was condensed to a small volume. Hydrogen chloride gas 
was bubbled into the ethereal solution to precipitate a yellow solid which was 
recrystallized from ethanol-ether to give [86] (0.68g, 79%), as a white solid m.p.
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198-1990C(LiL,1S7 169-171°C).
The 13C NMR, 'H  NMR and microanalydcal data for the 
2-alkyl-9-phenyl-2,3,4,4a-tetrahydro-l//-indeno[2,l-c] pyridines are presented in 
Tables 11,14 and 17 respectively.
5.42 Geometric Isomers of 2-Alkyl-9-Phenvl-2,3.4,4a- and
2,3,4,9-Tetrahvdro-lfMndenor2.1-c1pyridines.
5.42.1 2-Cvclohexvl-9-PhenvI-2.3.4.4a- and 23.4.9- 
Tetrahvdro-l//-Indeno[2,l-clpyridine HBr f841.
A solution of 2-cyclohexyl-9-phenyl-2,3-dihydro-l//- indeno[2,l-c]pyridine HBr [77] 
(4.10g, 0.01 mol) in ethanol (250ml) was hydrogenated over palladium (0.4g, 10% on 
activated carbon), at a pressure of 100 psi for 16h at room temperature. The catalyst 
was removed through celite, and the residual ethanolic solution was condensed at the 
pump. The product was recrystallized from ethanol- ether to give [84] (3.80g, 92%) as 
a white solid, m.p. 149-151°C.
The same procedure was used for the synthesis of geometric isomeric 
2-ethyl-9-phenyl-2,3,4,4a- and 2,3,4,9- tetrahydro-l//-indeno[2,l-c]pyridine HBr [82] 
and 2-(l-ethylpropyl)-9-phenyl-2,3,4,4a- and 2,3,4,9- 
tetrahydro-l//-indeno[2,l-cJpyridine HBr [83].
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5.42.2 2-Ethyl-9-Phenyl-2,3,4,4a- and 2,3,4.9-Tetrahvdro-l//-Indenor2.1-c1pvridine 
HCI [861.
To 2-ethyl-9-phenyl-2,3,4,4a-tetrahydro-l//-indeno[2,l-c] pyridine HBr [51] (l.Og, 
2.8mmol) was added ammonia solution (pH 10). The green mixture was extracted with 
ether (3x50ml), and washed with a saturated solution of ammonium chloride (50ml). 
The dried ethereal extract was condensed to a small volume. Hydrogen chloride gas 
was bubbled into the ethereal solution to precipitate a yellow solid which was 
recrystallized from ethanol-ether to give [86] (0.56g, 64%), as a white solid m.p. 
178-180°C
5.42.3 2-Benzyl-9-Phenvl-2.3,4.4a- and 2,3,4,9-Tetrahydro-l//-Indenor2,l-c] pyridine 
HBr [901.
To a solution of 2-benzyl-9-phenyl-2,3,4,4a-tetrahydro-l//- indeno[2,l-c] pyridine[62] 
(50mg, 0.12mmol), in absolute ethanol (10ml) was added palladium catalyst (10 mg, 
5% on activated carbon). The mixture was stirred for three weeks at room temperature, 
the catalyst was removed, and the filtrate was evaporated in vacuo to give [90] 
(40mg,80%) as a yellow solid, m.p. 105-110°C. The product was not further purified.
The 13C NMR, JH NMR and microanalytical data for the 2-alkyl-9-phenyl-2,3,4,4a- 
and 2,3,4,9-tetrahydro-l//- indeno[2,l-c]pyridines are presented in Tables 12,15 and 
17 respectively.
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5.43 The 2-Alkyl-9-Phenvf-2,3,4,9-Tetrahvdro-l/if- Indenor2,l-c]pyridines.
5.43.1 2-Hexyl-9-Phenvl-2.3.4,9-Tetrahydro-l//- Indcnpr2.1-c]pyridine HBr [851.
A solution of 2-hexyl-9-phenyl-2,3-dihydro- IH- indeno[2,l-c]pyridine HBr [76](2.90g, 
0.01 mol) in ethanol (250ml) was hydrogenated over palladium (0.3g, 10% on activated 
carbon), at a pressure of lOOpsi for 48h at room temperature. The catalyst was removed 
through celite, and the residual ethanolic solution was condensed at the pump. The 
product was recrystallized from ethanol-ether to give [85](2.22g, 78%) as a white solid, 
m.p. 176-177°C.
5.43.2 2-Phenethvl-9-Phenvl-2,3A9-Tetrahydro-l//- Indenor2,l-c1pvridine HCI T881.
A saturated solution of hydrogen chloride in dry ether was added dropwise to 
2-phenethyl-9-phenyl-2,3,4,4a- tetrahydro-l//-indeno[2,l-c]pyridine (l.Og, 2.4mmol) 
in absolute ethanol until the solution went cloudy. The suspension was cooled and the 
product was collected and washed with ether (2x25ml) to give [88] (0.77g, 89%) as a 
white solid, m.p. 140-141°C.
The above method was used to synthesise
2-phenethyl-9-phenyl-2,3,4,9-tetrahydro-lf/-indeno[2,l-c] pyridine HCI [89].
The 13C NMR, *H NMR and microanalytical data for the
2-alkyl-9-phenyl-2,3,4,9-tetrahydro-l//-indeno[2,l-c] pyridines are presented in Tables 
13,16 and 17 respectively.
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Tabic 11: l3C NMR Data for the 2-Alkyl-9-Phenyl-2.3.4.4a-Tetrahydro-l//-lndeno(2,l-c]pyndmes.
COMPOUND CH (non-Ar) C H 2 Ar-CH A r-£ , N-Rb
(51)


































2 x C H 2
a) epimeric signals.
b) see Table 17 for structure of R.
c) includes signals in R.
Tabic 12: l3C NMR Data for the 2-Alkyl-9-Phenyl-2.3.4.4a- and 2,3.4,9-Tetrahydro-l//-
lndeno[2.1 -c)pyndines.
COMPOUND CH (non-Ar) C H 2 Ar-CH Ar-Cq N-R*
[82]












































a) H-4a CH signals.
b) H-9 CH signals.
c) see Table 17 for structure of R
Tabic 13: MC NMR Data for the 2-Alkyl-9-Phenyl-2.3.4.9-Tetrahydro-l//-lndeno|2.1-c|pyndincs.









5 x CH2 
13.85 CHj
[88]


















a) see Table 17 for structure of R.
b) epimeric signals of H-9.
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Table 14: 270 M H z »H NMR Data for the 2-Alkyl-9-Phenyl-
2,3,4,4a-Tetrahydro-l//-Indeno[2,l-c]pyridines.
Assignment 



















3.27, m 3.76a, dd 3.43, m
H2-3 3.58, m 3.66, m 3.70, m 3.81, m
axll-l 4.18, m 4.27, m 4.65, m 4.41, m
cq 1 1 - 1 4.18, m 4.27, m 4.65, m 4.41, m
Ar-H 7.33, m 7.58, m 7.66, m 7.63, m
N-Rb 2.72, s 1.27*, t 
3.27a, q
3.53, m 3.43, m
a) unresolved signals.
b) see Table 17 for structure of R.
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[82] [83] [84] [102]
axH-4 1.58, m 1.50, m 1.45, dqa 1.42, dqa
H-4a/Hr 3
Hr l
4.14, m 4.42, m 3.67,m 4.07, m
eqH-4 2.72, m 2.65, m 2.84a, dd
H-9 4.34, br 4.47, br 4.20, br 4.68, br
Ar-H 7.54, m 7.55, m 7.68, m 7.59, m
N-Rb 1.23, t
6.96 Hz. CH 3  
3.5. q







b) see Table 17 for structure o f R.
Table 16: 270 M H z  ‘ H N M R  Data for the 2-Alkvl-9-Phenyl- 
2.3,4,9-Tetrahydro-l/y-Indcno[2,l-cJpyridincs.
Assignment 
of protons [85] [88] [89]
H2-4 2.94, br 4.44, m 3.19.m
H2-3 3.21, br 3.50, m
H2-2 4.08, br 3.83, m
H-9 4.72, brd 4.89, brd 4.82, brd
Ar-H 7.62, m 7.67,m 7.61,111
N -R a 1.72, m 4.44, m 3.19, m
a) see table 17 for structure of R.
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Table 17: Analytical Data for the N-2 Alkyl Substituted Phenindaminc Analogues.
6
CO M POUND
FO R M U LA
R = YIELD
(% )
SOLVENT M.P. / °C  
(DECOMP.)
FOUND (% ) (REQUIRED) 
C H N
[51]*
C ,9 H 1 9N.HBr
c h 3 59 EtOH/Et20  184-185 6 6 . 8  5.81 3.97 
(66.7 5.85 4.09)
[79]*
C 2 0 H 2 I N.HBr
c h 2 c h 3 6 6 EtOH/Et20  182-184 67.2 6.21 3.90 
(67.4 5.90 3.93)
[80]*
C 2 5 H j3 N.HBr.2 H 2 O








Butyl 89 EtOH/Et20  159-161 68.9 6.85 3.47 
(69.3 7.04 3.52)
(84]b
C2 4 H 2 7 N.HBr
Cyclohexyl 92 EtOH/Ei20  149-151 69.9 6.74 3.36 
(70.2 6.83 3.41)
(85]c
C 2 4 H 2 9 N.HBr
Hexvl 78 EtOH/EhO 176-177 69.7 7.34 3.34 
(69.9 7.28 3.40)
(87]b
C 2 0 I I 2 iN .H C I.H 2()
CH 2 C Hj 64 Et0H/Et20  178-ISO 72.3 7.11 4 20 
(72.8 6.96 4.25)
[8 8 ]c
C 2 5 H 2 3 N.HCI.2 H 2 O
CH 2Ph 92 EtOl I/Et20  I88-1S9 73.3 6.59 3.42 
(73.3 6.51 3.30)
[89]c
C2 6 H 2 5 N .HCLl.SH 2O
CH 2 CH 2 PIi 89 EtOH/F.t20  140-141 75.3 6  76 3.38 
(75.1 6.97 3.35)
a) 9,9a-enc isomers.
b) a mixture of 9,9a- and 4a,9a-cne isomers
c)4a,9a-ene isomers.
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5.5 THE 2-Alkvl-9-Phenyl-2,3A4a,9,9a-Hexahydro-l/y- Indenor2,l-clpyridines.
5.51 All ciy-9-Phenvl-2.3,4.4a.9,9a-Hexahvdro-l//- Indenor2.1-clpyridine HBr [931.
A solution of 2-benzyl-9-phenyl-2,3-dihydro-IH- indeno[2,l-c]pyridine HBr 
[72](14.0g, 34mmol) in ethanol (95%, 250ml) was hydrogenated with palladium (l.Og, 
5% on activated carbon) at 70°C, and lOOpsi for 6h. The catalyst was removed and the 
filtrate was evaporated in vacuo to a small bulk. Ether was added until the solution 
went cloudy. Crystals of [93] were collected and dried. (7.60g, 68%), m.p. 235-237°C. 
(Lit.,180 275-277°C). (Found: C, 65.2; H, 6.11; N, 4.20 C18H20BrN requires C, 65.5; H, 
6.06; N, 4.24%).
The HBr salt (6.0g, 18mmol) was treated with ammonia solution (pHIO), then extracted 
with ether (3x50ml), washed with a saturated solution of ammonium chloride (50ml), 
and dried. The ethereal solution was evaporated to give a colourless oil which solidified 
on standing, (4.2lg, 94%), m.p. 84.5-85.5°C.
5h (CDC13, HBr salt) 8.93(1H, s, NH), 8.68(1H, s, NH), 7.35(9H, m, Ar-H), 4.56(1H, d, 
J9>9a 5.9Hz., H-9), 3.4(1 H, brs, H-4a), 3.27(1H, m, J9 9a 5.9Hz., H-9a), 2.65(6H, m, 
H r l» H 2-3 ,H 2-4).
8C (CDC13, HBr salt) 142.81-136.32 (3 x Ar-Cq), 128.86-122.67 (6 x Ar-C), 42.13 
(C -l), 40.28 (C-3), 20.86 (C-4), 39.76 (C-9a), 53.03 (C-9), 42.62 (C-4a).
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5.52 Trans-9-Phenvl-23AAsL,9,9a.-Hcxah\dro-lH- Indenor2,l-cl pyridine HC1T941.
The foregoing product [93](2.70g, 1 lmmol) was boiled under reflux with a solution of 
potassium hydroxide in n-butanol (25%, 50ml) for 24h. The cooled mixture was 
evaporated. The product was dissolved in ether and washed with brine (50ml). The 
ethereal extract was dried (Mg S04) and concentrated in vacuo to a give a colourless 
oil.
A solution of the oil in dry ether was treated with ethereal HC1, and the above named 
product was recrystallized from absolute ethanol, (2.52g, 80%), m.p. 249-250°C. 
(Found: C, 75.5; H, 6.92; N, 4.79 C18H20C1N requires C, 75.7; H, 7.01; N, 4.90%).
SH (CDC13, HC1 salt): 9.50(2H, s, NH^, 7.39(9H, m Ar-H), 4.78 (1H, d, J9>9a 9.9Hz., 
H-9), 3.37(1H, m, J3 6.2Hz., J4a-9a 5.2Hz., J3 5.9Hz„ H-4a), 3.22(2H, dd, J4lt9l 5.2Hz.
J9 9a 9.9Hz., H-9a), 3.11(6H, m, H2- l, Hz-3, Hz-4).
6c (CDC13, HC1 salt) 145.83-142.10 (3 x Ar Cq), 128.57-123.54 (6 x Ar-C), 41.55 
(C -l), 41.29 (C-3), 25.13 (C-4), 39.15 (C-9a), 50.08, (C-9), 45.93 (C-4a).
5.53 Cts-2-Phenethvl-9-Phenvl-2.3.4.4a.9.9a- Hexahvdro-lf/- Indenor2.1-clpyridine 
Hydrochloride T951.
To a stirred slurry of all cw-9-phenyl-2,3,4,4a,9,9a- 
hexahydro-l//-indeno[2,l-c]pyridine [93](0.25g, l.OOmmol), dried potassium 
carbonate (0.15g, l.lOmmol) and potassium iodide (0.06g, 0.50 mmol) in dry 
acetonitrile (20ml) was added a solution of (2-bromoethyl)benzene (0.20g, l.lOmmol) 
in dry acetonitrile (5ml), the resulting mixture was refluxed gendy for 18 h. The
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(3x50ml). The ethereal layer was washed with water (2x1 Oml), dried (MgS04), and 
concentrated in vacuo to give a colourless oil, which was converted to the 
hydrochloride salt. The product was recrystallized from ethanol-acetone to give [95] 
(0.32g, 82%) as white crystals, m.p. 258-260°C. (Found: C 79.9, H 7.29, N 3.53 
C26H2.7N.HCl requires C 80.1, H 6.93, N 3.59%).
SH (DMSO-d6, HC1 salt): 10.98(1H, s, NH), 7.45(14H, m, Ar-H), 4.69(1H, d, J99a 
5.9Hz., H-9), 3.48(2H, br, N-CH2), 3.36(1H, brs, H-9a), 3.26(1H, m, H-4a), 3.07(2H, 
m, H2- 1), 2.96(2H, m, ^ -3 ), 3.26(4H, m, H2-4, N-CH2CH2Ph).
5C (DMSO-d6, HC1 salt): 167.85-131.85 (5xAr-Cq), 129.12-123.41 (8xAr-CH), 56.66 
(N-CH2), 50.82 (C -l), 47.71 (C-3), 29.32 (C-4), 21.31 (N-CH2CH2Ph), 52.48 (C-9), 





To a solution of the 3-benzoyl-l-benzyl-4-hydroxy-4- phenylpiperidine (16.0g, 
43mmol) in dry toluene (75ml), was added 2,2,2-trichloroethylchloroformate (9.14g, 
43mmol) portionwise. The mixture was stirred at room temperature for 24h. The 
solution was diluted with ether (100ml), and washed with water (50ml), then with a 
saturated solution of ammonium chloride (50ml). The organic layer was dried (Mg 
S04), filtered, and evaporated to dryness at the pump to yield a yellow oil which 
solidified overnight. Recrystallizatiom from absolute ethanol gave [96] (12.01g, 61%), 
m.p. 115-116°C (Found: C, 55.6; H, 4.56; N, 2.85. C21H20GI3NO4 requires C, 55.2; H, 
4,38; N, 3.07).
SH (CDCI3): 7.91 (10H, m, Ar-H), 5.22 (1H, s, OH), 5.09 (0.5H, d, J2 12.1Hz„ 
NC02CH2CC13), 4.95 (0.5H, d, J2 11.7Hz„ NC02CH2CC13), 4.79 (0.5H, d, J2 11.9Hz., 
NC02CH2CC13), 4.66 (0.5H, d, J2 12.1Hz., NC0 2CH2CC13), 4.56 (1H, m,H-3), 4.27 
(2H, m, H2-2), 3.65 (2H, m, H2-6), 1.96 (2H, m, H2-5).
5c (CDC13): 146.15 (0=0  carbamate), 134.28-124.39 (8 x Ar-C), 125.04 (-CCI3), 75.28 
(CX)CH2C a3), 73.47 (C-4), 50.24,49.75 (2 x C-3), 44.05,43.56 (2 x C-l), 43.01,40.90 
(2 x C-6), 39.83,39.54 (2 x C-5).
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5.62 3-Benzovl-4-Hvdroxv-4-Phenvlpiperidine HC1T971.
The foregoing carbamate [96](10.0g, 22mmol) was dissolved in acetic acid (150ml), 
zinc dust (11.40g, 180mmol) was added portion wise to the solution and the suspension 
was heated at reflux for 2h. The cooled mixture was stirred further for 2h. The zinc was 
removed. The filtrate was evaporated in vacuo to a small volume and treated with 
ammonia solution (pHIO). The mixture was extracted with ether (5x50ml), dried (Mg 
SO4) and evaporated to give a yellow oil, which was converted to the hydrochloride 
salt. The product was recrystallized from absolute ethanol to give [97] (3.8lg, 55%) as 
a white solid, m.p. 145-146°C (Found C, 66.6; H, 6.28; N, 4.35. C18H2oC1N02.0.5H20  
requires C,66.2; H, 6.43; N, 4.29%). No NMR data were recorded.
5.63 2-Benzyl-9-Phenvl“2,3-dihydro- 1//-Indenpr2.1 -cl pyridine-2-(2,2,2-trichloroethyl) 
Carbamater991.
2-Benzyl-9-phenyl-2,3-dihydro-l//-indeno[2,l-c]pyridine HBr [72] (16.64g, 40mmol) 
was basified with ammonia solution, and the green mixture was extracted with ether 
(4x50ml) and washed with brine. The ethereal extract was dried and evaporated to 
dryness to give a dark green oil, (12.60g, 94%).
The oil (12.60g, 38mmol) was dissolved in dry toluene (150ml), and to this was added
2,2,2-trichloroethyl- chloroformate (8.0g, 38mmol) dropwise. The green solution 
turned yellow. Stirring was continued in an anhydrous environment for 5 days. The 
solution was then washed with HC1 (6N, 2x50ml), water (50ml). The dried solution 
was concentrated in vacuo to give a yellow solid. Recrystallization from absolute
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5h (CDCI3): 7.61(9H, m, Ar-H), 6.82(1H, dt, H-4a), 4.80(4H, m, H2- l, -C02CH2CC13), 
4.55(2H, dd, 3.7Hz., 15.8Hz., ^ -3 ).
5C (CDCI3): 133.83, 133.66 (2 x Ar-Cq), 128.77-122.31, (7 x Ar-CH), 119.94,119.78 
(2xC-4), 75.22 (-C O ^ H ^ C y , 44.01,43.49,42.07 (3 x CH2).
5.64 9-Phenyl-2.3-Dihvdro-l//-Indenor2.1-c1pyridinc HC1 flOOl.
Zinc dust (10.92g, 170mmol) was added to the carbamate [88](9.00g, 12mmol) in 
acetic acid (150ml) at 0°C. The reaction mixture was stirred at room temperature for 
2h., heated at reflux for 2h, and cooled to room temperature and stirred for 16h. The 
zinc was filtered off, and the solution was distilled at the pump. To the product was 
added water (30ml), and ammonia solution (50ml, pH > 10). The aqueous solution was 
extracted with ether (5x75ml). The ethereal extract was washed with brine (2x50ml), 
and dried, then condensed at the pump to a small volume. Ethereal HC1 was then added 
ponionwise to precipitate the solid which was recrystallized from ethanol-ether to give 
the above named product, (2.9lg, 49%), m.p. 222-223°C. (Found: C, 72.5, H, 5.58; N,
4.64 C18H 16C1N.H20  requires C, 72.1; H, 6.01; N, 4.67%).
5h (DMSO-d6): 9.92(2H, s, NH2), 7.86(9H, m, Ar-H), 7.11(1H, t, J3 4.0Hz, H-4), 
4.40(2H, s, Hr  1), 4.15(2H, d, J3 4.0Hz., Hr  3).
5C (DMSO-d6): 141.67-137.55 (3 x Ar-C,), 129.12-120.85 (6 x Ar-CH), 133.60 (C-9), 
132.62 (C-9a), 124.68, (C-4a) ,119.94 (C-4), 41.61,40.51 (C -l, C-3).
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5.65 2-Benzvl-9-Phenvl-2.3.4.9-Tetrahvdro-l//-Indenor2,l-cl 
pvridine-2-(2.2.2-trichloroethvl) Carbamate flO ll.
2,2,2-Trichloroethyl chloroformate (8.48g, 40mmol) was added dropwise to a solution 
of the free base of [81](13.35g, 40mmol) in dry toluene (200ml). The mixture was 
stirred for 3 days, and then diluted with ether (100 ml), washed with HC1 (6N, 50ml), 
brine (50ml) and the organic layer dried (MgS04) and evaporated in vacuo. The 
product was purified through a silica bed (eluent: toluene), to give a thick yellow oil, 
(15.67g, 93%) b.p. was not recorded. The product was used without further 
purification.
5.66 9-Phenvl-2.3.4.4a and 2.3.4.9-Tetrahvdro-l//- Indenor2.1-c1pvridine HC1 [1021.
The foregoing carbamate [101](15.57g, 370mmol) was heated at reflux with zinc dust 
(17.33g, 270mmol) in acetic acid (150 ml) for 2.5h. The zinc was filtered and the acidic 
solution was concentrated to a small volume. Water (30 ml) was added and the 
suspension was basified with ammonium hydroxide solution (pH 10). The solution was 
extracted with ether (5x75 ml), dried (MgS04) and evaporated to dryness. The resulting 
yellow oil was converted to the hydrochloride salt to give a yellow solid which was 
purified with charcoal, and then recrystallized from acetone to give [102] (4.67g, 43%) 
as a white solid m.p. 206-207°C (Found: C, 74.9; H, 6.29; N, 4.78.
C18H 18C1N.0.25H20  requires C, 74.99; H, 6.47; N, 4.86%).
5h (DMSO-d6, HC1 salt): See Table 15.
5C (DMSO-d6): 147.51-134.72 (9 x Ar-Cq), 128.96-118.84 (10 x Ar-CH), 55.10 (C-9a), 
45.99 (C-4a), 42.33,45.03,41.09,27.57,19.20 (C -l, C-3, C-4).
184
5.7 THE ARECOLINE ROUTE.
5.71 Diastereomeric Methyl 1 -Methvl-4-Phenylpiperidine-3- Carboxylatcs.
Arecoline hydrobromide (Methyl 1-methyl-1,2,5,6- tetrahydronicotinate HBr(20.0g, 
0.085mol) was basified with potassium carbonate (50% w/v, 2x50ml). The aqueous 
suspension was extracted with toluene, dried (MgS04), and condensed to give the 
yellow oil of arecoline, (12.35g, 94%).
A suspension of magnesium turnings (3.74g, 154mmol) in dry ether (50ml) was placed 
in a 3-necked flask fitted with a condenser and a separating funnel. A drying tube was 
placed at the top of the condenser. Bromobenzene (24.18g, 154mmol) in dry ether was 
added dropwise from the separating funnel to the stirred mixture. The reaction was 
initiated with a crystal of iodine. After addition, reflux was maintained for a further 0.5 
h, then cooled to -10°C in an ice-acetone bath. Arecoline (11.90g, 77mmol) was added 
dropwise with stirring at -10°C. The reaction mixture was added to crushed ice (50g) 
and acidified with cold hydrochloric acid (6N, 80ml). The aqueous layer was collected 
and treated with potassium carbonate (50% w/v, 150ml), and the insoluble magnesium 
hydroxide was removed by centrifuge. The aqueous layer was extracted with ether 
(8x100ml), dried over Mg S04. The ethereal layer was evaporated in vacuo to give the 
yellow oil (16.10g, 90%) of the above named product, b.p. 126-130°C/0.4mm Hg. 
(Lit.187 124-128°C/0.5 mmHg).
8h(CDC13, free base): 7.33(5H, m, Ar-H), 3.94(1H, m, H-4, H-3, eq H-2), 3.42(3H, 2xs, 
CO2CH3), 3.37(3H, m, eq H-6, ax H-6, ax H-2), 2.98(3H, 4xs, N-CH3), 2.73(1H, m, 
eqH-5), 2.24(1H, m, ax H-5).
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6c(CDC13, free base): 170.77 (C=0 ), 139.99,138.69 (2x £<,), 128.70-126.76 (6x 
Ar-CH), 54.85-54.20 (2x C-2,2x C-6), 51.96, 51.70 (2x CO^Hj), 45.63-35.65 (4x 
CH), 43.59,43.46 (2x N-CH3), 29.45, 28.87 (2xC-5).
5.7.2 Separation of the Diastereomers of Methyl l-Methvl-4- 
Phenvlpiperidine-3-Carboxvlates.
5.72.1 a-Trans-it 3-CO?Me r-4-Ph)-Methvl l-Methvl-4- 
Phenylpiperidine-3-Carboxylate HC1 fl041.
A saturated solution of hydrogen chloride in dry ether was added dropwise to a solution 
of diastereomers of methyl l-methyl-4-phenylpiperidine-3-carboxylate (16.10g, 
69mmol) in dry ether. The white precipitate was washed with ether (2x50 ml) and 
recrystallized from ethanol to give [104] (2.66g, 14.3%) as colourless crystals, m.p. 
216-217°C,. (Found: C, 62.1; H, 7.59; N, 5.26. C14H2oC1N02 requires C, 62.3; H, 7.59; 
N, 5.19%).
mlz: 233(M+, 100), 174(13), 160(7), 155(3), 44(19).
5.72.2 B-Cis-(c 3-CO?Me r-4-Ph)-Methvl l-Methvl-4- Phenvlpiperidine-3-Carboxylate 
HC1 ri051.
The mother liquor from [104] was condensed at the pump to give a white solid which 
was recrystallized from acetone giving [105] (8.69g, 47%) as a white solid, m.p. 
190-192°C.
A small portion of the salt (0.5g) was then basified with aqueous ammonia, and
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extracted with ether (4x25ml). The ethereal solution was dried and evaporated to 
dryness to give cfr-methyl l-methyl-4-phenylpiperidine-3-carboxylate, m.p. 53-54°C. 
(U t187 55-58°C).
mlz: 233(M+, 78), 174(34), 155(26), 96(13), 70(12), 44(100).
5.73 a-Trans-(t 3-COOH r-4-Ph)-l-Methyl-4-Phenylpiperidine- 3-Carboxylic Acid 
HC1 [1061.
To a solution of the a-methyl l-methyl-4-phenylpiperidine- 3-carboxylate HC1 [104] 
(l.Og, 3.7mmol) in water (5ml) in a round-bottomed flask was added concentrated 
hydrochloric acid (6ml) and a few boiling stones. The mixture was then heated at 
90-95°C for 0.5 h, at which time methanol and excess HC1 was collected. The residue 
was evaporated to dryness and the product was recrystallized from absolute ethanol to 
give [106] (0.64g, 68%) as colourless prisms, m.p. 215-216°C, (Lit,187 214-216°C) 
(Found: C, 60.0; H, 7.07; N, 5.31 C13H17NO2.HC1.0.5C^H5OH requires C, 60.32; H, 
7.59; N, 5.02%).
5h (400 MHz, DMSO-d6, HC1 salt): 7.35(5H, m, Ar-H), 3.65(1H, m, eq H-2), 3.45(1H, 
m, ax H-2), 3.39(1H, td, 3.6Hz., Jax/ax 8.2Hz., ax H-4), 3.18(2H, t, J3 12.2Hz., 
H2-6), 2.97(1H, td, 3.6Hz., 8.2Hz., axH-3), 2.79(3H, s, N-CHj), 2.21(1H,
qd, Jax/eq 3.6Hz., J3 12.6Hz.,eqH-5), 1.91(1H, dd, J3 12.2 Hz., axH-5).
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5.74 B-Cis-(c 3-COOH r-4-Ph)-l-Methvl-4-Phenylpiperidine- 3-Carboxvlic Acid HC1
UfiZL
A solution of the P-methyl l-methyl-4-phenylpiperidine- 3-carboxylate [105](7.5g, 
27mmol) dissolved in water (25ml) and concentrated hydrochloric acid (30ml) was 
distilled at 90-95°C for 1 h. The residue was evaporated to dryness and the product was 
recrystallized from absolute ethanol to give [107] (5.13g, 74%) as flake-like crystals, 
m.p. 205-206°C, (Lit,187 212-213°C) (Found: C, 59.8; H, 7.14; N, 5.41 
C13H17NO2.HC1.0 .5C2H3OH requires C, 60.32; H, 7.59; N, 5.02%).
8h (400 MHz, DMSO-d6, HC1 salt): 7.32(5H, m, Ar-H), 3.68(1H, d, J 12.9Hz„ eqH-2), 
3.63(1H, m, axH-2), 3.40(2H, m, axH-4, eqH-3), 3.15(2H, m, H2-6), 2.80(3H, s, 
N-CH3), 2.47(1H, qd, 3.6Hz., J3 13.7Hz., eq H-5), 1.95(1H, m, ax H-5).
5.75 2-Methvl-9-Oxo-2.3A4a,9,9a-Hexahydro-l//- Indenor2.1-c1pyridine HC1 fllOl.
To the a-acid HC1 [106](0.5g, 2.0mmol) was added thionyl chloride (10ml) with 
cooling. The mixture was left to stand for 4 h. Excess thionyl chloride was removed by 
vacuum distillation. The product was azeotroped with tetrachloromethane (2x20ml) to 
remove the last trace of thionyl chloride.
To this acid chloride (crude) dissolved in tetrachloromethane (10ml), was added 
anhydrous aluminium chloride (1.35g, lOmmol) portionwise with stirring at 40°C, until 
no more gas evolved. The mixture was stirred for 0.5h at 40°C, cooled and poured into 
crushed ice (20g). The aqueous layer containing the keto product was separated, and 
concentrated HC1 (10ml) was added. The aqueous layer was washed with ether (2x50 
ml), and then treated with ammonia solution (pH=10). The product was extracted with
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ether (5x50ml), dried (MgS04), concentrated, and converted to the HC1 salt, which 
recrystallized from ethanol-ether to give [110] (0.12g, 26%), m.p. 190.5-191°C. 
(Lit,187 208-210°C).
A similar procedure was adopted for the (3-acid [96], to give [110] in a 40% yield, m.p. 
189-190°C.
IRCVtfuzx/cm'1, nujol mull): 3400(NH), 3100(CH-Ar), 2900(CH), 2600(N-Me), 
1710(C=O), 1600(Ph).
8H(DMSO-d5, HC1 salt): 11.75 (1H, 2xs, +N-H), 7.7 (4H, m, Ar-H), 3.86(1H, brs., eq 
H-l), 3.63(1H, dd, 6.0Hz., Jgem 14.9Hz., axH-1), 3.30(3H, m, H2-3, H-9a), 
2.79(3H, 2xs, N-CH3), 2.41(2H, m, eq H-4, H-4a), 1.53(1H, m, ax H-4).
5c(DMSO-d6, HQ salt): 201.81 (C=0), 156.56,133.86 (2x Ar-Cq), 135.22-123.80 (4 x 
Ar-CH), 51.28 (C-l), 48.32 (C-3), 28.99 (C-4), 45.24 (C-9a), 33.92 (C-4a), 42.84 
(N-CH3).
mlz: (M+, 100%), 184(37), 44(18).
5.7.6 9-Hvdroxv—2-Methvl-9-Phenvl-2.3.4.4a.9.9a- 
Hexahydro-l//-Indenof2,1-clpvridine m il.
To a solution of bromobenzene (80 mg, O.lmmol) in dry THF(30 ml), was added 
butyllithium (1.0 M solution, 5ml) dropwise at -78°C. The solution was stirred at that 
temperature for 15 mins. To the mixture was added
2-methyl-9-oxo-2,3,4,4a,9,9a-hexahydro-l//-indeno[2,l-c] pyridine [110] (lOOmg,
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0.5mmol) dropwise at the same temperature. The suspension was allowed to warm to 
room temperature, and then poured into iced water (50 ml). Hydrochloric acid (25ml) 
was added, and the aqueous layer was washed with ether (4x20ml). The acidic solution 
was then neutralized with ammonia, and the product was extracted with ether (4x25ml), 
dried, and condensed at the pump to give a crude oil, (99mg, 71%). The above named 
product was used in the next step without further purification.
5.7.7 2-Methvl-9-Phenyl-2,3A4a-Tetrahydro-l//- Indenor2,l-c]pyridine HC11861.
Thionyl chloride (10ml) was added to 9-hydroxy-2-methyl- 
9-phenyl-2,3,4,4a,9,9a-hexahydro-l//-indeno[2,l-c]pyridine HC1 [111] (90mg, 
0.3mmol) with stirring. The mixture was stoppered and left to stand at room 
temperature for 24 h. Excess thionyl chloride was removed by distillation, and the 
product was basified with ammonia solution (20ml), and stirred at room temperature 
for 24 h. The product was extracted with ether (4x50ml). dried (MgS04), evaporated in 
vacuo to give a dark yellow oil which was converted to the HC1 salt. Recrystallization 




To a solution of 2-bromopyridine (16mg, O.lmmol) in dry THF(10 ml), was added 
butyllithium (1.0 M solution, 1ml) at -78°C. The solution was stirred at that 
temperature for 15 mins. To the mixture was added 2-methyl-9-oxo- 
2,3,4,4a,9,9a-Hexahydro-l//-indeno[2,l-c]pyridine (20mg, O.lmmol) dropwise at the 
same temperature. The suspension was allowed to warm to room temperature, and then
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poured into iced water (10ml). Concentrated hydrochloric acid (10ml) was then added, 
and the aqueous layer was washed with ether (4x20ml). The acidic solution was then 
basified with ammonia, and the product was extracted with ether (4x25ml), dried 
(MgS04), and evaporated in vacuo to give a yellow oil. To the oil, was added ethereal 
HC1, and the resulting yellow solid was collected, (13mg, 36%). The product was not 
further purified. ]H NMR showed a broad peak at 5.18ppm corresponding to the OH 
which disappeared with a D20  shake.
m/z: 280(M++H, 1), 262(M+-H20 , 3), 78(Py, 4), 71(41), 57(100), 44(63).
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5.8 Other Analogues of Phenindamine.
5.81 3-Benzvl-4-Hvdroxv-l-Methvl-4-PhenylDiperidine HC1 f!201.
A mixture of 3-benzoyl-4-hydroxy-1 -methyl-4- phenylpiperidine (l.Og, 3.38mmol) 
anhydrous hydrazine (5.0g, 156mmol) was heated under reflux for 2 h. Excess 
hydrazine was removed by distillation under vacuum. To the formed hydrazone was 
added triethylene glycol (30ml), and potassium hydroxide (0.5g). The suspension was 
heated under reflux for 3h, at which time the evolution of gas (N2) had ceased. The 
product was extracted with ether (4x50ml). The ethereal layer was dried (MgS04) and 
then condensed at the pump to give a yellow oil, which was fractionated to give [120] 
(0.20g, 21%) as a colourless oil b.p. 121-124°C/2mmHg.
IR (vmJtt/cm_1, liquid film): absence of C=0 stretch at 1690.
5.82 3-Benzvl-l-Methyl-1.2.3,6-Tetrahydropvridine [1211.
A solution of 3-benzyl-4-hydroxy-1-methyl-4- phenylpiperidine (50 mg) in acetic acid 
(5ml) and concentrated hydrochloric acid (5ml) was heated under reflux for 6 h. The 
cooled mixture was then condensed to dryness at the pump, and then basified with 
ammonia solution. The product was extracted with ether (5x30ml). The ethereal extract 
was dried over MgS04, and then evaporated in vacuo to give a dark oil. TLC showed a 
multicomponent mixture which was not further investigated.
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5.83 4-Hvdroxv-3-(a-hvdroxvbenzvl)-4-Phenylpiperidine HC1[98].
To a solution of 3-benzoyl-l-benzyl-4-hydroxy-4- phenylpiperidine HC1 [61](2.50g, 
7.54mmol), in absolute ethanol(50ml), was hydrogenated with palladium hydroxide 
(25mg, 5% on activated carbon) at 70°C for 2h at 50 lbs psi. The catalyst was removed 
and the filtrate was condensed at the pump. The remaining solid was recrystallized 
from acetone to give crystals [98] (2.06g, 82%), m.p. 193-194°C, (Found: C, 67.2; H, 
6.82; N, 4.34 CjgH^ClNC^ requires C; 67.6; H, 6.89; N, 4.38). The absence of the 
C=0 stretching at 1690 cm'1 was noted.
5h (DMSO-d*, HC1 salt): 9.21(2H, brs, NH2), 7.51(10H, m, Ar-H), 3.38(1H, s, OH), 
5.15(1H, d, J3 3.7Hz., OH), 4.48(1H, d, J 2.9Hz., CH), 3.39(3H, m, eqH-6, axH-2, 
eqH-2), 2.85(2H, m, eqH-5, axH-6), 2.22(1H, td, J 9.16Hz., J 12.8Hz., axH-3),
1.70(1H, d, J 14.6Hz., axH-5).
5C (DMSO-d6, HC1 salt): 147.16-143.13 (3x Ar-Cq), 127.89-125.00 (6 x Ar-CH), 71.10 
(CH), 47.74 (C-4), 41.90 (C-2), 39.47 (C-6), 37.43 (C-5).
5.84 Attempted Synthesis of 3-(benzylidene)-4-Phenyl- 1.2.5.6-Tetrahvdro-pyridine 
Oxalate.
4-Hydroxy-3-(a-hydroxybenzyl)-1 -methyl-4-phenylpiperidine HC1 [98] (1.70g, 
5.3mmol) was boiled under reflux with concentrated hydrochloric acid (50ml) and 
acetic acid (25ml) for 5h. The cooled mixture was reduced to a small volume at the 
pump, basified with concentrated ammonia solution, and extracted with ether (4 x 
50ml). The ethereal extract was dried(MgS04), and then titrated with a saturated 
solution of ethereal oxalic acid to give a product, which was recrystallized from
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analysed and found to be (N-benzoylethyl)-N-(3-E-(phenyl}prop-2-ene)- amine oxalate 
[122], (1.18g, 68%) as white crystals, m.p. 179-180°C (Found: C, 67.3; H, 6.16; N, 4.71 
C20H21NO5 requires C, 67.6; H, 5.92; N, 3.94%).
IR ('W /crn '1, KElr disc): 1700(C=O), 1500(Ar), 1600cm-'(Ar), 1650(C=C) cm4 .
SH (DMSO-d6, oxalate salt): 9.68(2H, brs., NHj), 8.00(10H, m, Ar-H), 6.87(1H, d, ],rans 
16.1Hz., CH=CHPh), 6.14(1H, m, CH=CHPh), 3.82(2H,d, J3 6.0Hz„ CH2), 3.56(2H, 
brs, CH2), 3.31(2H, bsr., CHj).
8C (DMSO-d6, oxalate salt): 197.17(C=0), 165.16-135.77 (3 x C,), 136.45-128.05 (6 x 
Ar-C), 126.66 (CH=CHPh), 120.53 (CH=CHPh), 48.52 (CH2), 41.16 (CH2), 34.70 
(CH2).
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5.9 SYNTHESIS OF 1.3-DIMETHYL-4-PIPERIDONE.
Methyl 2-Methvl-3-(methylamino)propanoate H291.
A solution of methyl methacrylate (189g, 1.89mol) in absolute ethanol (125ml) was 
added dropwise with stirring to an ice-cooled solution of methylamine (33% w/v in 
IMS, 125ml, 1.35mol) over a period of 3 h. The clear solution was stirred for a further 3 
h, and then left to stand in the dark at room temperature for 4 days. The resulting pale 
yellow solution was condensed in vacuo, and fractionated to give [129] (125.0g, 51%) 
as a colourless oil, b.p.42-44°C/3.0 mmHg. (Lit.198 48.8-49.5°C/8 mmHg).
IR (Vmax/cnf1, liquid film): 3320(N-H), 1740(C=O), llOO(C-O-C).
5h (CDC13): 3.70(3H, s, C0 2CH3), 2.98(1H, m, CH2-CH[CH3]), 2.71(2H, m, N-CH2), 
2.42(3H, s, N-CH3), 1.19(3H, d, J3 7.0Hz, CHtCHj]).




A solution of methyl 2-methyl-3-(methylamino)propanoate [129] (34.88g, 0.266mol) 
and ethyl acrylate (26.63g, 0.266mol) was left in the dark for 10 days. The resulting 
amber-coloured mixture was fractionated to give [130] (45.1g,73%) as a colourless oil 
b.p. 120°C/3.0 mm Hg. (Lit.,198 105-107°C/4mmHg).
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SH (CDCI3): 4.17(2H, q, J3 7.1Hz„ COzQfcCH,), 3.67(3H, s, C0 2CH3), 2.72(4H, m, 2 
xN-Qk), 2.46(2H, m, N-CHjCHj), 2.30(1H, m, CH[CH3]), 2.23(3H, s, N-CH3), 
1.28(3H, t, J3 7.1Hz., COCH2CH,), 1.14(3H, d, J3 6.8Hz.,CH[CH,]).
8C (CDCI3): 176.22, 172.42 (2xC=0); 60.59 (CH2CO); 53.13,52.45 (2xN-CH2); 32.60 
(COjCHj); 51.38 (COjCHj); 42.10 (CH); 38.37 (N-CH3); 15.28 (CH[CH3]); 14.08 
(CHjOHj).
1.3-Dimethyl-4-piperidone [1371.
To a stirred suspension of bird shot sodium (4.6g, 0.2mol) in dry xylene (100ml) was 
added methyl 3-[N-(2-ethoxycarbonylethyl)-N-methylamino]-2-methylpropano ate 
[130] (46.25g, 0.2mol) dropwise. The mixture, protected from moisture, was heated in 
an oil bath at 60°C. When the initial reaction had subsided, the mixture was heated 
under reflux for 3 h, by which time all the sodium had reacted. The resulting dark 
coloured liquid was cooled and added with stirring to iced water (200g). The aqueous 
layer was collected, washed with diethyl ether (2x100ml), and acidified with 
concentrated hydrochloric acid. The acidic mixture was heated under reflux for 4 h (a 
negative result was obtained with ferric chloride solution). The reaction mixture was 
cooled, concentrated to a small bulk, and basified with solid potassium hydroxide. The 
crude product was extracted with ether (18x100 ml), dried (MgS04), and evaporated in 
vacuo to give a yellow oil which was fractionated to give [137] (9.9 lg, 39%) as a 
colourless oil b.p. 40-42°C/2mm Hg. (Lit.,198 43-43.5°C/5.5 mm Hg).
5h (DMSO-d6): 3.02(2H, m, Hr 2), 2.74(3H, m, Hr 6, H-3), 2.27(3H, s, N-CH3), 
2.20(2H, m, 1^-5), 0.88(3H, d, J3 6.6Hz., CHtCBj]).
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8C (DMSO-d6): 210.18 (0=0), 63.09 (C-2), 55.98 (C-6), 45.12 (C-3), 43.95 (N-CH3),
40.64 (C-5) 11.68 (CH[CH3]).
5.91 REDUCTION OF 1.3-DIMETHYL-4-PIPERIDONE.
5.91.1 Lithium Aluminium Hydride Reduction.
A suspension of lithium aluminium hydride (1.90g, 0.05mol) in dry ether (30ml) was 
stirred vigorously for 0.5 h. To the resulting slurry was added a solution of
1.3-dimethyl-4-pipcridone (6.35g, 0.05mol) in dry ether (30ml) dropwise (at a rate 
sufficient to maintain gentle reflux). The mixture, protected from moisture, was heated 
under reflux for a further 10 h. The reaction mixture was cooled, and the excess LAH 
was decomposed carefully. The ethereal layer was collected, dried (MgS04), and 
evaporated in vacuo to give a colourless oil of diastereomeric
1.3-dimethyl-4-piperidinols, which was fractionated, (5.56g, 86%), b.p. 78-80°C/2 mm 
Hg. (Lit.,196- 78.0°C/ 1mm Hg).
A mixture of isomers was detected in the *H NMR (2.4:1 ratio of trans to cis 
respectively).
5.9.1.2 Trans-it 3-Me r-4-OH)-l,3-DimethyI-4-Piperidinol 1T381.
The foregoing l,3-dimethyl-4-piperidinol (5.0g, 39mmol) from the LAH reaction were 
dissolved in dry ether (20ml). Dry hydrogen chloride gas was bubbled into the solution 
until no more solid precipitated. The white solid was collected, and recrystallized from
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absolute ethanol-ether to give colourless crystals of the title product, m.p. 183-185°C. 
( l i t ,192 183-184°C). The free base was liberated by treatment with ammonia solution 
and extracted with ether. The ethereal layer was dried, evaporated in vacuo and 
fractionated to give [138] as a colourless liquid which solidified on standing, (3.37g, 
67%), m.p. 32-32.5°C.
§H (CDCI3): 3.84(1H, s, OH), 3.05(1H, td, axH-4), 2.81(1H, m, eqH-2), 2.77(1H, m, 
eqH-6), 2.23(3H, s, N-CH3), 1.98(1H, dd, axH-2), 1.93(1H, m, axH-6), 1.66(3H, m, 
H2-6, axH-3), 0.98(3H, d, J3 5.7Hz., CHtCHj]).
5C (CDQ3): 73.72 (C-4), 61.85 (C-2), 54.59 (C-6), 45.70 (C-3), 38.53 (N-CH3), 34.48 
(C-5), 15.60 (CH[CH3]).
mJz: 129(M+, 60), 128(62), 112(33), 96(9), 84(26), 70(30), 58(48), 43(100), 27(9).
5.91.3 Aluminium Zyopropoxide Reduction.
l,3-Dimethyl-4-piperidone [137] (3.23g, 25mmol) in distilled wopropanol (60 ml) was 
added to a solution of aluminium wopropoxide (3.21g, 25mmol) in wopropanol (30ml) 
in a 250 ml flask fitted with a Vigreux column and a condenser. Reflux was maintained 
for 16 h, whereby most of the wopropanol was removed by distillation. The residue was 
hydrolysed with ice-cold ammonia solution and the product extracted continuously 
with chloroform for 36 h. The extract was dried (MgS04), evaporated to dryness and 
fractionated to give a mixture of diastereomers of l,3-dimethyl-4-piperidinols (3.04g, 
94%).
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A mixture of isomers was detected in the NMR (1:1 ratio of the a-trans and P-c/j 
isomers).
5.9.1.4 Platinum Oxide Reduction.
A solution of 1,3-dimethyl-4-piperidone [137] (0.5g) in absolute ethanol (30ml) was 
catalytically hydrogenated with platinum oxide (O.lg) at 50 psi, and at room 
temperature for 16 h. The catalyst was removed through a bed of celite, and the filtrate 
was evaporated to dryness and fractionated to give a colourless oil (86%).
NMR investigation showed a mixture of the a-trans and P-ris diastereomers of
1,3-dimethyl-4-piperidinols were present in the ratio of 1:2.7.
The same procedure was repeated at 20psi. A 6:1 ratio of the cisitrans isomers were 
detected in the 1H NMR.
IR (v^ /cm '1, liquid film): 3200(0-H).
5.92 SEPARATION OF THE ISOMERS OF U-DIMETHYL-4- PIPERIDINOL.
5.92.1 Trans-(t 3-Me r-4-OCOMe)-1.3-Dimethyl-4-Piperidvl Acetate Hydrochloride 
ri401.
A solution of l,3-dimethyl-4-piperidinol (l.Og, 7.8mmol) in ethyl acetate (30ml), was 
added dropwise to a solution of acetyl chloride (0.16g, 20mmol) in ethyl acetate (30ml) 
with stirring over a period of 1 h. The mixture was heated at reflux for 24 h and left to 
stand for a further 48 h at room temperature, at which time, crystals of the above named
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product precipitated. The product was collected and recrystallized from absolute 
ethanol, (1.43g, 89%), m.p. 212-213°C. (Lit.,196 208-210°C). The mother liquor was 
retained.
5h (DMSO-dfi): 11.50(1H, s, +N-H). 4.81(1H, td, 4.4Hz., 10.3Hz., axH-4),
3.59(4H, m, H-2, H-6), 2.95(3H, s, COCH3), 2.92(5H, brs, N-CH3, axH-5, axH-3), 
2.01(1H, qd, eqH-5), 1.10(3H, d, J3 6.3Hz., CHtCIfc]).
5C (DMSO-dg): 170.15 (C=0), 75.77 (C-4), 61.12 (C-6), 53.58 (C-2), 45.57 (N-CH3), 
35.48 (OCOCH3), 30.62 (C-5), 20.98 (CH[CH3]), 15.47 (CH[CH3]).
5.92.2 Trans-it 3-Me r-4-OH)-L3-Dimethyl-4-Piperidinol ri381.
A suspension of LAH (0.37g, lOmmol) in sodium dried ether (20ml) was stirred 
vigorously for 15 mins. To the resulting slurry was added a solution of 
trans-1,3-dimethyl-4- piperidyl acetate [140] (1.67g, lOmmol) dropwise at a sufficient 
rate to keep the solution refluxing. The mixture, protected from moisture, was heated 
under reflux for 8 h. The reaction mixture was cooled to 0°C, and the unreacted LAH 
was decomposed carefully with water (0.4ml), sodium hydroxide (5N, 0.2ml) and water 
(0.6ml). The ethereal layer was decanted, dried (MgS04), evaporated in vacuo and 
fractionated to give [138] as a colourless oil. The oil solidified on standing, (1.13g, 
88%), m.p. 32-33°C. (mixed m.p. 32-33°C with earlier method).
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5.92.3 Cis-(c 3-Me r-4-OCOMe)-l,3-Dimethvl-4-Piperidvl Acetate Hydrochloride
im
The mother liquor from the trans-1,3-dimethyl-4-piperidyl acetate was basified with 
ammonia solution and the free base was extracted with ether. The ether was dried 
(MgS04) and evaporated to dryness. The acetate ester (1.50g, 12mmol) was dissolved 
in ethyl acetate (50ml) and added dropwise to a solution of acetyl chloride (2.40g, 
30mmol) in ethyl acetate (50ml) with stirring. The solution was refluxed for 24 h in an 
anhydrous environment. The solvent was removed and the solid was recrystallized 
from ethanol-ether at 5°C to give [141] (2.27g, 88%) as colourless crystals, m.p 
138-140°C. (Lit.,196 145-146°C).
5h (DMSO-d6): 11.35(1H, s, +NH), 4.90(1H, brd, bw 21.0Hz., b0J 6.0 Hz., eq H-4), 
3.22(2H, m, H ^ ) , 2.96-2.77(2H, m, H2-6), 2.74(3H, s, N-CH3), 2.36(1H. m, ax H-3), 
2.09(3H, s, OCOCH3), 1.96(2H, m, H2-5), 0.85(3H, d, J3 6.6Hz., CHtCHg]).
5C (DMSO-d6): 169.83 (COCH3), 66.85 (COCH3), 53.58 (C-6), 47.75 (C-2), 42.36 
(N-CH3), 31.20 (C-4), 26.89 (C-5), 20.73 (CH[CH3]), 14.01 (CH[CH3]).
5.92.4 Cis-(c 3-Me r-4-OH)-1.3-Dimethvl-4-Piperidinol f!391.
A suspension of LAH (0.37g, lOmmol) in sodium dried ether (20ml) was stirred 
vigorously for 15 mins. To the resulting slurry was added dropwise a solution of 
c/j-l,3-dimethyl-4- piperidyl acetate [141] (1.67g, lOmmol) at a sufficient rate to keep 
the solution refluxing. The mixture, protected from moisture, was further refluxed for 8 
h. The reaction mixture was cooled to 0°C, and the unreacted LAH was decomposed 
carefully with water (0.4ml), sodium hydroxide (5N, 0.2ml) and water (0.6ml) again.
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The ethereal layer was decanted, dried (MgS04), and evaporated in vacuo to give the 
crude c/.s-l,3-dimethyl-4-piperidinol, which was fractionated to give [139] (1.03g,
80%) as a colourless oil, b.p. 100-104°C/1.0mm Hg.
6h (CDCI3): 3.75(1H, dd, bw 13.7Hz., b05 7.8Hz., eq H-4), 3.28(1H, brs, OH), 2.38(3H, 
m, H2-2, eq H-6), 2.25(3H, 2xs, N-CH3), 2.10(1H, m, ax H-6), 1.87-1.64(3H, m, H2-5, 
H-3), 0.98(3H, 2xd, J3 7.0Hz„ CHtCHJ).
8c (CDClj): 73.76,67.12 (2 x C-4), 61.95,57.34 (2 x C-2), 54.69,50.01 (2 x C-6), 
46.19,45.80 (2 x N-CH3), 38.63,35.13 (2 x CH[CH3]), 34.61,32.60(2 x C-5), 15.63, 
14.69(2 x CH[CH3]).
mlz: 129(M+, 60), 128(63), 112(33), 96(9), 84(27), 70(30), 58(49), 43(100), 27(9).
5.93 SYNTHESIS OF 1.2-DIMETHYL-4-PIPER1DONE.
Ethyl 3-Methvlaminobutyrate.
To ethyl crotonate (39.55g,0.35mol) was added to methylamine (32ml, 33% in IMS, 
0.36mol), and absolute ethanol (35ml). The mixture was left to stand in the dark at 
room temperature for 5 days and then heated under reflux for 8h. The solvent was 
removed, and the orange liquid was fractionated to give the above named compound 
(40.6 lg, 80%) as a light yellow oil,, b.p. 70°C/10 mm Hg, (Lit.,199 72°C/12.5 mm Hg).
IR (vmax/cm‘l, liquid film): 1730(C=O).
8h(CDC13): 4 .16(2H, q, OCH2CH3), 2.95(1 H, m, CH[CH3]), 2.50(3H, s, N-CR,),
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2.29(2H, d, CHCH2CO), 1.36(3H, d, CH(CH3)), 1.21(3H, t, CH2CH3).
8C (CDC13): 172.0 (C=0), 60.03 (OCH2CH3), 52.28 (CH[CH3]), 41.50 (CHCH2CO), 
33.75 (N-CH3), 20.15 (CH{CH3J), 14.35 (CH^CH;,).
Diethyl 3.4-Dimethyl-4-Azaheptanedioate T1431.
A mixture of ethyl 3-methylaminobutyrate (34.88gt 0.24mol) and ethyl acrylate (24g, 
0.24mol) was kept in the dark at room temperature for 10 days. The resulting amber 
coloured liquid was fractionated to give [143] (42.93g, 73%) a colourless oil b.p. 
120°C/3.0 mm Hg. (Lit.,192 129°C/6 mm Hg)
IR (vm„/crn-1, liquid fiim): 1730, 1750(C=O).
8h (CDCI3): 4.20(4H, q, 2 x OCH2CH3), 3.33(1H, m, CH[CH3J), 2.49-2.83(6H, m, 2 x 
CH2CO, N-CH2), 2.33(3H, s, N-CH3), 1.43(6H, t, 2 x  CH2CH3), 1.20(3H, d, 
CHICHjJ).
8C (CDC13): 171.62 (2 x C=0), 59.59 (2 x OCH2CH3), 55.37 (CH[CH3)), 48.65 




Diethyl 3,4-dimethyl-4-azaheptanedioate (43.00g, 0.19mol) was added dropwise to a 
stirred suspension of bird shot sodium (4.30g, 0.19mol) in dry xylene (170ml). When 
the initial reaction had subsided, the mixture was refluxed for 3 h. The resultant dark 
liquid was cooled overnight and added with vigorous stirring to iced water (lOOg). The 
aqueous layer was separated, washed with ether (2 x 50ml) and made acidic with 
concentrated hydrochloric acid (150ml, pH 1.0). After refluxing for 4 h, the reaction 
mixture was condensed (75ml), and excess sodium chloride was filtered off. The 
filtrate was basified with potassium hydroxide pellets, and the product was extracted 
with ether (20 x 100ml), dried (MgS04), and distilled to give a dark yellow liquid, 
which was fractionated to give [144] (7.29g, 30%) as a light yellow liquid, b.p. 
70°C/3.0 mm Hg. (Lit.,200 55-57°C77 mmHg).
IR (vmax/cm'*, liquid film): 1730(C=O).
5h (CDCL3): 1.20(3H, d, CH(CH,)), 2.43(3H, s, N-CH3), 2.20(6H, m, Hr 3, Hr 5, 
H2-6), 3.00(1 H, m, CH[CH3]).
5C (CDC13, Free base): 207.16 (C=0), 58.52 (C-2), 54.55 (C-6), 48.59 (C-3), 41.44 




A suspension of lithium aluminium hydride (1.30g, 34 mmol) in dry ether (20ml) was 
stirred vigorously for 0.5 h. To the resulting sluny was added a solution of 
1,2-dimethyl-4-piperidone [144] (4.30g, 34 mmol) in dry ether (20ml) dropwise, at a 
rate sufficient to maintain gentle reflux. The solution, protected from moisture, was 
heated under reflux for a further 1 h. The reaction mixture was cooled, and the excess 
LAH was decomposed carefully. The ethereal layer was collected, dried (MgS04), and 
evaporated to give a colourless thick oil of the above title compound, which was 
fractionated, (3.3 lg, 76%), b.p. 78-80°C/2 mm Hg.
8h (CDC13): 4.07(0.23H, quintet, J3 3.4Hz., eq H-4), 3.63(0.77H, tt, 4.58Hz.,
11.18Hz., ax H-4), 3.38(1H, brs, OH), 2.89(1H, dq, J3=3.4Hz„ H-2), 2.66(1H, m, 
eq H-6), 2.28(3H, 2 x s, N-CHj), 2.13(1H, tn, ax H-6), 1.99-1.49(4H, m, Hj-S, H2-5), 
1.15(3H, 2xd, J3 6.6Hz., CH[CHjJ).
8C (CDC13): 68.37,57.47 (2 x C-4), 55.07,50.17 (2 x C-6), 43.40,41.09 (2 x C-3), 
42.68,42.07 (2 x C-2), 42.13 (N-CH3), 35.06,32.92 (2 x C-5), 20.47 (CH[CH3]).
5.94.2 a-1.2-Dimethyl-4-Piperidinol Hydrochloride T1451.
Isomeric l,2-dimethyl-4-piperidinols (l.Og, 7.8mmol) were dissolved in absolute 
ethanol ( 10ml), treated with hydrogen chloride gas until the solution turned cloudy. 
Crystals of the above named product precipitated (0.80g, 61%), m.p. 120-122°C.
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8h (DMSO-dg, HC1 salt): 10.7(1H, s, +N-H), 3.67(1H, tt, ax H-4), 2.39(1H, m, H-2), 
3.10(2H, m, H2-6), 2.70(3H, s, N-CH3), 2.00(2H, m, H ^ ) , 1.75(2H, m, Hr 5), 
1.15(3H, d, J3 6.0Hz., CHfCHj]).
8c (DMSO-ds, HC1 salt): 67.40 (C-4), 56.99 (C-6), 54.85 (C-3), 43.72 (C-2), 42.13 
(N-CH3), 35.23 (C-5), 20.66 (CH[CH3]).
5.94.3 Reduction of 1.2-Dimethvl-4-Piperidone With Platinum Oxide.
To crude 1,2-dimethyl-4-piperidone (lOOmg) in absolute ethanol (10ml), was added 
platinum oxide (20mg), and the suspension was hydrogenated at room temperature for 
24 h. The catalyst was removed, and the filtrate was concentrated to give a yellow oil. 
When acetone (10ml) was added to this oil, white solid of [3-1,2-dimethyl-4-piperidinol 
[146] precipitated, (35mg, 35%).
The JH NMR showed that the 4-methine proton (54.1, br) to be in the equatorial 
position.
5.95 SYNTHESIS OF HISTRYL ANALOGUES.
5.95.1 7rfl/is-l,3-Dimethyl-4-Piperidyl Benzhydryl Ether HC1 [1481.
Trans-1,3-Dimethyl-4-piperidinol [138] (0.5g, 3.89mmol) was added to anhydrous 
potassium carbonate (0.8g, 5.81mmol), and the mixture was agitated for 15 mins. A 
solution of chlorodiphenylmethane (1.05g, 4.26mmol) in dry toluene (10ml) was then 
added and the mixture was heated under reflux at 130°C for 3 h. The reaction mixture 
was diluted with water (10ml), and extracted with ether. The organic layer was
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separated, dried (MgS04) and evaporated at the pump to give the ether as an oil. The 
oil was treated with ethereal HC1 to precipitate a solid which was recrystallized from 
acetone to give [148] (0.24g, 15%) as colourless crystals, m.p. 125-126°C. (Found: C, 
68.4; H, 7.89; N, 4.03. C20H25NO.HCl.H2O requires C,68.65; H, 8.07; N,4.00%).
5h (DMSO-d6, HC1 salt): 7.43(10H, m, Ar-H), 5.68(1H, s, Ph2CH-), 3.24(3H, m, 
axH-4, eqH-2, eqH-6), 2.84(1H, m, axH-2), 2.66(3H, s, N-CH3), 2.180H, m, axH-6, 
eqH-5, axH-5), 1.77(1H, dd, axH-3), 0.98(3H, d, J3 6.2Hz., CHtCHj]).
5C (DMSO-dg, HC1 salt): 143.17,142.03 (2 x Cq), 128.28-126.24 (5 x Ar-CH), 79.30 
(OCHPh2), 75.32 (C-4), 56.92 (C-2), 51.51 (C-6), 41.97 (N-CH3), 34.25 (CH[CH3]), 
20.72(C-5), 14.92 (CH[CH3]).
5.95.2 Cis-1.3-Dimethvl-4-Piperidvl Benzhvdrvl Ether oxalate [1491.
Cis-1,3-Dimethyl-4-piperidinol [139] (l.Og, 7.75mmol) was agitated with anhydrous 
potassium carbonate (1.60g, 11.6mmol) for 15 min. a solution of 
chlorodiphenylmethane (1.73g, 8.54mmol) in dry toluene (10ml) was then added and 
the mixture was heated under reflux at 140°C for 3 h in an anhydrous condition. The 
cooled suspension was filtered and the filtrate was condensed to give a yellow oil. The 
oil was dissolved in ether, and to this was added oxalic acid in methanol. The mixture 
was left to stand for 2 h, at which time a white solid precipitated. The solid was 
collected, washed with ether (2x20ml), and recrystallized from ethanol-ether to give 
[149] (0.68g, 23%) as a white solid, m.p 142.5-143.5°C. (Found: C, 68.3; H, 7.12; N, 
3.70. QqH^NCMCOjH^ requires C, 68.5; H, 7.01; N, 3.68%).
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6h (DMSO-d6, oxalate salt): 9.53(2H, s, (COjH^), 7.41 (10H, m, Ar-H), 5.66(1H, s, 
OCHPhj), 3.52(1H, brs, bw 21.0Hz., b0J 9.0Hz„ eqH-4), 3.12(2H, m,H2-2), 2.95(2H, 
dd, H j-6), 2.71(3H, s, N-CH,), 2.05(2H, m, eqH-3, eqH-5), 1.79(1H, m, axH-5),
0.90(3H, d, J3 6.6Hz„ CH[CH3]).
5C (DMSO-d6, oxalate salt): 165.16 (C=0 oxalate), 143.39,142.32 (2 x Ar-Cq), 
128.41-126.49 (4 x Ar-CH), 79.98 (OCHPh2), 70.02 (C-4), 54.46 (C-2), 48.42 (C-6), 
42.68 (N-CHj), 32.62 (CH[CH3J), 25.72 (C-5), 14.63 (CH[CH3]).
5.95.3 g-l,2-Dimethvl-4-Piperidvl Benzhvdrvl Ether HC1 fl511.
a-l,2-Dimethyl-4-piperidinol [145] (l.Og, 7.75mmol) was heated with anhydrous 
potassium carbonate (1.60g, 11.6mmol) and chlorodiphenylmethane (1.73g, 8.54mmol) 
at 140°C for 3h in an anhydrous condition. The cooled suspension was filtered and the 
filtrate was reduced in vacuo to give a yellow oil. The oil was dissolved in ether, and to 
this was added ethanolic HC1. The mixture was left to stand for 2 h, at which time a 
white solid of the above named product precipitated, (0.54g, 21%), m.p. 153-154°C.
SH (CDC13, HC1 salt): 10.8(1H, brs, +N-H), 7.35(10H, m, Ar-H), 5.70(1H, s, OCHPh2), 
3.53(1H, m, axH-4), 3.36(1H, m, eqH-6), 3.09(1H, m, axH-6), 2.93(1H, m, axH-2), 
2.63(3H, s, N-CH3), 2.20(2H, m, eqH-5, eqH-3), 1.71(2H, m, axH-5, axH-3), 1.30(3H, 
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